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ABSTRACT 
This work describes the investigation of bioerodible polyanhydrides as controlled 
drug delivery vehicles. The polymers studied are based on the l,6-bis(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) monomers. These two materials erode 
at vastly different rates and can be combined in random copolymers or blends to achieve 
tailored erosion kinetics. The hydrophobic nature of these materials offers the potential to 
stabilize proteins, and their mutual incompatibility and semicrystallinity provide an 
interesting phase behavior, which can be exploited to aid in tailoring the release kinetics. 
Theoretical and experimental description of the microstructure of polyanhydride copolymers 
reveals the details of the microstructure, which are essential to understanding the erosion and 
drug release kinetics. Injectable drug delivery systems based on polyanhydride microspheres 
are developed and tested in vitro and in vivo to ascertain drug release kinetics and immune 
responses to a model antigen, tetanus toxoid (TT). Tailored release profiles of small 
molecular weight drugs are demonstrated by combining microspheres with different erosion 
kinetics in "cocktails." This concept is extended to vaccine formulations, where it is 
demonstrated that the in vivo immune response mechanism can be tuned by altering the drug 
release kinetics. To achieve control of the immune response mechanism, TT-loaded 
microspheres providing a controlled release are combined with unencapsulated antigen or 
delivered without the addition of unencapsulated antigen. Hypotheses regarding the 
phenomena controlling the immune response are discussed. Finally, accurate erosion and 
drug release kinetics models are developed that incorporate details of the polymer 
microstructure and offer molecular level descriptions of the complex process of erosion to 
aid future developments of polyanhydride systems for biomedical applications. 
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CHAPTER 1 
INTRODUCTION 
1.1 Bioerodible Polyanhydride Microspheres as Vaccine Delivery Vehicles 
History demonstrates that aggressive vaccination campaigns are capable of virtually 
eliminating many dangerous diseases (e.g. polio, small pox). Public health initiatives aimed 
at specific diseases, though successful in the United States and other western countries, may 
fail in less developed countries due to lack of adequate public health services, patient 
compliance, education, and record keeping. Dropout rates after initial vaccine doses reach as 
high as 70% in developing regions[l]. Improved vaccine delivery techniques that require 
only a single dose to confer protective immunity would help make mass immunization 
programs successful in underdeveloped and developing countries. For instance, tetanus is 
responsible for over 700,000 neonatal deaths annually, half of which could be prevented by 
immunization alone[2]. In 2003 The National Institutes of Health listed the development of 
single dose vaccines as the number one grand challenge in global health[3], 
Bioerodible polymers show great potential as vehicles for controlled drug delivery, 
offering significant improvements over conventional drug delivery methods. For example, 
devices made from bioerodible polymers have been used to increase the stability of 
macromolecular drugs by preventing exposure to conditions which could cause 
denaturing[4], target specific organs and tissues by modifying the surface of the device to 
confer affinity for specific cell types[5], and achieve sustained and controlled drug release 
profiles by modulating the release rate [6-12]. 
There are two primary mechanisms of drug release exhibited by bioerodible, 
polymeric, controlled-release devices. These two mechanisms of release are illustrated in 
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Figure 1.1. Diffusion-controlled release occurs when drug release is governed by diffusion 
of dissolved drug from the device in response to a concentration gradient. This is the typical 
release mechanism of hydrogel systems that swell in the presence of water, facilitating drug 
diffusion. Diffusion-controlled drug release occurs over a time scale that is short with 
respect to the time scale of device erosion. In contrast, erosion-controlled release occurs 
when diffusion is much slower than device erosion. Erosion-controlled devices typically do 
not swell. Rather, dissolved drug is released as the device shrinks. 
a. 
V •' o • 
Swelling Diffusion within swollen 
zone, continued swelling 
Diffusion, continued 
swelling, device erosion 
A A 4 
A A 
• IB A 
Erosion Erosion, release Erosion, release' 
A A A 
A A 
Figure 1.1. Two mechanisms of drug release: Diffusion-controlled release (a.) is governed 
by swelling of the polymer matrix and diffusion of solute (triangles) within the device (dark 
gray areas represent unswollen polymer, light gray areas represent swollen polymer). 
Erosion-controlled release (b.) does not involve appreciable swelling or drug diffusion, but is 
governed by device shrinkage. 
Note that erosion control occurs when water is prevented from penetrating into the 
bulk of the polymer. Many bioerodible polymers exhibit "bulk" erosion, allowing water to 
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penetrate into the bulk of the polymer and degrade it from the inside. When swelling and 
bulk erosion occur over similar time scales, the kinetics of drug release are more complex 
than simple diffusion-controlled release. A good review of controlled release from polymers 
is given by Ottenbrite[13], 
Langer, Mathiowitz, and co-workers have shown that polyanhydrides are a 
particularly promising class of polymers for drug delivery, due to their chemistry[6-9,12, 14-
18] and biocompatibility[ 19-24]. Polyanhydrides of aliphatic and aromatic dicarboxylic 
acids have hydrophobic regions separated by relatively hydrophilic acid anhydride bonds. 
The general structures of these polyanhydrides are illustrated in Figure 1.2. 
O O 
Il II 
-- (CH2)n - C — O — C -
o O 
// \ O — (CH2)m — O / /  i - O - C  
Figure 1.2. Generalized chemical structures for aliphatic poly(dicarboxylic alkane 
anhydride) (top) and aromatic poly[bis-p(carboxyphenoxy) alkane] (bottom). 
The anhydride bonds are hydrolyzed under physiological conditions, resulting in 
polymer degradation and subsequent erosion. However, water does not penetrate into the 
bulk of the hydrophobic polymer[25]. Thus, degradation and erosion occur at the surface, 
rather than in the bulk. Since water is prevented from penetrating into the bulk of the device, 
surface eroding polymers are particularly well suited for sustained release and drug 
stabilization. Additionally, polyanhydrides of varying hydrophobicity have erosion rates that 
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span several orders of magnitude[6]. The potential for not only sustaining the release of a 
drug, but also achieving desirable release profiles can be realized by combining 
polyanhydrides with differing erosion rates in an advantageous way. 
Like most polymer blends, binary blends of aliphatic and aromatic polyanhydrides 
tend to phase-separate based on thermodynamic compatibility. Polyanhydride copolymers 
have also been shown to microphase separate when their composition is rich in one 
component[26]. Typically, microphase separation is a property of block copolymers. 
However, the polyanhydride monomers discussed here are sufficiently long, and the 
segment-segment interaction parameter sufficiently high that microphase separation occurs 
even in random copolymers. For extreme compositions, the high relative abundance of one 
component results in a "block-like" structure for the copolymer with relatively long 
sequences of the more abundant monomer punctuated by short sequences of the less 
abundant monomer. This "block-like" characteristic permits microphase separation similar 
to that observed for true block copolymers. Copolymers with compositions near 50:50 do 
not microphase-separate since relatively long sequences of one monomer are extremely rare. 
Microphase separation is an additional property of polyanhydride systems that can be 
exploited to aid in the stabilization of macromolecular drugs and tailoring release profiles. 
Bioerodible polymer microspheres as drug delivery vehicles offer the advantage of 
not requiring surgical implantation, since they can be injected in suspension; they also do not 
require surgical removal. Also, since the drug loaded in a microsphere remains separated 
from that in other microspheres, a further advantage is the potential to administer multiple 
drugs in a single injection, which for compatibility reasons would otherwise need to be 
separated. 
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The design of injectable vaccine delivery vehicles composed of bioerodible polymer 
microspheres requires a detailed understanding of microstructural characteristics of the 
polymer, interactions between the polymer matrix and the antigen, and the release 
characteristics of the system. The microstructural characteristics of interest include the 
morphology of the microphase separation, the length scale of the microdomains, and the 
crystallinity of the polymer matrix. All of these characteristics have the potential to affect 
the erosion and drug release kinetics. Interactions between the antigen and the polymer 
include desirable interactions that increase the solubility of the antigen in the polymer, 
conserve its biological activity, and partition it preferentially into phase-separated 
microdomains. Undesirable interactions may cause the antigen to denature or cause it to 
become insoluble in the polymer matrix. Also, as the polymer is degraded, the degradation 
products must not interact unfavorably with the antigen. The release kinetics is determined 
primarily by the phenomena associated with polymer erosion. For surface eroding polymers, 
erosion can be described as the sum of three processes: polymer degradation, dissolution of 
degradation products, and diffusion of monomer and drug from the device. The polymer 
erosion may also be affected by the presence of the drug itself (e.g. dissolved drug may 
reduce the crystallinity of the polymer, thereby enhancing the degradation rate). 
The overall objective of this work is to develop a controlled-release device based on 
polyanhydride microspheres for the delivery of tetanus toxoid (TT). This will be 
accomplished by meeting the following three goals: 
1. Describe in detail the microstructure of polyanhydride copolymers and the effects of 
this microstructure on drug/antigen distribution within and release from microphase-
separated polyanhydrides. 
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2. Design TT-loaded polyanhydride microspheres and perform in vitro and in vivo 
studies to discern antigen release profiles and antibody production in order to 
maximize protective immunity. 
3. Formulate and solve a mathematical model to predict and tailor copolymer 
microstructure effects on drug/antigen release mechanisms. 
The polymer system selected for this study is copolymers of sebacic acid (SA) and 
1,6-bis(p-carboxyphenoxy)hexane (CPH). The repeat units of this polymer system are 
shown in Figure 1.3. 
Figure 1.3. Structures of poly[ 1,6-bis(j?-carboxyphenoxy)hexane], poly(CPH), (left) and 
poly(sebacic acid), poly(SA), (right). 
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Bioerodible polymers offer a unique combination of properties that can be tailored to 
suit nearly any controlled drug delivery application. By far the most common bioerodible 
2.1 Introduction 
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polymers employed for biomedical applications are polyesters and polyethers (e.g. 
poly(ethylene glycol), polylactide, polyglycolide and their copolymers). These polymers are 
biocompatible, have good mechanical properties, and have been used in many controlled 
release applications. However, their chemistries are limited, thereby restricting structural 
modifications resulting in tailored properties. Over the past two decades, researchers have 
begun investigating alternative biodegradable polymers, resulting in a vast body of literature 
on both the synthesis of, and mechanisms of drug release from, biodegradable polymers. 
Drug release may be controlled by several mechanisms including diffusion of the 
drug through a matrix, dissolution of the polymer matrix, and degradation of the polymer. 
The chemistry of the polymer matrix may be tailored to facilitate drug stabilization, target 
delivery to specific tissues, or alter the release kinetics. Bioerodible polymers erode in vivo, 
thus obviating the need for surgical removal after the useful lifetime of the device has 
expired. The erosion may actually determine the drug release kinetics, or may occur on a 
time scale much slower than that of drug release. 
It is important to distinguish between erosion and degradation. Erosion is mass loss 
from a bioerodible polymer and may be a consequence of polymer dissolution or degradation 
of the polymer backbone, followed by dissolution of the degradation products. Degradation 
typically occurs by hydrolysis of the polymer backbone, the kinetics of which is a function of 
the polymer chemistry. Thus, erosion is the sum of several elementary processes, one of 
which may be polymer degradation. 
Some biodegradable chemistries are listed in Table 2.1 (Pierre and Chiellini, 1986; 
Staubli et al., 1990; Weinberg et al., 1998; Siepmann and Goepferich, 2001). Pierre and 
Chiellini (1986) have summarized hydrolysis mechanisms for many biomedically relevant 
systems. Degradation half-lives range from millennia (for amides, carbonates, and 
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urethanes) to minutes (for the fastest degrading anhydrides) (Pierre and Chiellini, 1986). 
Though all of these chemistries are hydrolyzable, hydrolysis rates vary depending not only 
on the functional group (Pierre and Chiellini, 1986; Albertsson, 1995), but also what lies 
between the functional groups. Polyyanhydrides, for example, are one of the most labile 
classes, and their hydrolysis is shown in Scheme 2.1. 
Table 2.1. Functional groups found in bioerodible polymers. 
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Scheme 2.1. Hydrolysis of polyanhydrides to carboxylic acids. 
Erosion is typically characterized by either occurring on the surface or in the bulk. 
Surface erosion is controlled by the chemical reaction and/or dissolution kinetics, while bulk 
erosion is controlled by diffusion and transport processes such as polymer swelling, diffusion 
of water through the polymer matrix, and the diffusion of degradation products from the 
swollen polymer matrix. The processes of surface and bulk erosion are compared 
schematically in Figure 2.1. These two processes are idealized descriptions. In real systems, 
the tendency towards surface versus bulk erosion behavior is a function of the particular 
chemistry and device geometry (Tamada and Langer, 1993). Surface erosion may permit the 
stabilization of macromolecular drugs and offers the potential to tailor release profiles by 
tailoring the composition and drug distribution. 
Polyanhydrides are typically characterized as surface eroding because the anhydride 
bond itself is quite reactive with respect to hydrolysis, but the structure of the dicarboxylic 
acid monomer can render the polymer very hydrophobic, thereby limiting water ingress. 
These materials are interesting for controlled drug delivery due to the wide range over which 
the degradation kinetics can be varied. Thus, polyanhydrides have emerged as an extremely 
diverse and promising class of polymers for drug delivery and other biomedical applications. 
This review will discuss the novel chemistries and synthesis, characterization, and 
applications of polyanhydrides as surface erodible biomaterials for drug delivery. 
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Figure 2.1. Schematic comparing surface and bulk erosion. In surface erosion (top), water 
does not penetrate far into the bulk, but hydrolyzes functional groups on the surface. The 
resulting monomers dissolve and diffuse away from the device. In bulk erosion (bottom), 
water penetrates into the bulk, polymer may dissolve, and is ultimately hydrolyzed into 
monomer. 
Several synthesis routes have been investigated to design polyanhydrides, and these 
are discussed in Section 2.2. Section 2.3 reviews the microstructural characterization of 
homopolymers, blends, and copolymers of polyanhydrides. Section 2.4 discusses the 
important features that affect erosion and drug release kinetics and reviews some of the 
modeling efforts that have been undertaken to predict erosion and drug release. Section 2.5 
discusses the design of polyanhydride drug carriers with respect to delivery routes, 
mechanisms of release, and factors affecting release profiles. Finally, Section 2.6 presents 
some of the future directions for polyanhydride research. Polyanhydrides have a variety of 
microstructural characteristics that affect the release profiles of encapsulated drugs. It is 
important to accurately describe the microstructure to predict and tailor drug release profiles. 
If the effects of these microstructural characteristics can be accurately understood, they can 
13 
be exploited to control drug release profiles and effectively design controlled release 
formulations. 
2.2 Chemistry and Synthesis 
2.2.1 Early synthesis of polyanhydrides 
Synthesis of polyanhydrides from the aromatic dicarboxylic acids (isophthalic and 
terephthalic acids) by melt polycondensation was first reported by Bucher and S lade in 1909. 
In the early 1930's Hill and Carothers explored the synthesis of aliphatic polyanhydrides for 
use as fibers for the textile industry. Hill (1930) reported the polymerization of the aliphatic 
adipic acid, and later, Hill and Carothers (1932) reported the polymerization of sebacic acid, 
both by melt polycondensation and dehydrochlorination. The melting points of these 
polymers were too low and hydrolysis was too fast for them to be of use as fibers, and the 
study of anhydrides was abandoned. 
In the late 1950's through the mid 1960's Conix (1957; 1958; 1966) reported the 
synthesis of the poly[a,co-bis(p-carboxyphenoxy)alkanes], improving the fiber and film 
forming properties of polyanhydrides. From 1959-1962, Yoda (1959; Yoda and Akihisa, 
1959), being encouraged by the work of Conix, synthesized random copolymers by melt 
polycondensation and alternating copolymers by dehydrochlorination, from a variety of 
aliphatic and aromatic monomers in attempts to improve the fiber and film properties of 
polyanhydrides. Windholz (1965) later patented a similar process for producing 
polyanhydrides as intermediates in the production of polyesters. Polyanhydride 
homopolymers and copolymers containing heterocyclic rings (Yoda, 1962a; Yoda, 1962b), 
and aliphatic and aromatic thioethers (Yoda, 1962c) were also synthesized by Yoda. Despite 
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these efforts, polyanhydrides remained inferior to polyesters and other classes of polymers, 
never gaining prominence in the textile industry. 
2.2.2 Synthesis of polyanhydrides for drug delivery 
Interest in polyanhydrides waned until the 1980's when Langer and coworkers 
(Rosen et al., 1983) suggested that their biodegradability would make them suitable for 
controlled drug delivery applications. Their initial study was conducted with poly[bis(p-
carboxyphenoxy)methane] (PCPM) made by melt polycondensation and they showed near 
zero order release kinetics of a model drug (cholic acid) from compression-molded PCPM 
slabs (Rosen et al., 1983). These first results on drug release from polyanhydrides initiated 
what has now been two decades of extensive research. The same group studied additional 
chemistries (Leong et al., 1985) as well as alternate synthetic routes (Leong et al., 1987). 
The melt polycondensation and dehydrochlorination syntheses discussed in Section 2.2.1 
were explored, along with a third route, dehydrative coupling (Leong et al., 1987; Chasin et 
al, 1988). An alternative solution technique for the polymerization of poly(terephthalic 
acid) (PTA) is offered by Subramanyam and Pinkus (1985). Domb et al. (1993) reviewed 
several polymerization methods including melt polycondensation, ring opening 
polymerization, solution polymerization (dehydrohalogenation and dehydrative coupling), 
and interfacial polymerization (dehydrohalogenation). A review of the important 
polyanhydride synthesis routes follows. 
2.2.2.1 Melt polycondensation. Melt polycondensation is performed by first 
acetylating the dicarboxylic acids by refluxing in excess acetic anhydride in a dry 
atmosphere, and then melting under vacuum to remove the condensation byproduct. This 
procedure is represented in Scheme 2.2. Domb and Langer (1987) improved upon the melt 
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polycondensation technique (Scheme 2.2) to obtain higher molecular weight homopolymers 
and copolymers of aliphatic and aromatic dicarboxylic acids. They obtained weight average 
molecular weights of up to 137,300, for poly(sebacic acid) (PSA). In the same study (Domb 
and Langer, 1987), the synthesis of poly[ 1,3-bis(p-carboxyphenoxy)propane] (PCPP), 
poly[ 1,6-bis(p-carboxyphenoxy)hexane] (PCPH), poly( 1,4-phenylenedipropionic acid) 
(PPDP), and poly(dodecanedioic acid) (PDDA), as well as the copolymers P(CPP-SA), 
P(CPP-DDA), and the copolymer of sebacic acid with isophthalic acid P(IPA-SA) was 
reported. A method for copolymer synthesis was patented by the same authors (Domb and 
Langer, 1988b). 
HO-U—R-J—OH + HO-M—CH^U—OH H c_il_L0JJ_R JLLC)-!!— CH3 
2 Ar, N2 3 L Jn 3 
O O O O  O O O O  
H3C-Jto-^R-^to J—CH3 -heat~ H3C—Îto J—R-J-^-O^J—CH3 3 1 Jn 3 vacuum 1 Jm»n 
Scheme 2.2. Polyanhydride synthesis via melt polycondensation involves first the formation 
of oligomeric acetylated prepolymers, followed by condensation under vacuum. Acetic acid 
is formed as a byproduct of the second reaction. 
Methods employing a variety of coordination catalysts were also reported (Domb and 
Langer, 1987). The anhydride interchange reaction mechanism for the melt 
polycondensation (Scheme 2.3) has been proposed by Albertsson and Lundmark (1990a). 
This mechanism may also result in the formation of lower molecular weight cyclic 
macromers and contribute to the high polydispersity characteristic of the resulting polymers 
(Domb and Langer, 1987). Gupta (1989) patented a melt polycondensation procedure from a 
bis(trimethylsilyl)ester of a dicarboxylic acid and a diacid chloride that produces alternating 
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copolymers. The majority of recent work with polyanhydrides has been conducted using the 
polycondensation synthesis originated by Conix (1966) and later improved upon by Domb 
and Langer (1987). 
O O 
R—U—o—U—CH3 
R
'~ir°~irCH> 
o o 
Scheme 2.3. Anhydride interchange mechanism proposed for polymerization. The same 
mechanism may be responsible for cyclization. 
2.2.2.2 Dehydrochlorination. In the dehydrochlorination synthesis developed by 
Yoda (1959; Yoda and Akihisa, 1959) diacid chlorides are first formed by either reacting 
dicarboxylic acids with phosphorous pentachloride or refluxing dicarboxylic acids in thionyl 
chloride. Reaction is then carried out in the presence of pyridine. Dehydrochlorination, 
(Schotten-Baumann condensation) offers two main advantages over melt polycondensation. 
First, it can be performed at much milder temperatures. Second, the copolymer sequence can 
be precisely controlled to form alternating copolymers. Leong et al. (1987) studied this route 
both as a solution technique, and at aqueous and non-aqueous interfaces. In general, 
somewhat lower molecular weights are obtained by this method than by the melt 
polycondensation (Leong et al., 1987). 
2.2.2.3 Dehydrative coupling. The third synthesis mechanism studied by Leong et 
al. (1987) is an extension of a technique used by previous researchers (Cabré-Castellvi et al., 
1981; Mestres, 1981) to form monomeric anhydrides, employing strong dehydration agents 
(e.g. organophosphorous compounds) such as those employed in peptide synthesis. A variety 
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of dehydration agents were studied. Of the three synthesis methods studied by Leong et al. 
(1987), this one yielded the lowest molecular weight, and presented the most difficulties with 
respect to product purification. 
To address purification, Domb and Langer (1988a) developed two techniques 
involving phosgene or diphosgene as coupling agents, both of which are single step 
polymerizations yielding pure product, by selective dissolution of either the polymer or the 
byproducts. A variety of polymers were synthesized including PSA, PCPP, PTA, PAA, 
PDDA, though only with PSA was a weight-average molecular weight above 15,000 
(16,300) obtained. Most of the polymers had weight-average molecular weights less than 
10,000. The advantages of this method are that relatively pure polymers are obtained without 
the exposure to extreme temperatures (Domb and Langer, 1988a). 
2.2.2.4 Ring opening polymerization. Dicarboxylic acid monomers that form 
monomelic anhydride rings, such as adipic anhydride (oxepane-2,7-dione), can be 
polymerized by ring-opening polymerization (Albertsson and Lundmark, 1988). A catalyst 
such as tin 2-ethylhexanoate, tin octanoate, aluminum isopropoxide, or «-butyl lithium is 
added and the reaction proceeds via an insertion mechanism (Albertsson and Lundmark, 
1990b; Edlund and Albertsson, 1999). Ring opening can be performed both in solution and 
in the melt (Albertsson and Lundmark, 1988; Albertsson and Lundmark, 1990b). Ropson et 
al. (1997) reported a mechanism for insertion in living polymerizations of adipic anhydride 
using aluminum alkoxides as initiators. Ring opening polymerizations are limited to 
chemistries capable of forming rings, but offer the capability of easily forming block 
copolymers via living polymerizations. Block copolymers of adipic anhydride with e-
caprolactone (Ropson et al., 1997) and trimethylene carbonate (Edlund and Albertsson, 
1999) have been formed by this synthetic route. Deng et al. (2003) have cleverly 
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surmounted the chemistry limitation by using potassium poly(ethylene glycol)ate as a macro-
initiator, thereby synthesizing a poly(adipic acid-Moc&-ethylene glycol) copolymer. The 
same group has also recently studied the use of dibutylmagnesium as an alternative initiator 
(Li et al., 2003). 
2.2.2.5 Polymerization with ketene. In an attempt to avoid the polymerization/ 
depolymerization equilibrium that occurs during melt polycondensation, Albertsson and 
Lundmark (Albertsson and Lundmark, 1988) also studied the irreversible reaction of adipic 
anhydride with ketene. However, they reported very little difference in molecular weights 
when two ketene syntheses were compared to melt polycondensation and ring-opening 
polymerization using a zinc catalyst (Albertsson and Lundmark, 1988). 
2.2.3 Chemistries of polyanhydrides used in drug delivery 
We have already mentioned a few of the polyanhydride chemistries that have been 
studied in drug delivery applications. Tables 2.2 through 2.7 present some of the 
polyanhydrides that have been explored for drug delivery applications and we briefly discuss 
the literature on each one. Copolymers are discussed separately. 
2.2.3.1 Aliphatic polyanhydrides. Aliphatic polyanhydrides (Table 2.2) together 
with the a,co-bis(p-carboxyphenoxy)alkanes are the most commonly studied polyanhydrides 
for drug delivery applications. Poly(sebacic acid) (PSA) was first suggested as a polymer for 
drug delivery by Langer and coworkers in 1987 and was among the monomers on which they 
studied alternative synthesis methods (Domb and Langer, 1987; Leong et al., 1987). 
Poly(dodecanedioic acid) (PDDA) is also synthesized by melt polycondensation and yields 
similar molecular weights (Domb and Langer, 1987). The synthesis of poly(adipic acid) 
(PAA) by multiple methods was discussed in Section 2.2.2. Poly(l ,4-cyclohexyldicarboxylic 
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acid) (PCDA) was first synthesized via melt polycondensation by Zhang el al. (2000; 2001). 
Domb and Nudelman (1995) reported the synthesis of the series of aliphatic polyanhydrides 
from PAA to poly(dodecanedicarboxylic acid) (PDX). 
Table 2.2. Aliphatic polyanhydrides. 
Structure Name 
O O 
II / X II 
x = 4 Poly(adipic acid) 
x = 5 Poly(pimelic acid) 
x = 6 Poly(suberic acid) 
x = 7 Poly(azalaic acid) 
x = 8 Poly(sebacic acid) 
x = 10 Poly(dodecanedioic acid) 
x = 12 Poly(dodecanedicarboxylic acid) 
PAA 
PPA 
PSA 
PAZ 
PSA 
PDDA 
PDX 
-o-
O O 
JL Poly(1,4-cyclohexane dicarboxylic acid) PC DA 
2.2.3.2 Polyanhydrides from unsaturated and fatty acid-derived monomers. 
Polyanhydrides based on unsaturated and fatty acid-derived monomers are shown in Table 
2.3. Poly(fumaric acid) (PFA) was fist synthesized by Domb et al. (1991) by both melt 
polycondensation and solution polymerization. The copolymer of fumaric acid and sebacic 
acid (P(FA-SA)) has been synthesized and characterized (Mathiowitz et al., 1990b; Domb et 
al., 1991). The mucoadhesive properties of this polymer have been shown to aid in 
increasing the bioavailability of encapsulated model drugs in oral delivery experiments 
(Chickering et al., 1995; Chickering et al., 1996). 
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Table 2.3. Polyanhydrides from unsaturated and fatty acid derived monomers. 
Structure Name 
O O 
-O-N—CH=CH Poly(fumaric acid) PFA 
O 
CHrt-CHj-Jj-CH -f-CHj-fi 
o 
0-lLf-CH2-^CH-(-CH2-^CH, 
Poly(Fatty acid dimer) 
(erucic acid) PFAD 
O O 
-O 'I ( CH;-)yCH=CH CH 
ch3-(-ch2-^ 
CH3-f-CH2-^-CH; 
Poly(Dimer acid) PDA 
Fatty acids have also been converted to difunctional monomers for polyanhydride 
synthesis by dimerizing the unsaturated erucic or oleic acid to form branched monomers. 
These monomers are collectively referred to as fatty acid dimers and the polymers are 
referred to as poly(fatty acid dimer) (PFAD). PFAD (erucic acid dimer) was synthesized by 
Domb and Maniar (1993) via melt polycondensation and was a liquid at room temperature. 
Desiring to increase the hydrophobicity of aliphatic polyanhydrides such as PSA without 
adding aromaticity to the monomers (and thereby increasing the melting point), Teomim and 
Domb (1999) and Krasko et al. (2002) have synthesized fatty acid terminated PSA. 
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Octanoic, lauric, myristic, stearic, ricinoleic, oleic, linoleic, and lithocholic acid acetate 
anhydrides were added to the melt polycondensation reactions to obtain the desired 
terminations. As desired, a dramatic reduction in the erosion rate was obtained (Teomim and 
Domb, 1999; Krasko et al., 2002). 
Teomim and Domb (Teomim and Domb, 2001) report the termination of PSA with 
monoesters of ricinoleic acid (i.e. cis-12-hydroxyoctadeca-9-enoic acid) and fatty acids. The 
fatty acids used in this study range in length from CIO to CI 8. The combination of PSA with 
FAD is not limited to terminal modification. P(FAD-SA) and P(fatty acid trimer-SA) 
(P(FAT-SA)) copolymers have been synthesized (Domb and Maniar, 1993) and their release 
properties have been studied (Tabata et al., 1993; Tabata and Langer, 1993; Shieh et al., 
1994; Tabata et al., 1994). 
Xu et al. (2001) synthesized the copolymers of a dimer fatty acid (dimer of oleic and 
linoleic acids) and sebacic acid (P(DA-SA)) by melt polycondensation of acetylated 
prepolymers. Degradation and drug release kinetics showed that increasing dimer acid 
content decreased the release rate (Xu el ai, 2001). 
Another class of PSA-fatty acid-based copolymers has been synthesized from the 
ricinoleic acid and ricinoleic half-esters with maleic and succinic anhydride, poly(sebacic-co-
ricinoleic acid maleate), poly(sebacic-co-ricinoleic acid succinate), and poly(sebacic-co-12-
hydroxystearic acid succinate) (P(SA-RAM), P(SA-RAS), and P(SA-HSAS)) (Teomim et 
al., 1999; Krasko et al., 2003). These syntheses result in poly(anhydride-co-esters). 
2.2.3.3 Aromatic polyanhydrides. Aromatic polyanhydrides (Table 2.4) are typically 
characterized by slow degradation rates, high melting temperatures, brittle mechanical 
properties, and low solubility in organic solvents compared to the aliphatic polyanhydrides. 
PCPM was the first aromatic polyanhydride to be synthesized as a candidate for controlled 
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Table 2.4. Aromatic polyanhydrides. 
Structure Name 
o-c-X \ // 
x = 1 Poly[bis(p- PCPM 
O carboxyphenoxy) methane] 
x = 3 Poly[1,3-bis(p- PCPP 
~ carboxyphenoxy) propane] 
x = 6 Poly(1,6-bis(p- PCPH 
carboxyphenoxy) hexane] 
-O-C—(\ />—c- Poly(Terephthalic acid) PTA 
Poly(isophthalic acid) PIPA 
O 
-O-C-f-CHj) x I I  -CH^C- Poly(phenylene dipropionic 
n acid) PPDP 
O 
— O — u — C H j - S —  C H ^ r  ch2-s-ch2 111 P°iy[2.2'-(p-j?| xylenedithio)diacetic acid] PXDA 
o-f-cHr} 
o 
x = 1 Poly[2-(p- PC PA 
carboxyphenoxy) acetic acid] 
x = 4 Poly[5-(p- PCPV 
carboxyphenoxy) valeric acid] 
x = 7 Poly(8-(p- PCPO 
carboxyphenoxy) octanoic acid] 
x = 3 Poly[1,3-bis(o-
carboxyphenoxy)propane] 
x = 6 Poly[1,6-bis(o-
carboxyphenoxy)hexane] 
Po-CPP 
Po-CPP 
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Table 2.4. (continued) 
Structure Name 
O-CH. ChL-O 
m , Poly[o-bis(p-
x û c j carboxyphenoxy)xylene] Po-p-CPX 
Poly[zn-bis(p- Pm-p-CPX 
carboxyphenoxy)xylene] 
O-CH CHHD 
Poly[o-bis(o-
carboxyphenoxy)xylene] 
Poly[m-bis(o-
carboxyphenoxy)xylene] 
Poly[p-bis(o-
carboxyphenoxy)xylene] 
Po-o-CPX 
Pm-o-CPX 
Pp-o-CPX 
O 
-o-
CF. O 
CF, 
Poly[4,4'-
(hexafluoroisopropylidine) 
bis-benzoic acid] 
PHFB 
drug delivery (Rosen et al., 1983). Other polymers in family of poly[a,&-(p-
carboxyphenoxy)alkanes that had originally been synthesized by Conix (1957; 1958; 1966) 
soon followed including PCPP, poly(terephthalic acid) (PTA) (Leong et al., 1985), and 
PCPH (Leong et al., 1987). Also included in the later study were poly(terephthalic-a/Z-
sebacic acid) (P(SA-a//-TA)), poly( 1,4-phenylene dipropionic acid) (PPDP) and poly[2,2'-
(p-xylylenedithio)diacetic acid] (PXDA) (Leong et al., 1987). Domb et al. (1989) 
synthesized several polyanhydrides based on co-carboxyphenoxyalkonoic acids including 
poly(carboxyphenoxy acetic acid) (PCPA), poly[5-(p-carboxyphenoxy)valeric acid] (PCPV), 
and poly[8-(p-carboxyphenoxy)octanoic acid] (PCPO) by melt polycondensation and studied 
the release of model drugs from them. Domb (1992) also synthesized poly(isophthalic acid) 
(PIPA) and poly(terephthalic acid) (PTPA) by melt polycondensation. 
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Campo et al. (1999) synthesized the ortho- isomers of PCPP and PCPH, poly[l,3-
bis(o-carboxyphenoxy)propane] (Po-CPP) and poly[ 1,6-bis(o-carboxyphenoxy)hexane] (Po-
CPH), in an attempt to improve the solubility and processability of these two polymers. 
Solubility was improved and crystallinity reduced, but Tgs were also lowered to below 
physiological temperature, which may limit their applicability as biomaterials. 
In an attempt to increase Tg of the poly[bis(o-carboxyphenoxy)alkanes], Anastasiou 
and Uhrich (2000a) replaced the alkane moiety by ortho-, meta-, and para-xylenes producing 
poly[o-/m-bis(p-carboxyphenoxy)xylene]s (Po-p-CPX, and Pm-p-CPX) and poly\o-/m-/p-
bis(o-carboxyphenoxy)xylene] s (Po-o-CPX, P/w-o-CPX, and Pp-o-CPX). They found Po-p-
CPX to be relatively insoluble and were unable to synthesize poly[p-bis(p-
carboxyphenoxy)xylene] because of the insolubility of the dicarboxylic acid (Anastasiou and 
Uhrich, 2000a). Po-o-CPX and Pm-o-CPX demonstrated the most favorable solubility and 
neither exhibited a melting temperature. All of the polymers synthesized had Tgs between 71 
and 101 °C (Anastasiou and Uhrich, 2000a). 
2.2.3.4 Copolymers of aliphatic and aromatic polyanhydrides. Researchers interested 
in polyanhydrides as candidates for drug delivery realized the value of co polymerizing 
aliphatic and aromatic residues. In this way, a large number of polymers could be made from 
only a handful of chemistries and chemical and physical properties could be tailored by 
combination. Initially, the goal was to obtain a variety of release times by making simple 
changes to the copolymer composition. The first such copolymer was P(CPP-SA) 
synthesized via melt polycondensation by Leong et al. (1985). The alternating copolymers 
of adipic acid, sebacic acid, and dodecanedioic acid with terephthaloyl chloride (?(AA-alt-
TA), P(SA-a//-TA), and P(DDA-aZf-TA)) and sebacic acid with isophthaloyl chloride and 
P(IPA-a/f-SA)) were produced by dehydrochlorination and the random copolymers P(CPM-
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SA) and P(CPH-SA) were produced by melt polycondensation for the first time in the 
extensive study by Leong et al. (1987). The copolymers P(IPA-SA) and P(CPP-DDA) via 
melt polycondensation were added to the repertoire of copolymers by Domb and Langer 
(1987). Domb (1992) later synthesized the copolymers P(CPP-IPA), P(IPA-TA), P(IPA-
FA), P(CPP-FA), P(FA-TA), P(SA-TA), and P(IPA-SA). 
Sanders et al. (1999) attempted to lower the melting points of aromatic 
polyanhydrides by substituting branched alkyl groups in place of the linear alkyls of P(CPP-
SA). They synthesized poly[ 1,2-bis(p-carboxyphenoxy)propane-co-sebacic acid] (P(l,2-
CPP-SA)), poly[ 1,3-bis(p-carboxyphenoxy)-2-methyl propane-co-sebacic anhydride] 
(P(CPMP-SA)), and poly [ 1,3 -bis(p-carboxyphenoxy)-2,2-dimethyl propane-co-sebacic 
anhydride] (P(CPDP-SA)), all of which had melting points below 165 °C. 
2.2.3.5 Poly(anhydride-co-imide)s. Another important class of polyanhydrides is the 
poly(anhydride-co-imide)s (Table 2.5). This class of polymers was first synthesized by 
Fontân and co-workers (De Abajo et al, 1971; Gonzalez et al, 1976) as potential candidates 
for fiber forming polymers. Staubli et al. (1990) developed a technique for incorporating 
amino acids into polyanhydrides by first reacting them with N-trimellitic acid. Uhrich et al. 
(1995) synthesized copolymers of trimellitylimido glycine, pyromellitylimido alanine and the 
monomers of PSA and PCPH by melt polycondensation and proposed the use of 
(P(TMAgly-SA), P(TMAgly-CPH), P(PMAala-SA), and P(PMAala-CPH)) as potential 
candidates to improve the mechanical properties of polyanhydrides. Flânes et al. (1996) later 
synthesized the copolymer of trimellitylimido L-tyrosine with PSA and PCPP (P(TMAtyr-
CPP-SA)) as a candidate polymer for vaccine delivery. 
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Table 2.5. Poly(anhydride-co-imide)s. 
Structure Name 
-O 
O 
O 
N-CH, 
* 
o o 
Poly(trimellitylimido 
glycine) PTMAgly 
-O 
O 
N 
O O 
-O 
O 
CH. 
N 
à o 
OH 
// 
CH. 
N-CH 
Poly(pyromellitylimido 
alanine) 
Poly(trimellitylimido 
tyrosine) 
PMAala 
PTMAtyr 
2.2.3.6 Poly(anhydride-co-ester)s and poly(anhydride-co-ether)s. Poly(anhydride-
co-ester)s (Table 2.6) were suggested as potential polymers for drug delivery and 
synthesized by Pinther and Hartmann (1990), and Kricheldorf and Jiirgens (1994). Other 
poly(anhydride-co-ester)s already mentioned in Section 2.2.2.4 include poly(adipic acid-
MocA>s-caprolactone) (V(AA-block-£-CL)), poly(adipic acid-6/ocA:-trimethylene carbonate) 
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Table 2.6. Poly(anhydride-co-ester)s. 
Structure Name 
CH — CH;rCH —CH —(— 
O—jp CH=CH 
O 
O A o Poly(Riconleic acid maleate) 
CH3-(-CH^CH-CH2-CH 
O C 
O 
CH3-(-CH2-^-ÇH —(-CH2-jJx 
O m CH 
L- O 
O 
A 
o 
o o. 
,o ex 
o o 
Poly(Ricinoleic acid 
succinate) 
RAM 
RAS 
Poly(12-hydroxystearic 
acid succinate) H SAS 
Poly[bis(o-
carboxyphenoxy) 
sebacate 
POPS 
O 
-o-
O 
O 11 I CH 
O 
X jn 
x = 2 poly(p-
carboxyphenoxy 
succinic monoester 
anhydride) 
PCPSM 
x = 4 poly(p- CPAM 
carboxyphenoxy adipic 
monoester anhydride) 
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(P(AA-6/ocfc-TMC)), and poly(adipic acid-i/ocÀ>ethylene glycol) (P(PAA-6/oc&-EG). 
Others have synthesized poly(anhydride-6/oc£-ethylene glycol) copolymers. Jiang and Zhu 
(1999) synthesized and characterized poly(sebacic acid-Moc/c-ethylene glycol) (P(SA-block-
EG)) and poly[(sebacic acid-co-trimellitylimidoglycine)-è/ocÂ:-ethylene glycol] (P[(SA-co-
TMA)-block-EG]) by melt polycondensation. The ethylene glycol segments were added by 
first acetylating polyoxyethylene dicarboxylic acid and then adding it to the PSA 
polymerization (Jiang and Zhu, 1999). Qiu and Zhu (2001) proposed the use of this material 
in laminated devices for pulsed release. P(SA-co-TMA-Wocfc-EG) and PSA were also used 
by Qiu and Zhu to make blends of poly[bis(glycine ethyl ester)phosphazene] in order to 
regulate the degradation rate of the phosphazene as well as to decrease its cost (Qiu and Zhu, 
2000). The in vitro and in vivo erosion kinetics of the P[(SA-co-TMA)-Wocfc-EG] containing 
blend was later studied in detail by Qiu (Qiu, 2002). 
Wu et al. (2000) showed the formation of self-assembled nanoparticles of P(SA-
block-EG) in an aqueous environment and studied their degradation as a function of pH and 
temperature. Fu et al. (2002) recently repeated the synthesis of (P(SA-block-EG) and studied 
the morphology and erosion kinetics of microspheres which they propose as vehicles for 
mucosal drug delivery. 
Poly(lactic acid) (PLA) has also been added to poly(SA) via melt polycondensation to 
produce the triblock copolymers poly(lactic acid-block-sebacic acid-block-lactic acid) (P(LA-
block-SA-block-LA)) by Slivaniak and Domb (2002). The PLA (D-, L-, and DL-) was 
incorporated by acetylation and addition to the PSA synthesis. The showed the formation of 
stable stereocomplexed particles with increased melting points and reduced solubility, and 
studied the degradation and drug release characteristics of the same (Slivniak and Domb, 
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2002). The stereocomplexes self-assemble as a consequence of the chirality in the PLA 
portions of the chains (Slivniak and Domb, 2002). 
Erdmann et al. (2000; Erdmann and Uhrich, 2000) recently synthesized novel 
poly(anhydride-co-ester)s containing salicylic acid in the backbone, by melt 
polycondensation of the disalicylic acid ester of sebacic acid, poly[bis(o-
carboxyphenoxy)sebacate] (PCPS) and the copolymer P(CPH-CPS). The release of salicylic 
acid (the active form of aspirin) from the former was studied in vitro and from the latter was 
studied in vivo (Erdmann et al., 2000; Erdmann and Uhrich, 2000). Similar polymers that 
release 5-amino salicylic acid, and p-nitro salicylic acid have been prepared by the same 
group for the treatment of Crohn's disease and tuberculosis, respectively (Anastasiou and 
Uhrich, 2000b; Krogh-Jespersen et al., 2000). 
Jiang and Zhu (2001) recently reported on the synthesis of poly(p-carboxyphenoxy 
succinic monoester anhydride) and poly(p-carboxyphenoxy adipic monoester anhydride) 
(PCPSM and PCP AM), and the copolymer P(CPAM-CPSM) as polymeric antimicrobial 
prodrugs for diseases such as malaria and hepatitis B. They also reported that PCPSM 
exhibits strong fluorescence, the intensity of which increases linearly with its molecular 
weight (Jiang et al., 2001a; Jiang et al., 2001b). They showed that when co-polymerized the 
fluorescence is maintained, though diminished approximately in proportion to the copolymer 
composition. 
2.2.3.7 Poly(anhydride-co-amide)s. The synthesis of poly(anhydride-co-amide)s 
(Table 2.7) of various chemistries was pursued by Hartmann and Schulz (1989) as a means of 
improving biocompatibility and extending the degradation times of polyanhydrides. This 
work also contains calorimetry data on the thermal transitions and spectroscopic 
characterization. 
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Table 2.7. Poly(anhydride-co-amide)s. 
Structure Name 
O 
-o- \\ // NH 
O JL o x = 2 poly{p-[carboxyphenoxy (ethyl)formamido]benzoic acid} x = 3 poly{p-[carboxyphenoxy (propyl)formamido]benzoic acid} 
x = 4 poly{p-[carboxyphenoxy 
(butyl)formamido]benzoic acid} 
PCEFB 
PCPFB 
PCBFB 
O 
-o 
CH: 
O 
NH- -CH 
O 
2 / 2  n Poly[o-acetyl-
p(carboxyethylformamido)benzoic PACEFB 
acid] 
O 
Jiang and Zhu (2001) became interested in synthesizing additional polyanhydrides 
with fluorescence after their discovery of the fluorescent properties of PCPS. They 
synthesized the series of poly(anhydride-co-amide)s poly (p- [carboxyphenoxy 
(ethyl/propyl/butyl)formamido]benzoic anhydride} (PCEFB, PCPFB, and PCBFB) (Jiang et 
al., 2001c). Only the ethyl polymer emitted strong fluorescence, which was consistent with 
their previous study of the poly(anhydride-co-ester)s of similar chemistry (Jiang and Zhu, 
2001). PCEFB can be modified with an acetyl ortho to the anhydride bond to form poly[o-
acetyl-/?(carboxyethylformamido)benzoic acid] (PACEFB), which also fluoresces and may 
have potential as a polymeric prodrug for the treatment of tuberculosis (Jiang el al., 2001b). 
The copolymers of P(CEFB-SA) and P(CACEFB-SA) were also synthesized and shown to 
exhibit decreased fluorescence in proportion to the decrease in mole fraction of the 
fluorescent monomer (Jiang et al., 2001b). These polymers may prove to be very valuable 
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for combining in vivo controlled release and drug targeting studies with non-invasive 
imaging techniques. The dependence of fluorescence on molecular weight may offer a 
powerful mechanism to conduct in situ analysis of in vivo degradation profiles (Jiang and 
Zhu, 2002). 
2.2.3.8 Other novel anhydride chemistries. The chemistry of polyanhydrides is by no 
means limited to the categories discussed in the preceding sections. A brief review of some 
of the additional chemistries that have recently been synthesized follows with a mention of 
their potential for application in drug delivery. 
2.2.3.8.1 Branched polyanhydrides. Branched PSA was synthesized by Maniar et al. 
(1990) by reacting sebacic acid in the presence of 1,3,5-benzenetricarboxylic acid and 
polyacrylic acid to improve the processability and mechanical properties of PSA. Weight 
average molecular weights above 200,000 were obtained in four of the eight compositions 
tested and all of the branched polymers had weight average molecular weights above 
140,000, though very little difference in the polymer properties from the properties of PSA 
other than molecular weight were observed (Maniar et al., 1990). Degradation profiles of the 
branched polymers were also similar to that for PSA (Maniar et al., 1990). Drug release 
profiles for these polymers are discussed in Section 2.4.1. 
2.2.3.8.2 Poly(anhydride-co-alkylene carbonate)s. Xiao and Zhu (2000) suggested 
accelerating the degradation of polycarbonates by incorporating anhydrides into the polymer 
backbone. This was accomplished by melt polycondensation of acetylated bis-
a,ro-(hydrodxy)alkalene carbonate oligomers. The polymers synthesized were 
poly(tetramethylene carbonate succinic half-ester anhydride) (PTMCSA) and 
poly(hexamethylene carbonate succinic half-ester anhydride) (PHMCSA). They observed an 
initially fast loss of molecular weight followed by much slower degradation in in vitro 
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degradation studies and attributed this to initial hydrolysis of the more labile anhydride bond, 
followed by slower hydrolysis of the carbonate bonds. 
2.2.3.8.3 Fluorinated polyanhydrides. Kaur et al. (2002) synthesized poly[4,4'-
(hexafluoroisopropylidine)bis benzoic acid] (PHFB) as an alternative to aromatic 
polyanhydrides with relatively low solubilities. Acetylated prepolymer did not polymerize 
readily by melt polycondensation, so trifluoroacetylated prepolymer was used instead and 
weight average molecular weight of up to 14,000 was obtained with some un-reacted 
monomer (Kaur et al., 2002). The authors suspected cyclization in the case of the acetylated 
prepolymer. The stability and degradation kinetics of PHFB were reported in the same study 
(Kaur et al., 2002). 
2.2.3.8.4 Poly(lithocholic acid). Gouin et al. (2000) recently reported the synthesis 
of poly(lithocholic acid) (PLCA) and its copolymer with sebacic acid (P(LCA-co-SA)) via 
both melt polycondensation and dehydrative coupling. The material was characterized 
thermally, and drug release kinetics and biocompatibility studies were also reported. 
Modulation of the release kinetics was shown via changes in the copolymer composition 
(Gouin et al., 2000). 
2.2.3.8.5 Poly(anhydride-co-urethane)s. In their investigation of polyanhydrides 
with novel chemistries, Hartmann et al. (1993) synthesized several poly(anhydride-co-
urethane)s and compared their degradation kinetics to the poly(anhydride-co-ester)s and 
poly(anhydride-co-amide)s with similar structures. Poly(anhydride-co-amide)s, and 
poly(anhydride-co-urethane)s degraded by hydrolysis of the anhydride bond only, but 
poly(anhydride-co-ester)s degraded at both the ester and the anhydride bond. 
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2.3 Polyanhydride Characterization 
2.3.1 Chemical characterization of polyanhydrides 
2.3.1.1 Chemistry of polyanhydrides assessed by FTIR and NMR. Fourier 
transform infrared spectroscopy (FTIR) and proton nuclear magnetic resonance spectroscopy 
('H NMR) have become standards for verifying the chemistry of polyanhydrides. The reader 
is referred to the synthesis literature in the previous section for spectra of specific polymers. 
The FTIR spectrum for PSA is shown in Figure 2.2. In FTIR the absorption characteristic of 
the anhydride doublets are typically found around 1740 and 1810 cm"1 for the aliphatic 
residues and 1720 and 1780 cm"1 for the aromatic residues (Domb et al., 1993). Excitation of 
the anhydride bond also absorbs at 1050 cm"1 (Leong et al., 1985). The acidic O-H bond 
absorbs between 3300 and 2500 cm"1 (Rosen et al., 1983). The combination of these 
absorbances can be used to assess hydrolytic degradation, and the relative intensities of the 
anhydride bonds can be used to verify copolymer composition. 
The analysis of ^ NMR spectra of aliphatic and aromatic polyanhydrides has been 
reported by Ron et al. (1991) and McCann et al. (1999), and Shen et al (2002), and 13C NMR 
has been reported by Heatly et al. (1998). In 'H NMR, the aliphatic protons have chemical 
shifts between 1 and 2 ppm, unless they are adjacent to electron withdrawing groups. 
Aliphatic protons appear at about 2.45 ppm when a to an anhydride bond and can be shifted 
even further when adjacent to ether oxygens. Aromatic protons typically appear with 
chemical shifts between 6.5 and 8.5 ppm and are also shifted up by association with 
anhydride bonds. 
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Wavenumbers (cm-1) 
Figure 2.2. FTIR spectra for PSA showing characteristic anhydride peaks between 1750 and 
1900 cm"1. 
The sequence distribution of copolymers can be assessed, for example in P(CPH-SA), 
by discerning the difference between protons adjacent to CPH-CPH bonds, CPH-SA bonds, 
and SA-SA bonds (Shen et al., 2002). FTIR and 'H NMR spectra for many of the polymers 
mentioned in Section 2.2 can be found in their respective references. Spectroscopy can also 
be used to assess drug-loading in these systems. Figure 2.3 is a !H NMR spectrum for p-
nitroaniline-loaded P(CPH-SA) (50:50). The combination of these two techniques provides a 
standard for verifying the chemistry of polyanhydrides. UV spectroscopy has also been 
reported for determining the chemistry of copolymers (Leong et al., 1985). 
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Figure 2.3. !H NMR of P(CPH-SA) 50:50 loaded with p-nitroaniline. 
2.3.1.2 Solubility of polyanhydrides. When Bucher and S lade first synthesized PTA 
and PIP A, they reported insolubility in low pH, aqueous media, and solubility of PTA in 
alkaline solutions. Most polyanhydrides synthesized in the century that has passed since then 
show similar behavior. Many polyanhydrides also exhibit extremely limited solubility in 
organic solvents. This can cause problems in both characterization and processing as many 
characterization techniques are conducted in solution, and co-dissolution is a common 
method of fabricating both polymer/polymer blends and polymer/drug systems. A careful 
survey of the literature reveals that chlorinated solvents (chloroform and dichloromethane 
(DCM)) are almost universal solvents (and in some cases the only solvents) for 
polyanhydrides. Leong et al. (1985) reported that PCPP and PCPH were soluble in 
tetrahydrofuran (THF) and N,N' -dimethylformamide (DMF) only immediately following 
polymerization, making characterization by GPC on these polymers rather inconvenient. 
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Domb et al. (Domb and Langer, 1987; Domb and Langer, 1988a; Domb et al., 1989) report 
the use of chloroform as a solvent for P(CPP-SA), PSA, PCPH, PPDP, PDDA, PCPV, and 
PCPO, but that PCPP, and PCP A are both insoluble in chloroform (Domb and Langer, 
1988a; Domb et al., 1989). PDDA and PAA are also reported to be soluble in chloroform 
(Albertsson and Lundmark, 1990b). Domb (1992) also studied the solubilities of PTA, 
PCPP, PIP A, and PFA in DCM, chloroform, and carbon tetrachloride and reported that all of 
them had less than 0.1% solubility (w/v). However, altering copolymer composition proved 
to be an effective method of improving the solubility of aliphatic polyanhydrides. Domb 
(1992) indicated slightly increased solublities of the 70:30 copolymers P(TA-SA), P(CPP-
SA), P(IPA-SA), and P(FA-SA), and increasing solubility as the PSA fraction was increased. 
More surprisingly, the copolymers made exclusively of the aromatic moieties (the 
hompolymers of which were insoluble) showed solubilities of greater than 1% (w/v) for 
some compositions (Domb, 1992). 
Several of the synthetic efforts outlined in Section 2.2 were motivated partially by the 
necessity of increasing the processability of polyanhydrides. Solubilities of the 20:80 
copolymers of P(CPP-SA) and P(FAD-SA) are compared by Domb and Maniar (1993). 
They reported improved solubility of the later over former in several organic solvents 
including (in order of decreasing solubility) THF, 2-butanone, 4-methyl-2-pentanone, 
acetone, and ethyl acetate. 
Altering the linearity of aromatic polyanhydrides has proven to be a successful 
strategy for increasing solubility. Campo et al. (1999) reported the solubility of Po-CPP and 
Po-CPH in THF to be 124 mg/ml and 130 mg/ml respectively. Anastasiou and Uhrich 
(2000a) reported that the ortho-isomers Po-o-CPX, Pm-o-CPX, Pp-o-CPX and Po-p-CPX 
also had improved solubilities in DMF, and all but the Pp-o-CPX had improved solubility in 
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THF, whereas the Pp-p-CVX could not be synthesized because its corresponding methyl ester 
monomer wasn't even soluble due to the rigidity of the three para- aromatic moieties in 
sequence. Other chemistries also demonstrated improved solubilities. The poly(anhydride-
co-ester)s and poly(anhydride-co-imide)s synthesized by Jiang et al. (Jiang and Zhu, 2001; 
Jiang et al., 2001c) demonstrated solubility in THF and the esters were also soluble in 
DMSO in addition to DCM. 
2.3.2 Characterization of thermal properties, crystallinity, phase behavior of 
polyanhydrides 
2.3.2.1 Thermal transitions. It is important to characterize the thermal properties of 
polyanhydrides that are proposed for drug delivery applications, as changes in crystallinity 
can affect degradation profiles and drug release kinetics. The anticipated dependences of 
chain structure on glass transition temperature (Tg) are evident in most of the polyanhydrides 
studied. The most rigid polymer, PTA, has a glass transition temperature of 245 °C and a 
melting point reported alternatively at 372 °C (Leong et al., 1985) and 400 °C (Yoda, 1963). 
As methylene groups are added to the para-aromatic polyanhydrides, the Tg and Tm generally 
exhibit systematic reductions. PCPM has a Tg reported at 86 and 92 °C and a Tm reported at 
196 °C. PCPP has a Tg that has been reported to be between 92 and 96 °C and Tm of between 
230 and 266 °C, while PCPH has a Tg that is difficult to detect, but found at 47-48 °C and Tm 
between 123 and 147 °C (Rosen et al., 1983; Leong et al., 1985; Leong et al., 1987; Domb 
and Langer, 1988a; Mathiowitz et al, 1990b; Domb, 1992; Campo et al., 1999). 
The branched aromatic polyanhydrides synthesized by Sanders et al. (Mathiowitz et 
al., 1990b; Sanders et al., 1999) demonstrated lower Tgs than the corresponding P(PCPP-SA) 
copolymers. The para- xylyl polymers synthesized by Anastasiou and Uhrich (2000a) (Pp-o-
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CPX and Pp-m-CPX) had systematically higher Tgs than the ortho- isomers (Po-o-CPX, Pm-
o-CPX, Pp-o-CPX ). 
For the aliphatic polyanhydrides, Albertsson and Landmark (1990a) report that the 
melting point increases as the number of methylenes between the anhydride bonds increases. 
For the series PAA, PSA, and PDDA, the melting points are 73, 80 and 107 °C, respectively 
(Albertsson and Lundmark, 1990a). Also, altering PSA by addition of fatty acid terminals 
lowers the melting point by as much as 12 °C from 82 °C to as low as 70 °C, depending on 
the specific fatty acid used (Teomim and Domb, 1999; Teomim and Domb, 2001). And 
PFAD is completely amorphous (Tabata and Langer, 1993). 
Staubli et al. (1991) offer an in depth analysis of the effects of sequence distribution 
on the Tg of poly(anhydride-co-imide)s and discuss the experimental results with respect to 
several applicable theoretical models of Tg. 
The change in melting point and glass transition of the copolymers as a function of 
copolymer composition are also of particular interest because this reveals information about 
the copolymer microstructure. This is discussed along with the crystallinity characterization 
in the following section. 
2.3.2.2 Crystalline Morphology of Polyanhydrides. Most of the commonly used 
polyanhydrides, including the copolymers, are semicrystalline. Crystallinity is characterized 
by a variety of techniques including differential scanning calorimetry (DSC) small-angle X-
ray scattering (SAXS) and X-ray diffraction (XRD). Optical microscopy of films can also be 
used to investigate the crystallinity of polyanhydrides. Because most polyanhydrides have 
Tms near or above room temperature, the crystallinity is a strong function of the thermal 
history. Therefore, the weight percents of crystallinity (Wc%) reported here are primarily for 
neat polymer purified and precipitated from the synthesis reaction and dried under vacuum. 
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Most of the polyanhydride homopolymers discussed here have Wc% in the range of 
50-60. For the aromatic polyanhydrides PTA and PCPP Wc% is around 60 (Mathiowitz et 
al, 1990b; Domb, 1992). As chain flexibility is increased, a corresponding decrease in the 
crystallinity is observed. PIP A and PCPH have Wc% of 50 and 20 respectively (Mathiowitz 
et al, 1990b; Domb, 1992). PFA, PSA, and PDDA all have a Wc% between 55 and 66 
(Mathiowitz et al., 1988; Mathiowitz et al, 1990b; Domb, 1992). Mathiowitz et al. (1990b) 
provide an excellent summary of the crystallinity of homopolymers and copolymers of PSA, 
PCPP, PCPH, PFA, P(SA-FA), P(SA-CPP) and P(SA-CPH) (Figure 2.4). Of the copolymers 
studied, only the copolymers P(FA-SA) in the composition range from 20:80 to 70:30 
exhibited two melting temperatures, indicating two separate types of crystals (Mathiowitz et 
al., 1990b). Data on thermal transitions, Wc%, and heats of fusion (AHf) are presented for an 
extensive range of copolymer ratios. Plots of the copolymer crystallinities as a function of 
the composition are reproduced in Figure 2.4. Crystallinity and heat of fusion data are 
summarized in Table 2.8. X-ray diffraction spectra can be found in the work by 
Subramanyam and Pinkus (1985), Leong et al. (1985), Mathiowitz et al. (1990b), and Jiang 
etal. (2001c). 
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Table 2.8. Crystallinity and thermal properties for a variety of polyanhydrides. 
Polymer Tg(°C) Tm(°C) AHf(J/g) Wc% References 
Aliphatic polyanhydrides 
PAA 70-79 37-78 (Albertsson and Lundmark, 
1988; Albertsson and 
Lundmark, 1990b; Domb and 
Nudelman, 1995) 
PPA 71.5 (Domb and Nudelman, 1995) 
PSU 77.9 (Domb and Nudelman, 1995) 
PAZ 71.8 (Domb and Nudelman, 1995) 
PSA 60 80-89 126-153 57-66 (Domb and Langer, 1987; 
Mathiowitz et al., 1988; 
Albertsson and Lundmark, 
1990b; Mathiowitz el al., 
1990b; Domb and Nudelman, 
1995) 
PDDA 88-95 107-123 56 (Domb and Langer, 1987; 
Mathiowitz et al., 1988; 
Albertsson and Lundmark, 
1990b; Domb and Nudelman, 
1995) 
PDX 94.4 (Domb and Nudelman, 1995) 
Aromatic polyanhydrides 
PTA 245 372-400 60 (Yoda, 1963; Leong et al., 
1985) 
PIA 259 50 (Domb, 1992) 
PDP a 100-113 (Domb and Langer, 1987; 
Leong et al., 1987) 
PCPM 86-92 196 (Rosen et al, 1983; Leong et 
of., 1987) 
PCPP 92-96 230-266 96.3-111 53-61.4 (Leong et al., 1985; Domb and 
Langer, 1988a; Mathiowitz et 
al., 1988; Mathiowitz et al, 
1990b; Domb, 1992; Campo et 
a/., 1999) 
aLeong et al. (Leong et al., 1987) reported that no Tg was observed above room temperature. 
bLeong et al. (Leong et al., 1987) reported that no Tg was observed above -20 °C. 
"Mathiowitz et al. (Mathiowitz et al., 1992) reported to be amorphous. 
dNo melting point observed (Anastasiou and Uhrich, 2000a). 
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Table 2.8. (condinued) 
Polymer Tg (°C) Tm (°C) AHf (J/g) Wc% References 
PCPH 47-48" 123-143 7.1 20 (Leong et al, 1985; Domb and 
Langer, 1987; Leong et al, 
1987; Mathiowitz et al, 
1990b; Campo et al, 1999) 
PCPA 185-205 (Domb et al, 1989) 
PCPV 12 50-74° (Domb et al, 1989; 
Mathiowitz et al, 1992) 
CPO 48-54 (Domb et al, 1989) 
Po-CPP 50 (Campo et al, 1999) 
Po-CPH 34 (Campo et al., 1999) 
Po-o-CPX 82 d (Anastasiou and Uhrich, 
2000a) 
Pm-o-CPX 71 d (Anastasiou and Uhrich, 
2000a) 
Pp-o-CPX 84 114 (Anastasiou and Uhrich, 
2000a) 
Po-p-CPX 101 d (Anastasiou and Uhrich, 
2000a) 
Pm-p-CPX 89 (Anastasiou and Uhrich, 
2000a) 
Other polyanhydrides 
PFA 41 246 67 60 (Mathiowitz et al., 1990b; 
Domb, 1992) 
PFAD 25-30 0 (Domb and Maniar, 1993) 
PCP AM 35.8 (Jiang and Zhu, 2001) 
PCPSM 36.4 (Jiang and Zhu, 2001) 
CEFB 81 (Jiang et al, 2001c) 
CPFB 73 (Jiang et al, 2001c) 
CBFB 60 (Jiang et al, 2001c) 
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Figure 2.4. Crystallinity of several polyanhydride copolymers as a function of composition. 
From (Mathiowitz et al, 1990b). Reprinted with permission. 
When drugs are incorporated into semicrystalline polymers, the crystallinity may be 
altered, depending on the interactions between the polymer and the drug (Shen et al., 2001a). 
The effects of drug loading on polymer crystallinity may offer some insights into release 
kinetics as will be discussed in Section 2.4.1. Mathiowitz et al. (1990a) reported the changes 
in melting point and degree of crystallinity for PSA and P(CPP-SA) 50:50 loaded with 
various model drugs at different loading levels. The effects on polymer crystallinity and 
melting point for different drugs provides information on the solubility of the drugs in the 
polymer matrix which, may be used to predict how drug loading will modify the polymer 
erosion kinetics and thus the drug release kinetics. Shen et al. (2001b) used wide-angle X-
ray diffraction (WAXD) and DSC to characterize the changes in crystallinity of PSA as a 
function of the loading of a compatible drug, /7-nitroaniline (PNA), and an incompatible drug, 
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brilliant blue (BB) (Shen et al., 2001b). The compatible drug reduces the crystallinity, while 
the incompatible drug has no effect on the polymer crystallinity (Figure 2.5). 
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Figure 2.5. WAXD spectra for: A) BB-loaded PSA, and B) PNA-loaded PSA. A) BB 
loading is (a) 0, (b) 15, (c) 30, and (d) 45. Note that as loading increases, the spectrum shows 
no change for the PSA crystallinity, but crystals of BB appear, indicating that the solute and 
polymer are immiscible. B) PNA loading is (a) 0, (b) 5, (c) 10, and (d) 15. Note that there 
are no peaks corresponding to PNA as the loading increases, however, the polymer 
crystallinity decreases with increased loading, indicating polymer/solute compatibility. From 
(Shen et al., 2001a) Reprinted with permission. 
2.3.2.3 Amorphous phase behavior and micro structure of polyanhydrides. Blending 
of polymers is a strategy commonly used to design materials with desirable properties for 
many applications. Few studies have investigated the amorphous phase behavior of 
polyanhydrides. Domb developed two techniques for qualitatively assessing polymer 
miscibility and reported the results for a variety of binary polyanhydride blends as well as 
blends of polyanhydrides with other biodegradable polymers (1993). Shakesheff et al. 
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(1995) studied the phase behavior of PSA blends with poly(DL-lactic acid) (PLA) and the 
effects of the phase behavior on erosion kinetics by novel techniques allowing in situ atomic 
force microscopy (AFM) and surface plasmon resonance (SPR). Surface enrichment in 
PSA/PLA blends has also been assessed by AFM (Chen et al., 1998). Chan and Chu (2002) 
used calorimetry and IR to characterize the phase behavior of PSA/poly(ethylene glycol) 
blends. Rigorous analysis of the phase behavior of polyanhydrides based on theoretical 
predictions is not found in the published literature. 
When describing erosion of and drug release from surface erodible polymers, it is 
often implicitly assumed that the matrix erodes uniformly, resulting in a uniform release 
profile for a homogenously dispersed drug. While this may be a valid assumption for some 
homopolymer systems, neglecting the effects of crystallinity, some multicomponent polymer 
matrices may exhibit microphase separation, even when the copolymers are random (Shen et 
al., 2001a). In such phase-separated systems, a drug will thermodynamically partition. 
The erosion of copolymers requires the hydrolytic cleavage of three bond types: the 
A-A bond, the A-B bond, and the B-B bond. If the degradation rates of these three bonds are 
unequal, as is likely the case, then the erosion will be inhomogeneous. And, if drugs are 
inhomogeneously distributed in the polymer matrix, the drug release profile will not follow 
overall device erosion (Shen et al., 2002). Therefore, it is necessary to accurately describe 
the microstructure of microphase-separated systems. 
The length scale on which this microphase separation occurs can be obtained by 
considering the sequence distribution of monomers in the copolymers. For instance, number-
average sequence lengths can be determined from rH NMR (Mathiowitz et al., 1990b; Ron et 
al., 1991; Tamada and Langer, 1992; Shen et al., 2002). One may estimate that the length 
scale of the phase-separated domains is likely to be less than <10 nm. The characterization 
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proves to be challenging as there are few microscopy or spectroscopy techniques that can 
resolve such small length scales. However, the effects on drug release kinetics are apparent 
(see Section 2.4.1). 
2.3.3 Biocompatibility of polyanhydrides 
Biocompatibility is an essential property of new biomaterials for drug delivery. 
Biocompatibility is always assessed with respect to specific applications and may be assessed 
with respect to cytotoxicity, allergic responses, irritation, inflammation, mutagenicity, 
teratogenicity, and carcinogenicity (Katti et al, 2002). The reviews by Katti et al. and 
(2002) Domb et al. (1997) provide good discussions on the biocompatibility studies that have 
been conducted with polyanhydrides over the past two decades. 
Leong et al. (1986) conducted experiments with the degradation products of P(CPP-
SA) to determine mutagenicity and teratogenicity. In the same study, PCPP and PTA were 
implanted in rat corneas and PCPP was implanted subcutaneously in rat abdomens for 
histology. Endothelial and smooth muscle cell cultures on P(CPP-SA), P(SA-TA), and PTA 
were also conducted to assess cytotoxicity. Mutagenicity and teratogenicity tests were both 
negative, and the in vivo experiments revealed no inflammation. Cell cultures exhibited 
normal proliferation and no abnormal morphologies (Leong et al., 1986). 
The biocompatibility of P(CPP-SA) implants in the brain was assessed by Brem et al. 
(1989) and Tamargo et al. (1989). In the former study the 50:50 copolymer was implanted in 
rabbit brains and compared to a gelatin based implant used in neurological surgery (Gelfoam) 
and induced similar mild reactions (Brem et al., 1989). In the latter study the 20:80 
copolymer was implanted in rat brains and was compared to Gelfoam® and a cellulose-
derived product (Surgicel®). Inflammatory response was similar to that induced by the 
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Surgicel®, but more severe than the Gelfoam®. No local or systemic toxicity was observed 
(Tamargo et al, 1989). The brain biocompatibility of P(FAD-SA) was investigated by Brem 
et al (1992) and found to be comparable to that of P(CPP-SA). 
Laurencin et al. (1990) conducted extensive local and systemic toxicity studies with 
P(CPP-SA), which also showed excellent biocompatibility and toxicology. Domb (1992) 
studied the biocompatibility of P(CPP-IPA), P(CPP-IPA-SA), and P(CPP-SA) by 
subcutaneous and intramuscular implants in rabbits. Inflammation occurred at week one and 
was more pronounced for the intramuscular implants, but subsided in all cases by week 4 
(Domb, 1992). Domb and Nudelman (1995) conducted subcutaneous biocompatibility 
studies in rats with poly(pimelic acid) (PPA), poly(azelaic acid) (PAZ), PSA, and PDDA 
resulting in mild inflammation but no encapsulation or other pathologies. The systemic and 
local biocompatibility of the ricinoleic acid-based polymers was investigated and confirmed 
by Teomim et al. (1999) by subcutaneous implantation in rats. Jiang et al. (2001a) assessed 
the biocompatibility of the poly(anhydride-co-ester)s PCP A, PCPS, and P(CPA-co-CPS) by 
subcutaneous implants in rats. Mutagenicity and toxicity were not observed, though mild 
inflammatory responses were observed. 
2.4 Degradation, Erosion, and Drug Release Kinetics 
2.4.1 Experiments 
2.4.1.1 Polymer stability. The degradation kinetics of several polyanhydrides have 
been assessed under different storage conditions, to determine the useful shelf life. Rate 
constants and activation energies for degradation of a variety of polyanhydrides in solution 
have been reported (Domb and Langer, 1989). In solution, degradation rate is an increasing 
function of temperature. Aromatic polymers such as PCPM, PCPP, and PCPH, and PDP all 
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maintain their molecular weights both in the solid state and in organic solution for up to a 
year, but aliphatic polymers show a first order decrease in molecular weight with time 
(Domb and Langer, 1989; Chasin et al., 1990). Domb et al. (1989) reported that the PCPV 
and PCPO were stable for six months when stored in vacuo at room temperature. However, 
when stored in concentrated chloroform solution, the molecular weights of both polymers 
were reduced by 50% in only about 3 hours. The degradation products could be 
repolymerized, proving that the degradation occurred primarily via the anhydride interchange 
and could be reversed (Domb et al., 1989). Chang and Chu (2003) showed that in humid 
environments, depolymerization results primarily in the formation of diacid products, and 
therefore occurs by hydrolysis. Domb (1992) also demonstrated the stability of aromatic 
copolymers stored both under dry argon and in DCM solution, and under exposure to y-
irradiation. The ortho-substituted aromatic polyanhydrides, salicylic acid-based 
poly(anhydride-co-ester)s, and ricinoleic acid based poly(anhydride-co-ester)s also 
demonstrate stability to y-irradiation (Erdmann et al, 2000; Bedell et al., 2001a; Krasko et 
al., 2003). From a study of these results and the studies of other polyanhydrides, storage in a 
dry atmosphere below -20 °C is recommended if polymers are not going to be used within a 
few days of synthesis (Tamada and Langer, 1992). 
2.4.1.2 In vitro degradation, erosion, and drug release kinetics. In vitro kinetics 
experiments are usually conducted on compression molded monolithic polymer tablets, slabs, 
or cylinders with well-defined surface areas. Compression molding is done above the glass 
transition and near the melting point. Drugs are incorporated by co-dissolution with the 
polymer or mechanical mixing in the melt. If erosion profiles are desired, the polymer 
samples can be removed from the dissolution media at the specified times, dried, and massed. 
Degradation and drug release requires an assay for the monomer or drug content of the 
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dissolution media. UV Spectrophotometry or HPLC are common techniques. Monitoring 
the appearance of a single component in the dissolution media is not a reliable method for 
characterizing the overall erosion rate of a multicomponent system, even when that system is 
surface-erodible. Such generalizations should be carefully avoided, particularly when the 
system contains hydrophilic and hydrophobic moieties. For example, Shieh et al. (1994) 
demonstrate that different drugs release from the same matrix with different kinetics. In this 
study, the model hydrophilic drug acid orange (AO) released faster than the PSA monomer 
from P(FAD-SA) (50:50) systems, diffusing out of the polymer matrix, while rhodamine b 
base (RhoB) released more slowly than the PSA monomer from the same system (Shieh et 
al., 1994). For other compositions, the AO release profile more closely matched the PSA 
degradation profile (Shieh et al., 1994). 
The in vitro degradation and drug release of polyanhydride formulations is not 
necessarily equivalent to the in vivo kinetics. For information on the in vivo kinetics, the 
interested reader is referred to the recent review by Katti et al. (2002) and the review by 
Domb et al. (1997). 
2.4.1.2.1 Modulating erosion rates and drug release rates. The erosion rate 
constants reported in the literature or estimated from degradation or erosion data for many of 
the polyanhydrides discussed in this review are summarized in Table 2.9. Many of the 
homopolymers exhibit zero-order degradation over the majority of the release time. As 
polymer hydrophobicity is increased, the erosion rates generally decrease, presumably due to 
the decrease in reactivity of the anhydride bond. However, increase in polymer 
hydrophobicity corresponds to increase in monomer hydrophobicity as well. The 
corresponding decrease in erosion may therefore be due to both degradation kinetics and/or 
monomer dissolution kinetics (Hanes et al., 1998). Evidence has also been presented (see for 
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Table 2.9. Erosion rate constants for many common polyanhydrides. 
Polymer 
Erosion rate 
constant 
(mol cm"2 day"1) 
Weight-average 
molecular weight Reference 
PSA 
PDDA 
PCDA 
PCPA 
PCPV 
PCPO 
PTA 
PCPM 
PCPP 
Po-CPP 
PCPH 
Po-CPH 
PCPS 
PCPA 
PXDA 
PFAD 
PHFB 
2.7 x 10" 
5.4 x 10"5,a 
9.3 x 10"5 
3.1 x 10"5 
1.3 xlO"5 
2.5 x 10"* 
3.2x10": 
3.4xl0-s/ 
1.1 x 10"7 
6.3 x 10"7 
1.4 x 10" 
1.2 x 10"5 
1.2 x 10"5 
5.3 x 10"5 
3.1 x 10"5 
1.6x10^ 
23,900 
32,700 
44,600 
33,300 
11,800 
15,000 
9530 
21,000 
7920 
15,700 
(Leong et al, 1987) 
(Albertsson and 
Lundmark, 1990a) 
(Zhang et al., 2001) 
(Domb et al., 1989) 
(Domb et al, 1989) 
(Domb et al, 1989) 
(Leong et al, 1985) 
(Rosen et al, 1983) 
(Leong étal., 1985) 
(Bedell et al, 2001a) 
(Leong et al., 1985) 
(Bedell et al., 2001a) 
(Jiang étal., 2001a) 
(Jiang et al., 2001a) 
(Leong et al., 1987) 
(Tabata and Langer, 
1993) 
(Kaur et al, 2002) 
Copolymer 
P(CPP-SA) 
Erosion rate 
constant 
(UB cm"2 day"1) 
Weight-average 
molecular weight Reference 
100:0 
85:15 
45:55 
21:79 
0:100 
1.4 
6.0 
80.0 
160.0 
210 
15,000 
9,840 
6,140 
12,030 
23,900 
(Leong et al, 1985) 
(Leong et al., 1985) 
(Leong et al., 1985) 
(Leong et al., 1985) 
(Leong et al, 1987) 
Polyanhydrides with other 
functional groups 
Erosion rate 
constant 
(Hg cm"2 day"1) 
Number-average 
molecular weight Reference 
P(A-co-U) 
P(A-co-A) 
P(A-co-E) 
8400 
3600 
2160 
9120 
5280 
2880 
480 
5900 
9100 
13,700 
6800 
10,800 
6,390 
10,900 
(Hartmann et al., 
1993) 
(Hartmann et al., 
1993) 
(Hartmann et al., 
1993) 
"Erosion experiment conducted at pH 7.2 
^Estimated from linear portion of sigmoidal profile 
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example Shakesheff et al., 1994) that crystalline domains erode much more slowly than 
amorphous domains. Thus, careful control of crystallinity may be necessary to accurately 
modulate erosion and drug release kinetics. 
Erosion rates of copolymers can also be modulated by changing the copolymer 
composition. As an example, erosion rates for three compositions of P(CPP-SA) are reported 
in Table 2.9. Similar results were reported by Domb and Maniar (1993) for the copolymers 
of P(FAD-SA). This study also showed that the copolymers degrade in a heterogeneous 
fashion, that is, at later times, the composition is richer in the more slowly degrading 
monomer. Note that erosion rates are varied over two orders of magnitude (Table 2.9). The 
same phenomenon was demonstrated by Shakesheff et al. (1995) for PSA/PLA blends by a 
novel technique allowing in situ AFM and SPR measurements. Further characterization of 
these blends revealed surface segregation of the PLA phase, which slowed erosion for high 
PLA content blends (Davies et al., 1996). 
Whether in copolymers or blends, inhomogeneous erosion has a non-trivial effect on 
drug release kinetics as will be shown later. Leong et al. (1985) demonstrated that the pH of 
the degradation media also has a dramatic effect on the erosion rate, which increases with 
increasing pH. The acceleration of degradation of polyanhydrides with increase in pH is 
widely reported and has been used to speed up experiments (Shakesheff et al., 1994). 
Molecular weight may also affect the erosion rate. Table 2.9 shows the degradation 
rate of a representative poly(anhydride-co-urethane), a poly(anhydride-co-amide), and a 
poly(anhydride-co-ester) of different molecular weights (Hartmann et al., 1993). For all of 
these polymers, the reported erosion rate decreases as the molecular weight increases. 
In their study of branched PSA (1990), Maniar et al. found that the molecular 
architecture of branched polymers affects the release kinetics in a variety of ways. They 
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found that the branched polymers degraded faster than linear PSA of comparable molecular 
weight (Maniar et al, 1990). They also noted that drug (morphine) release profiles were 
more characteristic of bulk erosion than surface erosion: An initial lag time during which 
very little drug was released was associated with the time required for water to swell the 
polymer. This was followed by a period of relatively fast release, which tapered off as the 
device disintegrated. The polymer matrix lost its mechanical integrity before the release 
experiment was complete (Maniar et al., 1990). Despite the increase in degradation rate, 
release rates from the polymer randomly branched with 1,3,5-benzene tricarboxylic acid 
were much lower than release rates from PSA (Maniar et al., 1990). The release from the 
graft type polymer branched with poly(acrylic acid) approached that of PSA (Maniar et al., 
1990). 
Evidence that drug loading modifies the erosion rate can be found in many drug 
release studies. Particularly at higher loadings, hydrophilic drugs tend to increase the overall 
erosion rate of the polymer (Park et al, 1996; Shen et al., 2002). This phenomenon is 
attributed to the contribution that the drug makes to the overall chemistry of the system, as 
well as porosity and voids that may form as hydrophilic drug crystals rapidly dissolve from 
the exposed surface (Sandor et al., 2002). One study of drug release from bioerodible 
polyanhydrides found a change in the drug release kinetics from zero-order to first order by 
simply changing the pH of the media or by changing the hydrophobicity of the drug (Park et 
a/., 1997). 
Finally, drug release profiles can be altered by altering the distribution of the drug in 
the polymer matrix. For purely surface eroding systems, it is theoretically possible to obtain 
any desired drug release profile by fabricating a device with the corresponding drug 
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distribution profile. Design and fabrication of devices with non-uniform drug distribution is 
discussed in Section 2.5. 
2.4.1.2.2 Surface changes during erosion. Albertsson and Lundmark (1990a) 
reported that during the degradation of PDDA, the surface showed a lower C/O ratio (from 
electron spectroscopy for chemical analysis (ESCA) studies) than in the neat polymer, 
indicating partial oxidation. Mathiowitz et al. (1993) discussed the effects of crystallinity 
and liquid crystallinity on the degradation kinetics in P(CPH-SA) and P(CPP-SA) 
copolymers. Evidence that crystalline domains degrade more slowly than amorphous 
domains is also reported in several studies (Shakesheff et al., 1994). 
The monomer solubility has a crucial effect on the surface characteristics of eroding 
polymer systems. Undissolved monomer deposited on the surface complicates erosion and 
release kinetics by presenting a diffusional barrier for drug release as well as water ingress. 
The compounding effect slows not only the release of monomer and drug, but also the 
prerequisite hydrolysis of the polymer backbone that results in release (Goepferich et al., 
1996). The solubilities of the class of aliphatic polyanhydride monomers from adipic acid 
(six carbons) to dodecandicarboxylic acid (14 carbons) vary from 50 mg/ml to <0.01 mg/ml, 
generally decreasing as the length of the methylene chain increases (Domb and Nudelman, 
1995). 
2.4.1.2.3 Chemical changes during erosion. Because the degradation products of 
polyanhydrides are acidic (see pKa's reported in Goepferich and Langer, 1993a), and the 
degradation is a strong function of pH, it has been hypothesized that during erosion the pH of 
the microenvironment very near the surface of a device may not be the same as that of the 
dissolution media. Dissolved drugs may also affect the local pH. This local pH is difficult to 
measure or estimate (Goepferich and Langer, 1993a), but may have profound effects on the 
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erosion and drug release profiles. Màder et al. (1997) employed spectral spatial 
paramagnetic resonance imaging and measured pH values inside eroding samples of P(CPP-
SA) as low as 4.5, though the dissolution media was buffered at 7.4. 
The composition of copolymers usually changes during erosion due to the disparity 
between the degradation kinetics of the two corresponding homopolymers. Actually, in 
binary copolymers there are three types of bonds that may all have different degradation 
kinetics: the A-A bond, the A-B bond, and the B-B bond. Spectroscopic techniques such as 
IR and NMR can be used to follow the kinetics of specific bond cleavage in copolymers 
(Heatley et al., 1998; Uhrich et al., 1998; McCann et al., 1999). Changes in molecular 
weight during degradation are frequently reported. The formation of relatively stable 
oligomers in copolymer erosion studies has been shown (Santos et al., 1999). The changes in 
molecular weight may also result in drastic shifts in thermal transitions during erosion 
(Bedell et al., 2001b). 
Figure 2.6 summarizes some of the important effects contributing to drug release 
kinetics discussed in this section. Drug release from a simple, homogeneous surface eroding 
system is shown schematically in Figure 2.6a and graphically in Figure 2.6c. Zero order 
release is obtained when the drug (represented by the circles) is uniformly distributed and the 
system erodes uniformly from the surface. Drug release from a phase-separated surface 
eroding system is shown schematically in Figure 2.6b. In this system, two polymer phases 
are present, one which erodes quickly (light gray), and one which erodes slowly (dark gray). 
Drug release accelerates initially because the inhomogeneous erosion and bursting of drug 
from the slow eroding phase lead to increase in surface area. At later times, the fast eroding 
phase is completely gone, and the degradation products from the slow eroding phase 
(triangles) form an insoluble barrier to transport, retarding the release. A sigmoidal release 
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profile results, as shown in Figure 2.6d. Additional effects, such as partitioning of the drug 
are not represented. 
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Figure 2.6. Mechanism of drug release from (a) homogenous, surface-eroding system, and 
(b) phase-separated surface-eroding system demonstrating some of the key factors affecting 
release as discussed in Section 2.4.1. Length scale of phase separation is enlarged for 
emphasis. 
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2.4.2 Modeling degradation, erosion and drug release kinetics 
Modeling the behavior of bioerodible polyanhydrides is complicated by the many 
phenomena contributing to release profiles described in the previous section. The 
degradation kinetics may be coupled to other processes, such as diffusion and dissolution, 
and the overall erosion kinetics represent the sum of all of these multiple processes 
(Goepferich, 1996a). The phenomena that contribute to erosion kinetics may be difficult or 
impossible to study independently (Goepferich, 1996b). Therefore, great care must be taken 
when formulating or applying a model to ensure that the phenomena described by the model 
are the dominant phenomena controlling the kinetics. A variety of models have been 
developed that account for different aspects of polymer microstructure, degradation kinetics, 
and drug loading. The recent review by Goepferich and Tessmar (2002) discusses 
degradation and erosion of polyanhydrides with an eye to developing more accurate models. 
And the review by Seipman and Goepferich (2001) discusses many of the recent models and 
could be used to aid in selection of the appropriate model for a given system. 
Burkersroda et al. (2002) provide a model that can be used to estimate whether a 
polymer is more accurately characterized as surface eroding or bulk eroding. In this model, 
the ratio of a characteristic time scale for diffusion to a characteristic time scale for 
degradation (comparable to a Deborah number) determines the 'erosion number,' 
s (Burkersroda et al, 2002). For s » 1, a device is surface eroding, whereas for s « 1, a 
device is bulk eroding (Burkersroda et al., 2002). A key component of this model is the 
device dimensions. Theoretically, even very hydrophobic polymers can be bulk eroding, 
provided the device is sufficiently small. If the polymer matrix itself is hydrophobic, the 
polymer degradation rate can be decreased by several orders of magnitude. 
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The simplest model for pure erosion control with kinetics dominated by a single rate 
constant and uniformly distributed drags was described by Hopfenberg (1976). This model 
says nothing about the various physical phenomena that contribute to erosion, and therefore 
fails to describe drag release profiles from many polyanhydride systems. Below we classify 
some of the models that can be found in the literature. 
2.4.2.1 Phenomenological models. The broadest class of models, phenomenological 
models, account explicitly for individual phenomena such as swelling, diffusion, and 
degradation by incorporation of the requisite transport, continuity, and reaction equations. 
This class of models is useful only if it can be accurately parameterized. As phenomena are 
added to the model, the number of parameters increases, hopefully improving the model's 
accuracy, but also requiring additional experiments to determine the additional parameters. 
These models are also typically characterized by implicit mean-field approximations in most 
cases, and model equations are usually formulated such that explicit solutions may be 
obtained. Examples from the literature are briefly outlined below. 
The transport and continuity equations for surface eroding polymers with two moving 
boundaries (defining a diffusion zone for drags inside the polymer matrix) were solved by 
Thombre and Himmelstein (1984). No account was made for inhomogeneities either in 
polymer matrix or the drug distribution, but the model was extended to account for the 
presence of a membraneous diffusive barrier at the surface. A later extension of the model 
accounted for an external mass transfer coefficient and changes in degradation rate and drag 
diffusivity with pH and the progress of degradation (Thombre and Himmelstein, 1985). This 
model was solved numerically. 
Batycky et al. (1997) developed a model applicable for bulk eroding systems. An 
interesting component of this model is the explicit accounting of the changes in the molecular 
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weight distribution with time via both end chain scission and random chain scission. 
Larobina et al. (2002) developed a model for release from copolymers that accounts for 
microphase separation in copolymers and partitioning of drugs into the phase separated 
microdomains. Two moving erosion fronts are assumed, leading to three regimes of release. 
Analytical solutions are obtained. 
2.4.2.2 Discretized models. Zygourakis and coworkers (1990; Zygourakis and 
Markenscoff, 1996) developed a discretized model in which cells are assigned a degradation 
time, upon exposure to solvent, based on their identity as either drug, polymer, solvent, or 
void. The initial distribution of cells can be modeled after the microstructure of the polymer 
matrix and multiple phases are explicitly accounted for. The solution is found numerically. 
Goepferich and Langer (1993b) developed a similar model, except that finite 
probabilities are assigned for the erosion of each cell type rather than predetermined erosion 
times. No account of drug release was made in this model, but the model was applied to 
materials with two types of polymer cells, designed to signify crystalline and amorphous 
phases. In a second publication, Goepferich and Langer also accounted for monomer 
diffusion through the eroding zone (Goepferich and Langer, 1995). The solution to this 
model is also obtained numerically. 
2.5 Design of Polyanhydride Carriers for Controlled Release 
Many model formulations of polyanhydrides have been tested both in vitro, and in 
vivo. The delivery schemes that polyanhydrides have been used for can be broadly grouped 
into three classifications - implantable systems for localized drug release, injectable systems, 
and aerosols for mucosal delivery. Each of these delivery routes presents a unique set of 
challenges and these are discussed below. 
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2.5.1 Implantable systems 
2.5.1.1 BCNU-loaded polyanhydride discs for treatment of glioblastoma multiforma. 
The encapsulation and release of l,3-bis(2-chloroethyl)nitrosourea (BCNU) in P(CPP-SA) 
20:80 wafers was the first implantable controlled release device based on polyanhydrides that 
was FDA-approved and marketed (Gliadel ®) (Chasin et al., 1988). BCNU was 
encapsulated by two techniques, trituration and co-dissolution, resulting in different release 
profiles (Chasin et al., 1990; Chasin et al., 1991). The triturated samples released faster than 
those prepared by co-dissolution, presumably due to more homogeneous loading in the 
samples prepared by co-dissolution. 
2.5.1.2 Laminated devices for pulsatile release. Jiang and Zhu (2000) and Qiu and 
Zhu (2001) have reported the fabrication of multilayered devices composed of stacks of 
compression-molded disks of alternating compositions. One type of disk is either P(SA-EG) 
or P[SA-co-TMAgly)-b-EG] and the other is a pH-sensitive, protein-loaded blend of, for 
example, poly(methacrylic acid) and polyethoxazoline. The release of model proteins, 
myoglobin, bovine serum albumin, and FITC-dextran, and compounds such as brilliant blue 
have been studied and pulsatile release profiles have been demonstrated (Jiang and Zhu, 
2000; Qiu and Zhu, 2001). 
2.5.1.3 Other devices. Erdmann et al. (2000) report the fabrication of devices for the 
localized delivery of salicylic acid from the poly(anhydride-co-ester)s mentioned in Section 
2.2.3. A unique feature of this drug delivery system is that the drug compound is part of the 
polymer backbone. Devices were implanted intraorally and histopathology was reported 
(Erdmann et al., 2000). Chasin et al. (1990) review fabrication and testing of implantable 
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formulations for other drugs including angiogenesis inhibitors for treatment of carcinomas 
and bethanechol for the treatment of Alzheimer's disease. 
2.5.2 Injectable systems 
Injectable polyanhydride systems for drug delivery usually consist of polymer 
microspheres suspended in an injection media. Langer and co-workers reported on three 
techniques for the fabrication of drug loaded polyanhydride microspheres: hot-melt, solvent 
removal, and spray drying (Mathiowitz and Langer, 1987; Bindschaedler et al., 1988; 
Mathiowitz et al., 1988; Mathiowitz et al., 1990a; Mathiowitz et al., 1992). The hot-melt 
technique used by Mathiowitz and Langer (1987) is performed by heating the polymer and 
drug in a non-solvent to a temperature above the melting point of the polymer and stirring to 
disperse the molten droplets. Subsequent cooling freezes polymer microspheres loaded with 
dissolved drug. This technique is only useful for polymers with melting points sufficiently 
low that the activity of the drugs is not affected by the heating. In the spray drying 
technique, polymer and drug are dissolved in a suitable solvent and a spray dryer is used to 
disperse small droplets into air where precipitation occurs (Mathiowitz et al., 1992). The 
third and most common technique found in the literature is solvent removal. In this 
technique, a polymer solution (containing drug) is dispersed in a non-solvent (Mathiowitz et 
al., 1988). An emulsion is formed. The solvent is extracted out of the droplets by the non-
solvent, precipitating the microspheres. Variations on the solvent removal technique have 
been optimized for several polymer/drug systems. Double emulsion or phase inversion 
techniques are used when the drug and polymer are not soluble in the same solvent (Chiba et 
al., 1997; Chickering et al., 1997; Thomas et al., 1997). Double walled microspheres have 
been produced by precipitating a second polymer solution onto previously fabricated 
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microspheres (Goepferich et al, 1994), and by allowing thermodynamic partitioning of two 
polymer solutions during the solvent removal process (Pekarek et al., 1994; Leach et al., 
1999). In vitro and in vivo degradation studies showed that the inner layer of P(CPP-SA) 
degraded before an outer layer of PLA in double walled systems (Leach and Mathiowitz, 
1998; Leach et al, 1998). 
Microspheres with precisely controlled sizes have been produced by a novel 
apparatus that uses acoustic excitation and a non-solvent carrier stream to form each droplet 
in the emulsion separately (Berkland et al, 2004). The morphology and hence the drug 
release kinetics of the microspheres are affected by the fabrication technique. The size of the 
microspheres can be modulated by changing the stirring rate in the hot melt and solvent 
removal techniques, however both of these techniques produce highly polydisperse size 
distributions (Mathiowitz and Langer, 1987; Mathiowitz et al, 1988). The surface and 
internal morphology of microspheres produced by various techniques have also been 
characterized, as these will affect the drug release kinetics. The hot-melt technique produces 
non-porous microspheres with crenellated surfaces (Mathiowitz and Langer, 1987). Solvent 
removal techniques can produce smooth microspheres, though porosity is difficult to control 
and crystalline polymers tend to have greater surface roughness (Mathiowitz et al., 1988; 
Mathiowitz et al., 1990a). Spray dried microspheres also have polydisperse size distributions 
and can have very porous structures. Mathiowitz et al. (1992) had difficulty preventing the 
microspheres made from some polymers from fusing into aggregates with this technique. 
Drug loading efficiencies and uniformity can vary depending on the compatibility of the drug 
with the polymer matrix and other characteristics of the fabrication technique. These 
morphological variations will also have a significant impact on the drug release kinetics, 
which are discussed in the next subsection. 
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An advantage of this type of delivery system is that microspheres displaying different 
release profiles (e.g. being composed of different polymers or different sizes) can be 
combined in cocktails to obtain release profiles that are the sum of the various release 
profiles from the individual formulations (Kipper et al, 2002). Multiple drugs could also be 
delivered this way in a single injection. 
Berkland et al. (Berkland et al, 2004) showed that for systems made by solvent 
removal, the precipitation kinetics play a crucial role in determining drug distribution within 
the microspheres, and thus the release profiles. For drugs that are incompatible with the 
polymer matrix, slow precipitation may result in surface segregation of the drug (Berkland et 
al, 2004). One way of controlling the precipitation kinetics is to carefully control the 
microsphere size. Smaller microspheres precipitate more quickly and therefore exhibit the 
most extended release profiles when the polymer/drug compatibility is low (Berkland et al, 
2004). In a study comparing release profiles from tablets and injectable granules (Tabata et 
al., 1994), it was shown that inhomogeneously distributed drug has little or no detectable 
effect on release profiles from tablets, while the release profiles from granules exhibit drug 
bursts at the beginning of the experiment. 
Proteins may be stabilized by encapsulation in polyanhydride microspheres. Stability 
of proteins with respect to water-induced aggregation has been demonstrated to be a function 
of polymer hydrophobicity for insulin and bovine somatotropin as model proteins (Ron et al, 
1993). Encapsulation and enzymatic activity of a variety of other proteins encapsulated in 
P(SA-FAD) was studied by Tabata et al. (Tabata et al, 1993). 
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2.5.3 Aerosols and systems designed for mucosal delivery 
Many therapeutic proteins must be delivered by injection as alternative delivery 
routes (e.g. oral) result in low bioavailability. This can be difficult, inconvenient, and 
painful, particularly for long-term treatments, for example, in the case of insulin 
administration for diabetes patients. Mucosal delivery offers an attractive alternative to 
injection, but poses some unique challenges. The formulation must be capable of stabilizing 
the drug, targeting delivery to the mucosa, remaining at the delivery site for extended 
periods, and facilitating trans-mucosal transport of the drug (Harris and Robinson, 1990). 
The characteristics of the various mucosa (buccal, nasal, gastrointestinal, and ocular) that can 
be quantified for design of controlled release devices are summarized by Harris and 
Robinson (1990). Theories of bioadhesion are briefly outlined by Chickering et al. (1995). 
Chickering and Mathiowitz (1995) developed a technique for investigating the 
bioadhesive properties of polymers and showed that p(FA-SA) demonstrated good 
bioadhesion. Two mechanisms of bioadhesion were proposed: surface free energy effects 
and hydrogen bonds between carboxylic acid residues in degradation products and mucin or 
epithelia (Chickering and Mathiowitz, 1995). The same authors showed that encapsulation 
of a model drug (ducimerol) in P(FA-SA) improved bioavailability in oral delivery 
experiments (Chickering et al., 1996). 
Fu et al. (2002) report the optimization of a fabrication procedure for microspheres 
based on the poly(anhydride-co-ether) P(SA-EG). The microspheres are fabricated by 
solvent removal process that produces a porous structure with densities in the range of 0.344 
and 0.077 g cm"3 and sizes that are optimized for delivery to the deep lung by inhalation (Fu 
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et al., 2002). An appropriate in vitro eell culture model for characterization of the particle-
epithelia system was also developed (Fiegel et al., 2003). 
2.6 Conclusions and Future Opportunities 
The past two decades have produced a revival of interest in the synthesis of 
polyanhydrides for biomedical applications. These materials offer a unique combination of 
properties that includes hydrolytically labile backbone, hydrophobic bulk, and very flexible 
chemistry that can be combined with other functional groups to develop polymers with novel 
physical and chemical properties. This combination of properties leads to erosion kinetics 
that is primarily surface eroding and offers the potential to stabilize macromolecular drugs 
and extend release profiles from days to years. The microstructural characteristics and 
inhomogeneities of multicomponent systems offer an additional dimension of drug release 
kinetics that can be exploited to tailor drug release profiles. 
The development of new polyanhydrides has sparked researchers to developed new 
device fabrication and characterization techniques, instrumentation, and experimental and 
mathematical models that can be extended to the study of other systems. The growing 
interest in developing new chemistries and drug release systems based on polyanhydrides 
promises a rich harvest of new applications and drug release technologies, as well as new 
characterization techniques that can be extended to other materials. Future endeavors will 
likely focus on multicomponent polyanhydride systems, combining new chemical 
functionalities to tailor polyanhydrides for specific applications. 
The release characteristics of polyanhydride systems could be used not only to 
develop clinical treatments, but also to induce chronic disease states as models for studying 
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immune function. Many current models of chronic diseases are based on induction of acute 
effects, which do not exhibit the same long-term behavior as the disease being modeled. 
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CHAPTER 3 
RESEARCH OBJECTIVES AND DISSERTATION ORGANIZATION 
3.1 Specific Goals 
In Chapter 1, compelling justification was provided for the development of controlled 
release vaccine formulations based on bioerodible polymer microspheres. A great deal of 
research has already been done to characterize the release properties of systems composed of 
several bioerodible polyanhydrides. The examination of this body of work, presented in 
Chapter 2, reveals that the release kinetics are significantly affected by a variety of system 
characteristics, from composition and processing to drug incorporation and the 
thermodynamics of the system. However, very little work has been done to connect the 
combined effects of the several important microstructural characteristics on the release 
kinetics. For example, no study to date has attempted to characterize the phase behavior of 
any binary polyanhydride blend system, let alone discern the effects of phase separation on 
release kinetics. Such fundamental characterization is essential for the continued study of 
polyanhydrides in controlled release devices. Though several mathematical models 
developed to describe the drug release kinetics from such systems have increased our 
understanding of the mechanisms of degradation, erosion, and release, no model developed 
to date has effectively solved the problem of predicting the release from polyanhydride 
microspheres by accounting for the several processes and system characteristics that have 
significant impact on release. 
In light of this review, the overall objective of our research is the design of an 
injectable system based on bioerodible polyanhydride microspheres for the controlled 
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delivery of vaccines. The design will include a predictive mathematical model that can be 
used to design systems with tailored release profiles. Such a model is necessary for tailoring 
the release from polyanhydrides to specific applications. The many processes affecting the 
release kinetics, occurring on both microscopic and macroscopic length scales, have their 
roots in the molecular architecture of the polymer/drug system. Thus, a comprehensive 
predictive model describing the release characteristics must link molecular descriptions of 
the system and their microscopic effects to macroscopic phenomena. As stated in Chapter 1, 
the specific goals (SGs) that must be met in order to attain the overall objective are: 
SGI. To describe in detail the microstructure of polyanhydride copolymers and the effects 
of this microstructure on drug/antigen distribution and release from microphase-
separated polyanhydrides. 
SG2. To design TT-loaded polyanhydride microspheres and perform in vitro and in vivo 
studies to discern antigen release profiles and antibody production in order to 
maximize protective immunity. 
SG3. To formulate and solve a mathematical model to predict and tailor copolymer 
microstructure effects on drug/antigen release mechanisms. 
SGI requires accurate characterization of the polymer system from both kinetic and 
thermodynamic standpoints. This includes a prediction of the phase behavior of binary 
homopolymer blends, crystallinity of the homopolymers and copolymers, and a detailed 
description of the amorphous microphase separation in "block-like" random copolymers. 
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Data obtained from in vitro release kinetics of both small molecular weight compounds and 
proteins will provide valuable information about the erosion and release kinetics of different 
compositions of the polymer system and different polymer/drug systems. 
SG2 requires the development of efficient microsphere fabrication techniques. 
Characterization of the microspheres will include drug loading, loading efficiency and size 
distributions in addition to in vitro release kinetics and in vivo responses to encapsulated 
drags. Tetanus toxoid (TT) will be used as the model antigen. Antibody production will be 
monitored and the system will be optimized to maximize protective immunity in an animal 
model. 
The data obtained from these studies will provide the necessary foundation for the 
development of a mathematical model to predict and tailor drug and antigen release profiles 
(SG3). The model will be developed in two stages. The first will be a phenomenological 
model with several simplifying assumptions of the microscopic structure of the polymer 
system. The model solution and fits to experimental data will help identify aspects of the 
system to which the release kinetics are sensitive and hence, which microscopic aspects of 
the system require more detailed description. In the second stage, further experiments will be 
designed to address these specific questions. 
3.2 Dissertation Organization 
The following seven chapters document the progress toward completion of each of 
these three goals. SGI is met by the work described in Chapters 4, 5, and 6. Chapter 4 
details the phase behavior of the poly(CPH)/poly(SA) blend system as investigated by small-
angle X-ray scattering (SAXS), atomic force microscopy (AFM), optical microscopy, and 
molecular simulation. The phase behavior of the blend system is interpreted via the segment-
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segment interaction parameter. This parameter can be used to predict the phase behavior and 
microstructure of the copolymers. Chapter 5 presents the crystallization kinetics of the 
copolymers determined by SAXS. The details of the copolymer crystallinity will be 
incorporated into the release kinetics models presented in subsequent chapters. A detailed 
understanding of the crystallization kinetics also provides insights on the effect of processing 
conditions on copolymer microstructure. In Chapter 6 the microphase separation of the 
copolymers is studied by solid-state NMR and SAXS. These results are briefly compared to 
theoretical descriptions of the polymer chain conformation based on parameters determined 
from the molecular simulations reported in Chapter 4. The details of this microstructure will 
be incorporated into the release kinetics models. 
Chapters 7 and 8 describe the work done in pursuit of SG2. Chapter 7 details the 
fabrication and characterization of drug loaded polyanhydride microspheres. In vitro release 
kinetics and tailored release profiles are discussed. Chapter 8 describes the fabrication and 
characterization of TT-loaded microspheres and their in vitro release kinetics. The results of 
in vivo antibody production studies are also reported. 
Chapters 9 and 10 contain the two erosion and drug release kinetics models 
developed for SG3. Chapter 9 presents the first generation of release kinetics models based 
on the experimental work presented in the previous chapters. This model makes several 
simplifying assumptions, strategically chosen to reveal the sensitivity of the model to the 
parameters of the system. In this way, several key characteristics of the system are identified 
which require further experimental work in order to improve the model. The second 
generation of this model is presented in Chapter 10. Improvements to the model include a 
detailed description of the copolymer microstructure and the explicit consideration of several 
additional phenomena that were previously neglected. 
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Chapter 11 offers some conclusions based on this research and discusses the future 
application of polyanhydrides to controlled release formulations. 
Figure 3.1 shows how all of the research endeavors discussed in the following seven 
chapters contribute to the completion of the specific goals of this research. 
Design of Single-Dose Tetanus 
Vaccine Based on Bioerodible 
Polyanhyrdride Microspheres 
SG2: Design and Test 
SG1: Describe Drug-Loaded SG3: Model Erosion and 
Polyanhydride Polyanhydride Drug Release Kinetics 
Microstructure Microspheres 
Chapter 4: Copolymer 
phase behavior by 
SAXS, microscopy 
and molecular 
simulation 
Chapter 5: Crystallization 
kinetics by SAXS 
Chapter 6: Copolymer 
microstructure by 
SAXS and SS NMR 
Chapter 7: Microsphere 
fabrication and 
characterization. In 
vitro release kinetics 
of small molecular 
weight drugs 
Chapter 8: TT-loaded 
microsphere 
fabrication. In vitro 
release kinetics. In 
vivo antibody 
response 
Chapter 9: First 
generation of erosion 
and drug release 
kinetics model 
Chapter 10: Second 
generation of erosion 
and drug release 
kinetics model 
Figure 3.1. Relationship of research activities discussed in Chapters 4 - 10 to specific goals. 
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CHAPTER 4 
UNDERSTANDING POLYANHYDRIDE BLEND PHASE BEHAVIOR USING 
SCATTERING, MICROSCOPY, AND MOLECULAR SIMULATIONS 
Reprinted from Polymer 45(10): 3329-3340, Copyright ©(2004), with permission from 
Elsevier. 
Matt J. Kipper1'2, Soenke Seifert3, P. Thiyagarajan4, and Balaji Narasimhan2'5 
4.1 Abstract 
The phase behavior of a biocompatible binary polyanhydride blend system composed 
of poly[l ,6-bis(p-carboxyphenoxy)hexane] (poly(CPH)) and poly(sebacic acid) (poly(SA)) is 
described. The phase behavior is determined from the CPH-SA segmental interaction 
parameter, %, obtained from in situ small angle X-ray scattering (SAXS) experiments. The 
predicted phase diagram has an upper critical solution temperature (UCST) with a critical 
point of 114 °C. The phase diagram is validated by optical microscopy (cloud point 
determination) of blend films. However, the full range of blend compositions is not 
accessible via cloud point measurements, because the melting point of poly(CPH) is above 
the critical point. Additionally, the poly(CPH) crystallinity interferes with cloud point 
determination because the length scale of the amorphous phase separation and that of the 
crystallinity are both near the limit of resolution of the optical microscope. The poly(CPH)-
1 Department of Chemical Engineering, Iowa State University. 
2 Graduate student, primary author. 
3 Advanced Photon Source, Argonne National Laboratory. Assisted with SAXS instrumentation. 
4 Intense Pulsed Neutron Source, Argonne National Laboratory. Assisted with interpretation of SAXS data. 
5 Major professor, corresponding author. 
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rich region of the phase diagram was investigated by ex situ atomic force microscopy on thin 
blend films. Finally, in order to validate the use of molecular simulations to study energetic 
and structural properties of this system, % is also computed from molecular dynamics both 
above and below the critical point. Excellent agreement is obtained for all three 
experimental methods and the computational technique. The results are compared to a 
simple group contribution method for computing the solubility parameters of the polymers. 
This technique fails to accurately predict the phase diagram. 
Keywords: Polyanhydrides, polymer blend phase behavior, SAXS, molecular dynamics 
4.2 Introduction 
The use of multicomponent polymeric materials for drug delivery offers the potential 
to provide tailored drug release profiles [1-4], drug stabilization [5], and drug targeting [6]. 
However, multicomponent polymer systems often exhibit phase separation, and many of the 
properties of interest are governed by the phase behavior of the material. Though phase 
separation may be exploited to achieve desired characteristics in a particular system, if poorly 
understood, it may also have effects on the ability of a device to control the drug release 
profile [7, 8]. Thus, design of drug delivery devices based on multicomponent polymer 
systems requires a detailed understanding of the phase behavior of the system of interest. 
Biodegradable polymers have found widespread acceptance as carriers for therapeutic 
compounds. In particular, many researchers have focused on poly(ester)s such as 
poly(lactide-co-glycolide) and poly(ether)s such as poly(ethylene oxide) as biomaterials for 
drug delivery, due to their biocompatibility. These systems are hydrophilic and release 
encapsulated drugs via bulk erosion. We are interested in drug release from hydrophobic 
systems. Hydrophobic biodegradable systems exhibit surface-erosion, which may stabilize 
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macromolecular drugs [9, 10]. They also have release profiles governed by the erosion 
kinetics, rather than diffusion and swelling, as is the case for hydrophilic, bulk-eroding 
systems. Polyanhydrides are ideal because the chemistry of the monomer units can be made 
hydrophobic, while the polyanhydride bond in the backbone remains hydrolytically labile. 
Polyanhydrides have been shown to have good biocompatibility. (See the recent reviews by 
Katti et al. [11] and Narasimhan and Kipper [12].) 
We are interested in polyanhydrides composed of the monomers l,6-bis(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) (Figure 4.1). These two materials 
erode at vastly different rates offering the opportunity to tailor release profiles by altering the 
composition [4, 8, 13]. 
Figure 4.1. Chemical structures of poly(CPH) (top) and poly(SA) (bottom). 
We have previously characterized the crystallinity of poly(CPH:SA) copolymers [13, 
14], the effects of drug loading on crystallinity [13], and the drug release kinetics of both 
microspheres [4, 15] and tablet [8] devices. Others have studied the release kinetics of 
similar polyanhydride systems, without providing details of the phase behavior [1, 16]. Our 
o 
o 
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previous work [8, 17] has revealed that release from the individual phases determines drug 
release profiles from surface-erodible, two-component systems when the two phases have 
different release kinetics. In surface-erodible multicomponent systems, drug release may 
either lead or lag the overall polymer erosion rate. The drug release kinetics is only 
explained by considering the release kinetics from the individual phases. In phase-separated 
systems, the drug release kinetics is governed by the phase behavior of the polymer system, 
the relative erosion rates of the constituent phases, the partition coefficient of the drug in the 
two phases, and the composition (relative amounts of the two phases) [17]. Thus, a 
comprehensive description of the release mechanisms requires intimate knowledge of the 
phase behavior. 
The miscibility of several polyanhydride systems has been qualitatively assessed 
experimentally by Domb [18], who investigated a variety of polyanhydride blends both in 
solution and melt. The miscibility of polyanhydrides with polyesters and polyethers has been 
studied by Shakesheff et al. [19], Chen et al. [20], and Chan and Chu [21]. However, the 
phase behavior of binary polyanhydride systems has not yet been comprehensively 
investigated. Our previous work has shown preliminary evidence that microphase separation 
exists in random copolymers of CPH and SA, and that this microphase separation affects the 
release profiles of dissolved drugs when the drugs partition in the two-phase system [8, 17]. 
In the present study, we determine the phase diagram of the poly(CPH)/poly(SA) 
blend system. The phase diagram is predicted from the CPH-SA segmental interaction 
parameter, %, determined from small-angle X-ray scattering (SAXS). The phase diagram is 
verified by optical microscopy and atomic force microscopy (AFM). The experimental work 
is complemented by the prediction of the poly(CPH)/poly(SA) blend phase behavior from 
molecular dynamics. Molecular dynamics also allows the prediction of the interaction 
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parameter in the phase-separated region, which SAXS cannot do. This prediction is 
compared to the SAXS data, in order to validate the molecular dynamics technique. 
Knowledge of the phase behavior of the blend system will be extended to copolymer systems 
(both random and block) in future work as we design new polyanhydride copolymers with 
precisely tailored architectures for drug delivery. 
4.3 Theoretical Background 
4.3.1 Polymer miscibility 
The Flory-Huggins theory for predicting the miscibility of polymers A and B 
calculates the Gibbs' free energy of mixing, AGmix, as [22] 
In equation 4.1 the <j)'s are the volume fractions of polymer A and B and the N's are their 
degrees of polymerization. The Flory-Huggins interaction parameter, /fh, represents the 
enthalpic component of the free energy of mixing. Note that volume change on mixing is 
neglected and the entropie terms only include combinatorial entropy. Because the entropie 
components are small and always favor mixing, %FH is a very important parameter. 
In the original Flory-Huggins theory, xfh is predicted by [22] 
R l n  ^  l n  +  Xfh^A^B mix _ (4.1) 
(4.2) 
In equation 4.2, AE^ is the energy of mixing per pair of monomers, scaled by the unit 
volume, Z represents the lattice coordination number and Vseg is the volume of a mole of 
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lattice sites. For off-lattice fluids, the coordination number loses some physical significance 
and becomes an adjustable parameter [23]. Methods to predict Z have been based on Monte 
Carlo packing algorithms that assume Z as the number of nearest-neighbor segments for each 
segment [24, 25]. Use of equation 4.2 requires a prediction of the energy of mixing and 
assumes that the interaction parameter scales with reciprocal temperature. 
Alternative temperature functionality can be introduced by modifying the equation for 
XFH resulting in a generalized interaction parameter, %, such as 
A and B are empirical constants for a particular system but can be related to non-
combinatorial entropie effects (A) and enthalpic interactions (B). Computational techniques 
for predicting % rely on predictions of the energy of mixing. 
The solubility parameter approach predicts miscibility based on the relative values of 
the Hildebrand solubility parameter, 5 [26]. The solubility parameter is the square root of the 
cohesive energy density 
Ecoh is the cohesive energy, which is defined as the increase in the potential energy of a 
system when all intermolecular interactions are turned off. 8 can either be obtained 
experimentally or it can be predicted. Predictions usually rely on group contribution 
techniques (such as those reviewed in [27]) and experimental techniques involve comparing 
the solubility of the polymer of interest in solvents with known solubility parameters. The 
(4.3) 
S = 
I V J (4.4) 
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former technique may require a database of known compounds and does not account for the 
particular interactions between specific moieties in the materials of interest. The latter 
follows the line of reasoning that if A dissolves B and A dissolves C then B dissolves C. An 
alternative computational technique for obtaining ECOh is described below in the section on 
the Amorphous Cell algorithm. 
Hildebrand and Scott [26] predict xfh as 
(4.5) 
The solubility parameter method can be used as a fast and simple screening method, 
but may provide misleading results when specific interactions between moieties in the two 
polymers (such as hydrogen bonds) that are not present in either of the homopolymers affect 
the solubility [28]. Another limitation is that since the interaction parameter computed from 
equation 4.5 is always positive, decreasing with temperature, and independent of 
composition, only UCST behavior can be predicted by this technique. 
4.3.2 Small-angle X-ray scattering (SAXS) 
SAXS experiments designed to probe the microstructure of amorphous polymers can 
be used to determine the interaction parameter. The intensity of scattered radiation, I, as a 
function of the scattering vector, q (q = 4 7t sin (9/2)/X;..6 = scattering angle and X is the 
wavelength of the incident radiation), is related to the structure factor, S(q), which represents 
the root-mean-square electron concentration fluctuation by 
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Here Aï] is the difference in electron density between the two components, V is the volume 
of a monomer (chosen as an SA monomer in our study), and ae is the scattering cross section 
of an electron (6.653 x 10"9 Â2). The electron densities are computed from the known mass 
densities of the polymers. (For the poly(CPH)/poly(SA) pair, Ar|= 0.0315, 0.0322, 0.0331 
and 0.0341 e" Â"3 at 140, 150, 160, and 170 °C respectively.) The structure factor is then 
related to the interaction parameter by de Gennes' random phase approximation [29]. 
(4.7) 
Here fb is the Debye structure factor and R<j,2 is the mean square radius of gyration. %s is the 
value of the interaction parameter at spinodal conditions. The parameters can be computed 
as [30,31] 
lim(/„(?!,V))s N 
v'-k*'2 (4.8) 
= 0.5 i i ^ + 
#7 
(4.9) 
(4.10) 
Here Na is the degree of polymerization of component A based on the monomer volume, V, 
in equation 4.7. (Because the volume of a CPH monomer is about twice that of the SA 
monomer, the monomer volume is taken as the volume of an SA monomer. Since the CPH 
monomer unit is symmetric, the degree of polymerization is computed assuming that 
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monomer is half the CPH monomer shown in Figure 4.1 - essentially resulting in a head-to-
head polymer). In equation 4.9, § is the volume fraction of component A, and RA2 is the 
mean square radius of gyration of molecules in component A. Substituting equation 4.8 into 
equation 4.7, one obtains (for § = 0.5) 
S(q)~l = 2[zs - %(T)]+ 2%s^ q2 (4.11) 
Linear extrapolation of the Zimm plot (S_1(q -> 0) vs. q2) gives the interaction parameter 
(from the intercept) and the radius of gyration (from the slope in a q region where qR<j, < 1.3). 
The approximation in equation 4.8 is valid in Guinier range (I(q) ~ exp(-Cq2)) that can be 
identified by a linear region in a Guinier plot (Ln[I(q)] vs. q2) where qR^ <1.3 [32]. 
4.3.3 Molecular dynamics (MD) 
Case and Honeycutt review several computational techniques for studying the phase 
behavior of polymer systems [23]. Here we use the Amorphous Cell algorithm available in 
the software package Materials Studio® from Accelrys Inc., which employs MD 
calculations, to predict the phase diagram of the poly(CPH)/poly(SA) blend system. This 
algorithm has been shown to be reliable for predicting bulk properties of polymeric systems 
[23, 33-35], We compare the MD predictions to a simple solubility parameter prediction 
technique. Our overall goal is to lay the foundation for studies aimed at characterizing 
blends of CPH-SA copolymers and drug solubilities and release kinetics from this polymer 
system. 
The Amorphous Cell algorithm computes cohesive energy densities from MD 
simulations on models of bulk amorphous polymer systems [36]. Periodic boundary 
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conditions are used to eliminate edge effects. As with any molecular simulation, it is 
imperative to begin with a reasonable starting configuration, since the CPU time required to 
simulate even very small times (e.g. nanoseconds) becomes prohibitively large for polymers 
[23]. Simulations are typically conducted over times on the order of picoseconds to a few 
nanoseconds on structures that are already assumed to be near equilibrium. Thus, the 
phenomena of mixing and de-mixing cannot be directly observed [36]. Rather, the energies 
of mixed and de-mixed configurations are compared to discern which is the more favorable. 
Theodorou and Suter [36] described an algorithm for the construction of amorphous cells 
based on a modified form of Flory's rotational isomeric states (RIS) theory [37]. Since then, 
some of their assumptions have been relaxed and the present model is fully atomistic, with no 
'united-atom' groups. Bond stretching, angle bending, and out-of-plane bending are all 
allowed in addition to dihedral angle rotation. The temperature in the current model is 
explicit, rather than simply being implied by the density. And, the newer condensed-phase 
optimized molecular potentials for atomistic simulation studies (COMPASS) force field [38] 
is used, rather than the consistent valence force field (CVFF). The amorphous cells are 
equilibrated and evolved using molecular dynamics. The energy of mixing per unit volume 
is computed from the cohesive energy densities of the two homopolymers and the blend via 
AEmx=A^f) +(1-A 
\ v J a  ( / B V J blend (4.12) 
X can then be computed from 
(4.13) 
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The coordination number Z has been dropped (c.f. equation 4.2) because in this algorithm 
AE^ is a bulk (rather than pairwise) energy of mixing per unit volume. 
The advantage of this technique is that direct simulation of the bulk state can be 
obtained, with careful system construction. Therefore, any non-combinatorial entropie 
effects can be implicitly included in the enthalpic calculation. For example, if one is 
interested in volume changes on mixing, MD can be performed in the NPT ensemble, 
allowing the density to change. Additionally, enthalpic effects that may be unique to the 
blend system (i.e. interactions between pairs of atoms or groups that do not occur in the 
homopolymer systems) are accounted for. These are neglected in the solubility parameter 
approach. 
4.4 Experimental 
4.4.1 Materials 
Sebacic acid (99%), N-methyl-2-pyrolidinone, and p-carboxy benzoic acid (99+%) 
were purchased from Aldrich (Milwaukee, WI). 1,6-dibromohexane (98%) was purchased 
from Acros (Fairlawn, NJ). Acetic anhydride, chloroform, and methylene chloride were 
purchased from Fisher (Fairlawn, NJ) and deuterated chloroform was purchased from 
Cambridge Isotope Laboratories, Inc. (Andover, MA). Petroleum ether (hexanes, 55% n-
hexane) was purchased from Fisher and dried and distilled over sodium and benzophenone 
(Fisher) before use. 
4.4.2 Polymer synthesis 
The homopolymers, poly(SA) and poly(CPH), were synthesized as previously 
reported [4], Briefly CPH diacid was synthesized by a method similar to that described by 
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Conix [39] for 1,3-bis(p-carboxyphenoxy) propane and purified by recrystallization from N-
methyl-2-pyrolidinone three times. CPH and SA diacids were acetylated to form the 
prepolymers by refluxing in excess acetic anhydride for 30 minutes (SA) or 60 minutes 
(CPH) under dry nitrogen sweep. Purification of the crude prepolymers was done using the 
methods previously reported [4], 
Melt polycondensation of the prepolymers was performed at 180 °C under vacuum 
(<0.5 mmHg) for 90 minutes. About 2 ml of acetic anhydride was added to 4 g of 
prepolymer prior to polymerization to ensure complete acetylation. The polymer was 
isolated by dissolution in methylene chloride and precipitation in dry hexane, followed by 
filtration and drying under vacuum. The polymers were desiccated under dry argon to 
prevent degradation. Blends were formed by co-dissolution in chloroform or methylene 
chloride, and evaporation at room temperature with gentle agitation when dry samples were 
required. 
4.4.3 Polymer characterization 
Polymers were characterized by 'H NMR in deuterated chloroform on a Varian VXR 
300 MHz spectrometer (Varian Inc. Palo Alto, CA). Molecular weight was assessed via gel 
permeation chromatography (GPC). GPC samples were dissolved in HPLC-grade 
chloroform and separation was done using PL Gel columns from Polymer Laboratories 
(Amherst, MA) on a Waters GPC system (Milford, MA). 50 fil samples were eluted at 1 
ml/min. Elution times were compared to poly(methyl methacrylate) standards from Fluka 
(Milwaukee, WI). Differential scanning calorimetry on a DSC-7 (Perkin Elmer, Shelton, 
CT) was used to characterize the thermal transitions of the polymers. Samples were heated at 
5 °C/min and the data were taken on the second heating cycle. The molecular properties are 
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listed in Table 4.1. The polycondensation synthesis typically results in high polydispersity 
index as noted in Table 4.1. 
Table 4.1. Molecular properties of polymers used in this study. 
Polymer Mn PDI Tg CQ Tm (°C) 
Poly(CPH) 14000 2.5 47 143 
Poly(SA) 10000 3.5 60 82 
4.4.4 SAXS Experiments 
Samples for SAXS were prepared by melting the polymer into custom aluminum 
sample holders with a thickness of 35 pm. These make ideal sample holders because the 
aluminum is fairly transparent to 12 keV X-rays used in these experiments, and the rigid pans 
maintain the sample thickness when the polymer is melted in the vertically mounted SAXS 
sample chamber. The sample thickness was 2.2 mm. SAXS measurements were carried out 
on the instrument at 12-ID beam line at the Advanced Photon Source [40]. A 15 cm x 15 cm 
CCD detector was used to measure the intensity of scattering and the direct beam intensity 
was measured using a photodiode. The sample chamber was equipped with a custom furnace 
for heating the samples without interfering with the beam, permitting in situ data collection. 
A 50:50 (v/v) blend sample was used and data were collected at 140, 150, 160 and 170 °C. 
We know from prior experiments that the blend would be phase separated at room 
temperature [14]. And, because we perform copolymerization under vacuum at 180 °C, 
yielding random copolymers [8], we anticipate that the blend would become miscible as the 
temperature approaches 180 °C. 
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Five data sets were collected at each temperature with exposure times of 0.5 seconds 
at an incident beam energy of 12 keV (X = 1.035 Â). The distance between the detector and 
the sample was 4 m. The scattering data were appropriately corrected and azimuthally 
averaged to obtain I'(q). 
The one-dimensional data were averaged for the five runs to obtain a single one-
dimensional data set for each condition. These data were then corrected by subtracting the 
scattering due to a blank aluminum holder and normalized to an absolute scale with a 
polyethylene standard according to 
Here I(q) represents the normalized intensity on an absolute scale, I'pe is the intensity of the 
polyethylene standard measured at identical configuration, and d?E and dsampie are 
respectively, the thicknesses of the PE standard (0.078 cm) and the sample, measured with a 
micrometer. The PE standard produces a peak at q = 0.0245 Â"1 whose absolute intensity is 
25.4 cm'1. 
4.4.5 AFM experiments 
Silicon wafers (approximately 1.5 cm x 1.5 cm) were cleaned by a modified version 
of the RCA clean procedure [41]. Briefly, wafers were soaked for ten minutes in an organic 
clean solution (70:15:15 deionized water: ammonium hydroxide: hydrogen peroxide), rinsed, 
and then soaked for ten minutes in an ionic clean solution (70:15:15 deionized water: 
hydrochloric acid: hydrogen peroxide). Both solutions were at 70 - 80 °C. No etch solution 
was used. Wafers were then cleaned using a CO? Snow Jet (Applied Surface Technologies, 
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New Providence, NJ). A 20 nm layer of gold was deposited on the wafers by sputter coating. 
Films were spun cast at 1500 rpm for 30 sec using a spin coater (Headway Research Inc., 
Garland, TX) from a 1% (w/v) solution of polymer in HPLC-grade chloroform, filtered 
through 0.2 pm PVDF membrane syringe filters (Pall Gelman, Portsmouth, UK) onto the 
gold-coated silicon wafers. This procedure results in films of uniform thickness of 200 nm. 
Films were dried at room temperature and atmospheric pressure for one hour. Films were 
annealed at temperatures of interest for up to 12 hours under vacuum (< 10"4 torr) in a custom 
built annealing oven equipped with a hot stage, turbo molecular pump, roughing pump, and 
vacuum gauge (MKS Instruments, Boulder, CO). Annealed films were quenched on dry ice 
under dry argon to below the glass transition temperature, in order to "freeze" the phase 
morphology prior to AFM experiments. 
AFM images were obtained on a Dimension 3000 Scanning Probe Microscope 
(Digital Instruments, Santa Barbara, CA). The AFM was operated in contact mode using an 
Ultrasharp silicon cantilever (Mikromasch, Tallinn, Estonia) with a force constant of 0.30 
N/m. All the films were about 200 nm thick, as measured by scratching the surface of the 
film and performing a line profile measurement with the AFM. Root-mean-square 
roughnesses were computed from AFM measurements as well. 
4.4.6 Optical m icroscopy 
Round glass coverslips from Fryer Company Inc. (Bloomington, MN) were cleaned 
by treatment in acetone, methanol, and chloroform at room temperature. Samples for optical 
microscopy were spun cast (500 rpm, 30 sec) onto the coverslips from 10% (w/v) solutions 
of polymer blends in HPLC-grade chloroform filtered with 0.2 fxm PVDF membrane syringe 
filters. The resulting films were approximately 50 to 100 pm thick. Samples were dried in 
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air and observed under a Nikon Eclipse ME600L microscope (Fryer) in reflected light mode 
using a lOOx long-working-distance objective. The microscope was equipped with a CCD 
camera (Hitachi Kokusai Electric Inc., Tokyo, Japan) and an A-200 heating stage (Fryer). 
The long working distance objective is necessary to protect the optics from the heating stage. 
4.4.7 Molecular dynamics simulations 
The MD simulations were conducted on a Dell Optiplex™ PC with an Intel® 
Pentium® 4 (3.06 GHz) processor and 1024 GB of RAM. The model systems were 
constructed using the Amorphous Cell module of the Materials Studio® 2.1 software 
package (Accelrys Inc., San Diego, CA). 
4.5 Results and Discussion 
4.5.1 Phase diagram from SAXS 
The SAXS data for the melts had significant contribution from voids especially in the 
low q region. The fast decay of the scattering from the voids becomes insignificant at q > 
0.01 À"1. This parasitic scattering from the voids, Ip, behaves as 
and must be subtracted. Provided that the voids have radii larger than the radii of gyration of 
the polymer chains, the constant, C, can be determined from the intercept of a plot of Iq4 vs 
q4 [42]. The region over which this correction is fit was chosen as the region below the 
Debye region from the Kratky-Porod plot [30]. The corrected scattering data are shown in 
Figure 4.2, and the Zimm plots of the same data at four temperatures are shown in Figure 4.3. 
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Interaction parameters were obtained from the intercepts of the Zimm plots following 
equation 4.11. The values of the interaction parameter are plotted in Figure 4.4, from which 
the temperature dependence of % can be extracted as: 
X ' -2.04 + 802 (4.16) 
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Figure 4.2. Corrected SAXS data for poly(CPH)/poly(SA) blend at T = 140 °C (X), 150 
°C(Q), 160 °C (A), and 170 °C (O). 
Because % decreases with temperature, the system becomes less miscible at lower 
temperatures, and an upper critical solution temperature (UCST) is predicted. This is 
consistent with the observations noted earlier. The critical temperature (% = %s) for the 
particular molecular weights studied here is 114 °C (from equations 4.10 and 4.16). The 
mean square radius of gyration, R^2, is determined from the slope in the Zimm plot by 
equation 4.11. The average value of R^ is 107 Â. The relatively high value of the R^ results 
from the high polydispersity of these polymers (see Table 4.1) as the R^ from scattering 
corresponds to the z-average radii of gyration of the polymers [43]. 
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Figure 4.3. Zimm plot of corrected SAXS data for T = 140 °C (X), 150 °C(0), 160 °C (A), 
and 170 °C (•). 
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Figure 4.4. Temperature dependence of % obtained from SAXS. 
Equation 4.16 can now be used in conjunction with the Flory-Huggins formulation of 
AGmix (equation 4.1) to predict the phase diagram. The spinodal curve (boundary between 
metastable and unstable regions) is defined by the locus of inflections in AGmjX/RT vs. <|) 
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plotted on the T-<|) plane [31]. And, the binodal curve (boundary between metastable and 
stable regions) is the locus of points of common tangency (equal chemical potential) in 
AGmjx/RT vs. (j) plotted on the T-<|) plane [31]. The phase diagram obtained is shown in 
Figure 4.5. 
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Figure 4.5. Phase diagram for poly(CPH)/poly(SA) blend system obtained from SAXS, and 
cloud point data from optical microscopy (•). The spinodal curve is indicated by the gray 
line, and the binodal curve is indicated by the black line. 
4.5.2 Cloud point curve from optical microscopy 
In order to verify the phase diagram obtained from the SAXS experiments, we 
performed in situ optical microscopy of blend films on a heating stage and recorded the cloud 
points. Below the critical point of the blend, phase separation is apparent, as concentration 
fluctuations in the film make the film appear cloudy. Upon heating through the first-order 
phase transition, the film homogenizes and becomes transparent. The cloud points for the 
poly(CPH)/poly(SA) blend system are plotted in Figure 4.5 along with a prediction of the 
binodal and spinodal curves predicted for the blends used to make the microscopy samples. 
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The cloud point curve closely matches the predicted binodal curve. The error bars on 
the cloud point data indicate the 5 °C confidence with which the temperature of the film is 
controlled and the cloud points can be accurately observed. 
Cloud points can only be obtained in regions of the phase diagram where 
inhomogeneities due to crystallinity are not observed. (Both poly(SA) and poly(CPH) are 
semicrystalline, as stated before.) For compositions rich in poly(SA) crystallinity does not 
interfere, as poly(SA) melts at 82 °C. Unfortunately, poly(CPH) has a melting point above 
the critical point of the blend and a glass transition temperature of only 47 °C. (See Table 
4.1.) So attempts to anneal blend films to rid them of poly(CPH) crystals are thwarted by 
crystallization during the cloud point observation. A further complication is that the length 
scale of the phase separation is very near the limits of the resolution of the microscope, so 
inhomogeneities due to amorphous phase separation cannot be discerned from those due to 
crystallinity. As the poly(CPH) content was increased, the apparent cloud point approached 
the melting temperature of poly(CPH) (143 °C), indicating that what was observed was 
actually the transition in the crystalline phase. Therefore, we were unable to accurately 
discern the cloud point for blend samples rich in poly(CPH) from in situ optical microscopy. 
4.5.3 AFMfor validating the CPH-rich region of the phase diagram 
Observation of cloud points in the poly(CPH)-rich region of the phase diagram 
requires microscopic methods with higher resolution than that provided by optical 
microscopy, so that crystallinity can be discerned from amorphous phase separation. To 
accomplish this, ex situ atomic force microscopy (AFM) experiments were performed. It 
was not our goal with the AFM experiments to actually find the cloud point, as this would be 
very inefficient without the ability to perform AFM in situ. Rather we performed the AFM 
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experiments in order to: A) determine an approximate length scale for the phase separation 
to verify that the cloud points observed in optical microscopy are real; and B) determine 
whether the predicted phase diagram accurately described the phase behavior in the 
poly(CPH)-rich region. Table 4.2 shows the compositions and temperatures studied. A 
temperature of 180 °C was chosen because this is the temperature at which we perform melt 
polycondensation to make copolymers. The 47:53 and 78:22 compositions were chosen 
because these are compositions from which we make copolymers. 
The AFM scans obtained are shown in Figures 4.6, 4.7, and 4.8. We observe that for 
thin films, the length scale of the phase separation is on the order of 1 pm (Figures 4.6 and 
Figure 4.7), which is about the limit of resolution of the optical microscope. Figure 4.6 
shows clear evidence of phase separation in the 47:53 and 78:22 blends at room temperature. 
The phase separation persists in the films annealed at 90 °C (Figure 4.7). Figure 4.8 shows 
the 47:53 and 78:22 blend films annealed at 180 °C. The root-mean-square roughnesses 
obtained from AFM are summarized in Table 4.2. It is instructive to note that the surface 
roughnesses for the phase-separated films are an order of magnitude higher than those for the 
homogenous films. The phase behavior observed in the AFM scans is consistent with the 
phase diagram shown in Figure 4.5. 
Table 4.2. RMS roughness of blend films obtained from AFM experiments. * indicates 
phase-separated systems. 
RMS Roughness (nm) 
Blend Composition 
Room Temperature 90 °C 180 °C 
47:53 CPH:SA 39.2* 32.8* 7.7 
78:22 CPH-.SA 73.5* 54.1* 4.2 
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Figure 4.6. AFM scans of as-cast poly(CPH)/poly(SA) blend films . (A) 5p.m x 5 (am scan of 
47:53; (B) 10 jam xlO^m scan of 78:22. RMS roughness is shown in Table 4.2. 
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Figure 4.7. AFM scans of poly(CPH)/poly(SA) blend films after annealing at 90°C and < 
10"4 torr. (A) 5 p.m x 5 |im scan of 47:53; and (B) 20 j-im x 20 p,m scan of 78:22. RMS 
roughness is shown in Table 4.2. 
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Figure 4.8. AFM scans of poly(CPH)/poly(SA) blend films after annealing at 180 °C and 
<10"4 torr. (A) 5 jam x 5 (o,m scan of 47:53 and (B) 5 pm x 5 fj,m scan of 78:22. RMS 
roughness is shown in Table 4.2. 
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4.5.4 MD simulations to predict energetic and structural parameters 
We conducted molecular dynamics simulations using the Amorphous Cell® 
algorithm described earlier to predict ECOh for each of the homopolymers and the 51:49 
poly(CPH)/poly(SA) blend. Systems were constructed in cubic simulation boxes with 
periodic boundary conditions, using a modification of Flory's rotational isomeric states (RIS) 
theory, employing the Meirovich scanning method [44]. This method looks ahead six bonds, 
while considering a maximum of 128 configurations when constructing the amorphous cells. 
The boxes were constructed according to the parameters in Table 4.3, containing CPH 
tetramers (80 backbone bonds) and/or SA heptamers (81 backbone bonds). The acid end 
groups of each chain were acetylated to eliminate the otherwise unrealistic concentration of 
acidic protons. For each set of conditions, five simulation boxes were constructed at a 
density of 0.6 g/cm3. The raw structures were equilibrated to the target density via 
subsequent NPT molecular dynamics. Special care was taken to ensure that speared and 
catenated phenyl rings were eliminated. Where necessary, configurations were manually 
repaired followed by short NVT molecular mechanics runs (1000 steps) to equilibrate the 
structures. 
Experimental densities for polyanhydrides are not reported in the literature, though 
Thomas et al. [3] estimate a density of 1.1 g/cm3. We predicted the densities listed in Table 
4.3 via NPT molecular dynamics simulations using the Andersen thermostat and Andersen 
barostat [45]. Van der Waals and Coulombic interactions were both summed by the Ewald 
method. (See description in [46] and references therein.) Runs of 100 ps (100,000 time steps 
of 1 fs) were required to equilibrate the density. 
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Table 4.3. Parameters used to define simulation boxes for NVT MD simulations. 
Composition #o f  
atoms 
Temperature Density 
(g/cm ) 
Box length 
(nm) 
Poly(CPH) 
(8 CPH tetramers) 1544 
363 
453 
1.1192 
1.0756 
25.90 
26.24 
51:49 Blend 
(4 CPH tetramers, 4 
SA heptamers) 
1636 
363 
453 
1.0656 
1.0185 
26.11 
26.50 
Poly(SA) 
(8 SA heptamers) 1728 
363 
453 
1.0017 
0.9397 
25.20 
26.99 
NVT MD simulations were then used to predict cohesive energy densities using the 
Andersen thermostat [45]. Simulations were run for 400 ps (400,000 time steps of 1 fs). The 
cell multipole method [47] was used for computing Coulombic interactions. At each 
temperature, the cohesive energy densities were sampled at 4 ps intervals. Temperature and 
potential energy were monitored at 1-ps intervals. The cohesive energy density was averaged 
over each of several starting configurations for each set of conditions. The energies of 
mixing were computed according to equation 4.12 and the interaction parameter was 
computed according to equation 4.13. The values for % are plotted in Figure 4.9 along with 
the values obtained from SAXS. These results are consistent, validating extrapolation of 
SAXS x into the immiscible region of the phase diagram, and demonstrating the value of the 
MD approach to predict energetics of the poly(CPH)/poly(SA) blend system. 
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Figure 4.9. Comparison of % values obtained from SAXS (•) and those computed from 
molecular dynamics (O). 
The molecular simulations permit the calculation of a variety of interesting structural 
parameters. In particular, characteristic ratios can be estimated (CŒ>CPH = 6.8 and COO,SA = 
4.8). These parameters will be used in future mesoscale studies, along with the predicted 
interaction parameters to investigate the phase behavior of both random and block 
copolymers. 
We compare the results from the molecular simulations to solubility parameter 
predictions based on a group contribution method. The method of Fedors (reproduced in 
[27]) was used to compute ECOh, which was scaled with our predictions of the densities to get 
ECoh/V. The results are reported in Table 4.4 and compared to the solubility parameters of 
known solvents. The interaction parameter for the poly(CPH)/poly(SA) blend computed 
from equation 4.5 is 0.125 at 298 K. However, from equation 4.16, the value of % is 0.65. 
The solubility parameters obtained from the group contribution method have no temperature 
dependence, so the critical temperature can be computed by rearranging equation 4.5 and 
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Computing the spinodal interaction parameter from equation 4.10. The critical temperature 
obtained in this way from the solubility parameters is 812 °C. Clearly, the solubility 
parameter approach is insufficient for accurately predicting the phase behavior of this 
system. 
Table 4.4. Solubility parameter predictions from the group contribution method of Fedors 
reproduced in [27]. Solubility parameters are reported at 298 K. 
Compound Ecoh/V (J/cm3) ô(J/cm3)m 
Poly(CPH) 443.6 21.1 
Poly(SA) 390.1 19.8 
Chloroform8 19.0 
Methylene Chloride8 19.8 
"Data from [26]. 
4.6 Conclusions 
The phase behavior of the poly(CPH)/poly(SA) blend system was studied by 
measuring the CPH-SA segmental interaction parameter, %, using in situ SAXS experiments. 
The predicted phase diagram is in good agreement with the cloud point measurement of 
poly(SA)-rich blends using optical microscopy. However, it was impossible to obtain cloud 
points for poly(CPH)-rich blends by optical microscopy, due to crystallinity, so this region of 
the predicted phase diagram was validated by AFM. The information from these three 
complementary techniques provides a complete description of the phase diagram of this 
system. The use of molecular dynamics to study this system was validated by the prediction 
105 
of the cohesive energy density and comparison to the experimental results. Both the 
experimental methods and the computational techniques were shown to be superior to the 
solubility parameter approach. 
More importantly, the accurate temperature dependence of % can now be used to 
predict the phase behavior of copolymer systems that is of interest for drug delivery 
applications. Knowledge of the phase behavior will enable the development of accurate drug 
release models and the rational design of controlled release devices. 
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CHAPTERS 
MORPHOLOGY OF POLYANHYDRIDE COPOLYMERS: 
TIME-RESOLVED SAXS STUDIES OF CRYSTALLIZATION 
This is a preprint of an article accepted for publication in Journal of Polymer Science Part B: 
Polymer Physics Copyright ©(2004), Wiley Periodicals, Inc. 
Matt J. Kipper1,2, Soenke Seifert3, P. Thiyagarajan4, and Balaji Narasimhan1,5 
5.1 Abstract 
Synchrotron Small Angle X-ray Scattering (SAXS) is used to study the isothermal 
crystallization kinetics of a family of polyanhydride copolymers, consisting of 1,6-bis(p-
carboxyphenoxy)hexane and sebacic acid monomers. In-situ SAXS experiments permit the 
direct observation of crystallization kinetics. Structural parameters (long period, lamellar 
thickness, and degree of crystallinity) are obtained from Lorentz-corrected intensity profiles, 
one-dimensional correlation functions, and interface distribution functions in order to obtain 
a comprehensive picture of the crystal morphology. The combination of these three analyses 
provides information not only on the lamellar dimensions, but also on the polydispersity 
(non-uniformity) of these dimensions. Where possible, the crystallization kinetics are 
interpreted using a modified version of the Avrami equation. The results can be used to 
1 Department of Chemical Engineering, Iowa State University. 
2 Graduate student, primary author. 
3 Advanced Photon Source, Argonne National Laboratory. Assisted with SAXS instrumentation. 
4 Intense Pulsed Neutron Source, Argonne National Laboratory. Assisted with interpretation of SAXS data. 
5 Major professor, corresponding author. 
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perform rational design of controlled drug release formulations as crystallinity affects drug 
release kinetics. 
Keywords: SAXS, crystallization, biomaterials, biodegradable 
5.2 Introduction 
Polyanhydrides have been extensively studied as potential vehicles for controlled 
drug delivery1"14. Their hydrophobicity, combined with the very high reactivity of the 
backbone with respect to hydrolytic degradation leads to surface erosion in most cases15'16. 
In this process, the overall hydrophobicity of the polymer matrix prevents water from 
penetrating into the bulk of the polymer. This may be advantageous for the stabilization of 
macromolecular drugs. Additionally, because diffusion is limited in the bulk polymer, drug 
release is determined by the erosion profile14'17. However, ample evidence exists to conclude 
that multiple phases exist in most bulk polyanhydride devices designed for drug 
delivery11'12,18"22. The semicrystalline nature of many polyanhydride homopolymers has also 
been reported. (See references in23). Because the erosion rate is strongly affected by the 
molecular interactions between water and bulk polymer, it is hypothesized that crystalline 
regions do not erode at the same rate as amorphous regions. The resulting non-homogenous 
surface erosion has been demonstrated experimentally19,20,24. Additionally, it has been shown 
that blends and copolymers of polyanhydrides exhibit phase separation25 and microphase 
separation11 respectively, which can have profound effects on drug release kinetics, 
particularly when drugs partition and when the two phases have different erosion rates12,17. 
Our research has focused on polymers based on the monomers 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) (Figure 5.1) because random 
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copolymers can be synthesized and these two materials erode at vastly different rates. 
Further, we have proposed that by exploiting the inherent microstructure of this system we 
can further tailor release profiles17. Thus we have pursued a detailed description of the 
microstructure of this system11'12'14'17'25'26. Previously we have characterized the 
microstructure by wide-angle X-ray diffraction, differential scanning calorimetry, and atomic 
force microscopy11'26. From these experiments, degrees of crystallinity and lamellar 
thickness in addition to thermal properties were determined. 
Figure 5.1. Poly(CPH) (top) and Poly(SA) (bottom). 
In the present work we investigate the kinetics of crystallization of the series of 
copolymers by synchrotron small-angle X-ray scattering (SAXS). This has proven to be a 
powerful technique for assessing the microstructure of semicrystalline polymers by 
permitting the acquisition of detailed data on time scales on the order of the crystallization 
kinetics27"31. 
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5.3 Experimental 
5.3.1 Polymer synthesis and characterization 
Polymers were synthesized as previously reported13, and characterized by differential 
scanning calorimetry (DSC 7, Perkin Elmer, Shelton, CT), gel permeation chromatography 
(GPC) (Waters Corp. Milford, MA), and proton nuclear magnetic resonance spectroscopy 
(*H NMR) in deuterated chloroform (VXR 300, Varian Inc., Palo Alto, CA). The results of 
the characterization are reported in Table 5.1. DSC samples were heated at 5 °C per minute 
and transitions were identified on the second heating cycle to confirm the previously 
obtained values23. GPC samples were dissolved in HPLC-grade chloroform and separation 
was done using PL Gel columns from Polymer Laboratories (Amherst, MA) on a Waters 
GPC system. 50 f_il samples were eluted at 1 ml/min. Elution times were compared to 
poly(methyl methacrylate) standards from Fluka (Milwaukee, WI). The *H NMR spectra 
were interpreted as follows32,33: Poly(SA): aliphatic protons 8 = 1.32 (multiplet, H8), 8 = 1.65 
(multiplet, H4), S = 2.35 (triplet, H2 a to carboxylic acid end group), and 8 = 2.45 (triplet, H2 
a to anhydride bond); acetyl protons 8 = 2.22 (singlet, H3 acetylated end). Poly(CPH): 
aromatic protons 8 = 6.95 (multiplet, H4), 8 = 7.99 (multiplet, H4 (3 to acetylated and 
carboxylic acid ends), and 8 = 8.08 (doublet, H4 a to internal anhydride bond); aliphatic 
protons 8 = 4.06 (triplet H2 a to ether oxygen); acetyl protons 8 = 2.22 (singlet, H3 acetylated 
end). Copolymers: CPH aromatic protons 8 = 7.9 - 8.15 (multiplet H4) and 8 = 6.85 - 7.05 
(multiplet H4); CPH aliphatic protons 8 = 4.06 (triplet H2 a to ether oxygen); SA aliphatic 
protons 8 = 2.35 (triplet, H2 a to carboxylic acid end group), and 8 = 2.45 (triplet, H2 a to 
anhydride bond); acetyl protons 8 = 2.22 (singlet, H3 acetylated end). 
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Table 5.1. Characterization of polymers used in this study. 
Polymer 
Tg 
(°C) 
Tm 
(°C) 
Actual Composition 
(CPH:SA) 
PDI 
Poly(SA) 62 81 0:100 10,300 3.5 
20:80 (CPH:SA) 50 67 17:83 9600 2.2 
50:50 (CPH: SA) a 50 48:52 6700 2.0 
80:20 (CPH:SA) 33 114 78:22 9700 2.1 
Poly(CPH) 48 143 100:0 14,300 2.8 
aNo Tg is observed above room temperature. 
5.3.2 SAXS experiments 
Samples were prepared for SAXS by melting the polymer into DSC aluminum 
sample pans (Perkin Elmer). These make ideal sample holders because the aluminum is 
fairly transparent to the high-brilliance X-rays used in this study, and the rigid pans maintain 
the sample thickness when the polymer is melted in the vertically mounted SAXS sample 
chamber. The thickness of each sample was accurately determined using a micrometer and 
the values were between 500 and 1000 |a.m. The samples were subsequently annealed in a 
DSC (DSC7, Perkin Elmer) by heating above the melting temperature for five minutes, and 
then rapidly quenched to below the Tg. The SAXS experiments were conducted at Beamline 
12-ID at the synchrotron beam source at Argonne National Laboratory34. A custom heating 
furnace was used which permits accurate temperature control without interfering with the 
beam, thus permitting in situ data collection. The incident beam energy was 12 keV (X = 
1.035 Â). A 15 cm x 15 cm CCD detector, at a distance of 2 m from the sample, was used to 
measure the intensity of scattering and the transmitted beam intensity was measured using a 
114 
photodiode on the beam stop. The scattering data were appropriately corrected and 
azimuthally averaged to obtain the one-dimensional intensity data, I'(q), as a function of 
scattering vector, q (q=47tsin(6/2)/X; 0=scattering angle; X=incident radiation wavelength). 
The resulting intensity data were corrected for the scattering from the blank aluminum 
sample pan. Data were collected at five-second, ten-second and 30-second intervals during 
isothermal crystallization at two temperatures (using separate samples) for each polymer. 
5.4 SAXS Analysis 
Several additional corrections to the raw data must be made prior to extracting the 
morphological parameters of interest. Noise reduction, particularly in the high-q region, is 
essential to obtain suitable signal-to-noise ratios. This was accomplished by the data 
smoothing technique proposed by Hsiao and Verma35. 
Here I; represents the smoothed data and I'j represents the raw data. This method is very 
effective at eliminating noise. The parameter n was set to zero at low q and increased 
linearly with the scattering vector to account for the higher signal-to-noise ratio at higher q. 
The finite q-range over which data is collected requires extrapolation in both the 
and to simultaneously correct for background scattering. This was done by fitting the high-q 
j  ^  I j -n  +  I j -n+1 + - I j -1  + I ' i + I ' i + l + I ' i + 2 + -  +  I '  
2n + l 
(5.1) 
high-q and low-q regions36. The Porod law35 was used to extrapolate the scattering at high-q 
region to 35 
(5.2) 
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Here ICOrr is the corrected intensity, ly is the background scattering, and Kp is the Porod 
constant. The background scattering was subtracted to obtain Icorr over the entire q range and 
the high q range decays as Kp q~4. Extrapolation to zero scattering vector in the region of the 
beam stop was accomplished by linear extrapolation of the log of the intensity: 
b(Ln)=aq + b (5-3) 
The resulting intensity profiles were then modified via the Lorentz correction to obtain I|(s) 
as 
I,(s)=Wl(s) (54) 
Here s = q/2%. Bragg's law was used to find the long period (LB) directly from the position 
of the first maximum in the Lorentz-corrected intensity profile, s*. 
L„ = -1 (5.5) 
s* 
The one-dimensional correlation function, y(r), offers more details of the 
microstructure36 and is found by taking the Fourier cosine transform of I;(s). 
;r(r) = — |° I, (s)cos(2%sr)ds 
Qi (5.6) 
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Here Qi is the invariant of the first file. The invariant was computed for each file as the area 
under the Lorentz-corrected intensity profile. 
Q=f I i ( s) i s  (5.7)  
From the one-dimensional correlation function, the long period is given by the position of the 
first maximum, r*. The degree of crystallinity, o% is obtained as 
ay=1 Q + A' 
1 _  Q + A'  aT> 0 '5  
(5.8) 
Here A is the absolute value of the correlation function at the first minimum. The ambiguity 
in equation 5.8 arises from the fact that the scattered intensity of a sample with crystallinity 
ay is identical to that with a crystallinity of 1- ay, necessitating additional information in 
order to absolutely determine the crystallinity. This ambiguity is dealt with in the next 
section. The electron density contrast between the crystalline and the amorphous domains 
can be obtained36 from 
/ v A'+Q' (Pc ~ p j  =  (5.9) 
Here (pc - pa)2 represents the electron density contrast (scattering cross sectional area per 
squared unit volume) between the crystalline and amorphous phases. A' and Q' represent the 
117 
values of A and Q normalized to an absolute intensity scale. Normalization is performed 
with reference to a polyethylene standard as previously described25. 
The interface distribution function, g(r), can also be used to obtain morphological 
data36. The interface distribution function is obtained by taking the Fourier transform of the 
interference function. 
g(r)=87r2 |°[lp -s2I,(s)]cos(2^sr)ds (5.10) 
Ip = !™s2I'(s) (5.11) 
For a lamellar system, the position of the first maximum in g(r), ri, gives the length scale of 
the smallest dimension. The second maximum (which is usually obscured by the nearby 
local minimum) indicates the length scale of the larger dimension. The long period is 
indicated by the position of the first minimum (rg). The crystallinity, ag, can be obtained as 
a  <0.5 
a„ =1 -^3 
1—L a ,  >0.5 
(5.12) 
By analyzing all three of these profiles, I|, y, and g, a comprehensive picture of the lamellar 
* ")0 TC T7 
structure is obtained. Others have observed the trend Lg > r > rg ' . It has been shown 
that the long period represented by Lb is close to the weighted average, while that given by 
the interface distribution function, r3, is least affected by the distribution of sizes and is 
therefore closer to the number average37"39. It has also been shown that the crystallinities 
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obtained from these analyses typically follow the trend cxy < a < ag39, though most authors 
report only œz. We compute both cty and ag for comparison and use ay to determine the 
crystallization kinetics. These trends will be discussed in the next section. 
The crystallization kinetics were fit to the Avrami equation31 
a/® , = 1 - expf- Z(t - r)n ] (5.13) 
a
zV =  0°)  
Here Oy(t = oo) is the equilibrium degree of crystallinity obtained from the one-dimensional 
correlation function. Z and n are geometric constants for the Avrami equation, x is an 
induction time required for the nucleation of crystals. 
5.5 Results and Discussion 
Plots of the smoothed and extrapolated intensity profiles for each polymer at each 
temperature are shown in Figure 5.2. The file number indicates the progression in time. As 
the experiment progressed the interval between files was increased from five seconds to ten 
seconds to 30 seconds. Figure 5.3 shows the Lorentz-corrected intensities obtained in each 
experiment. For all of the experiments conducted on polymers with SA content of 50% or 
greater, some residual crystallinity exists at the start of the experiment, despite the annealing 
during the sample preparation. This effect is most pronounced in the 50:50 copolymer. This 
is attributed to crystals nucleating during the quenching and the brief period of time required 
to heat the sample to the crystallization temperature. For the 50:50 copolymer, the glass 
transition is below room temperature, so the crystallinity has essentially equilibrated prior to 
the experiment. For the 80:20 copolymer and the poly(CPH) there is a significant induction 
time before any crystallization occurs. This is consistent with the observation that the melt-
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quench procedure was sufficient to eliminate the crystals. The temporal variation of the long 
period (LB) obtained from the Lorentz-corrected data in each experiment is plotted in Figure 
5.6. 
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Figure 5.2. Corrected and extrapolated intensity profiles for: a. poly(SA) at 67 °C, b. 
poly(SA) at 73 °C, c. 20:80 (CPH:SA) at 54 °C, d. 20:80 (CPH:SA) at 59 °C, e. 50:50 
(CPH:SA) at 37 °C, f. 50:50 (CPH:SA) at 42 °C, g. 80:20 (CPH:SA) at 75 °C, h. 80:20 
(CPH:SA) at 100 °C, i. poly(CPH) at 100 °C, and j. poly(CPH) at 122 °C. 
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Figure 5.3. (Continued) 
Figures 5.4 and 5.5 show the one-dimensional correlation functions and the interface 
distribution functions respectively. The morphological parameters obtained from these two 
sets of data (r*, r%, and Q) are shown in Figure 5.6. For the poly(SA) and the 20:80 
copolymer, the long period increases initially (for about the first 250 seconds). In the 
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experiments for which the crystallization was allowed to continue beyond this time 
(poly(SA) at 67 °C and 20:80 copolymer at 59 °C), the long period decreases, but the 
lamellar thickness remains constant. This decrease in the long period is also evident in the 
studies with all of the other copolymer compositions, and is attributed to secondary 
crystallization in the interlamellar space27. It is also noted that for all of the experiments the 
trend Lb > r* > rg is observed, which is consistent with the observations of others noted 
earlier. Correlating Lb to the weight average long period and % to the number average long 
period, it is apparent that the compositions rich in SA have a wider distribution of lamellar 
sizes than the 80:20 copolymer and the poly(CPH). This can be understood by the 
observation that for the 80:20 copolymer and poly(CPH), the long induction time for 
nucleation essentially results in the formation of lamellae at the crystallization temperature. 
However, in the SA-rich polymers, the residual crystallinity that remained after the 
quenching procedure contributes to the wider distribution of lamellar sizes. In all of the 
experiments, the invariant, Q, increases with time. Others have used the invariant to 
characterize the kinetics of crystallization28 when ag > 0.5. 
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Figure 5.4. One-dimensional correlation function profiles for: a. poly(SA) at 67 °C, b. 
poly(SA) at 73 °C, c. 20:80 (CPH:SA) at 54 °C, d. 20:80 (CPH:SA) at 59 °C, e. 50:50 
(CPH:SA) at 37 °C, f. 50:50 (CPH:SA) at 42 °C, g. 80:20 (CPH:SA) at 75 °C, h. 80:20 
(CPH:SA) at 100 °C, i. poly(CPH) at 100 °C, and j. poly(CPH) at 122 °C. 
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Figure 5.4. (Continued) 
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Figure 5.5. Interface distribution function profiles for: a. poly(SA) at 67 °C, b. poly(SA) at 
73 °C, c. 20:80 (CPH:SA) at 54 °C, d. 20:80 (CPH:SA) at 59 °C, e. 50:50 (CPH:SA) at 37 
°C, f. 50:50 (CPH:SA) at 42 °C, g. 80:20 (CPH:SA) at 75 °C, h. 80:20 (CPH:SA) at 100 °C, 
i. poly(CPH) at 100 °C, and j. poly(CPH) at 122 °C. 
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Figure 5.6. (Continued) 
For each experiment, the crystallinity is computed from both the one-dimensional 
correlation function (ay) and the interface distribution function (ag) via equations 5.8 and 
5.12 respectively. The temporal evolution of the crystallinity for each experiment is shown 
in Figure 5.7. For the poly(SA) the crystallinity equilibrates in about 100 seconds at both 
temperatures. The 20:80 and 50:50 copolymers show little change in the crystallinity with 
time, indicating that the crystallinity has already approached equilibrium prior to the start of 
the experiments. This is not surprising for the 50:50 copolymer since its glass transition is 
below room temperature, as noted earlier. For the 20:80 copolymer, apparently the crystals 
formed very rapidly during the quenching and the brief period required to heat the sample to 
the crystallization temperature. Consequently, for these three compositions, the structural 
changes observed in the experiments represent primarily changes in the crystal morphology, 
rather than changes in the crystallinity. 
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Figure 5.7. Crystallinity for: a. poly(SA) at 67 °C, b. poly(SA) at 73 °C, c. 20:80 (CPH:SA) 
at 54 °C, d. 20:80 (CPH:SA) at 59 °C, e. 50:50 (CPH:SA) at 37 °C, f. 50:50 (CPH:SA) at 42 
°C, g. 80:20 (CPH:SA) at 75 °C, h. 80:20 (CPH:SA) at 100 °C, i. poly(CPH) at 100 °C, and j. 
poly(CPH) at 122 °C. Oy = •; ag = A. 
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Figure 5.7. (Continued) 
For the poly(SA), the 20:80 copolymer, and the 50:50 copolymer, the most notable 
morphological change that is observed occurs in the long period. In the case of the poly(SA) 
crystallized at 67 °C and the 20:80 copolymer crystallized at 59 °C, the long period rises 
initially and then decays slowly at longer times. In both cases, changes in the crystallinity 
and the invariant are associated with the initial change in the long period. The subsequent 
decay in the long period must therefore correspond to a rearrangement of the crystals. Larger 
lamellae are melting while smaller ones are growing. The 20:80 copolymer crystallized at 
54°C exhibits the initial rise in the long period, though it is less pronounced, and the 
subsequent decay is not exhibited. For the poly(SA) crystallized at 73 °C, data were not 
collected at longer times, so the decay is not observed. For the 50:50 copolymer, it is 
interesting to note that the lamellar thickness and the long period are significantly higher for 
the experiment conducted at 42 °C than for the experiment conducted at 35 °C. This general 
trend is noted in all of the compositions (higher temperature corresponds to higher values of 
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the long period and lamellar thickness), but the difference seems excessive in the case of the 
50:50 copolymer. As the long period decays slightly in the 50:50 copolymer crystallized at 
42 °C, the degree of crystallinity increases, so it follows that a different equilibrium for the 
microstructure is obtained at the higher temperature than at the lower temperature, whereas 
the equilibrium morphology for the lower temperature is very similar to that already obtained 
prior to the experiment. 
The 80:20 copolymer and the poly(CPH) do crystallize during the experiment. For 
both of these polymers, the increase in the crystallinity corresponds to a decrease in the long 
period despite the relatively constant lamellar thickness. This indicates that the 
crystallization is occurring via a lamellar insertion mechanism, that is some lamellae are 
growing in the interlamellar space. For both the poly(CPH) and the 80:20 copolymer, the 
crystallization occurs more slowly at the higher temperature. This is due to the fact that the 
higher temperature is approaching the melting temperature, although the chains are more 
mobile, the free-energy benefit of crystallization is lower due to the increase in entropy with 
increased temperature. 
In all of the experiments, we have chosen to define Oy as A/(Q+A). There is no 
question that this is the correct assignment in the case of the 80:20 copolymer and the 
poly(CPH) as it is obvious from the intensity plots (figures 5.2 and 5.3) that no crystallinity 
exists at the start of the experiment and the alternative assignment for cty would result in a 
very high degree of crystallinity initially. A similar argument can be made for the poly(SA) 
and the 20:80 copolymer. Based on the intensity evolution, we expect the crystallinity of 
these polymers to grow with time. The crystallinity for the 50:50 copolymer is more difficult 
to assign. Here we have relied on our previous experiments (DSC and WAXD) that indicate 
a crystallinity for the 50:50 copolymer that is less than 50%. Similar lines of reasoning were 
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used for the assignment of ag, noting that for the poly(SA), ag crosses the 0.5 mark at some 
point during the experiment. At this point the alternative equation is used. With respect to 
the crystallinity, we make one final note that the trend ag > Oy is consistent for all of the 
experiments. The lamellar thickness, the long period, the degree of crystallinity, and the 
electron density contrast of each of the equilibrated structures are compared in Table 5.2. As 
noted earlier, the morphological parameters increase with increasing temperature for each 
polymer. For each experiment exhibiting suitable changes in oty, the crystallization kinetics 
are fit to the Avrami equation. The constants are listed in Table 5.3. The parameter t is 
negative for the 20:80 and 50:50 copolymers, and represents the progress of the 
crystallization prior to the start of the experiment, so these values are not reported. It is 
notable that the 50:50 copolymer exhibits the highest value of the rate constant Z. This 
follows from the fact that the glass transition for this polymer is lowest, and the polymer 
chains are therefore most mobile. Also, note that the rate constant increases with increasing 
temperature for the 80:20 copolymer, also indicating increasing mobility of the polymer. 
The increase in the induction time with increasing temperature for the 80:20 copolymer is 
attributed to the increase in entropy at increasing temperature, which lowers the free-energy 
benefit obtained upon crystallization. The Avrami exponent, n, is essentially unity for all of 
the experiments. This indicates that the nuclei do not sporadically form, but are 
predetermined, and that crystallization is restricted to a single dimension. This observation is 
consistent with the previous comments on the longer induction time for nucleation for the 
CPH-rich polymers and the wide distribution of lamellar sizes due to pre-existing lamellae in 
the SA-rich polymers. 
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Table 5.2. Comparison of morphological characteristics obtained at equilibrium for each 
experiment. 
Polymer 
Lamellar 
T thickness (Â) 
(°C) 
r oty ri 
Long period (Â) 
LB Î3 
Degree of Density 
crystallinity contrast 
Pc — Pa X 10 
(A"') 
Oy CCo 
Poly(SA) 67 28 52 136 126 101 0.22 0.54 1.06 
73 38 54 154 137 100 0.29 0.52 0.85 
20:80 (CPH:SA) 54 40 42 123 119 96 0.34 0.45 0.92 
59 42 47 137 136 114 0.31 0.37 1.4 
50:50 (CPH:SA) 37 40 46 144 133 107 0.30 0.42 0.83 
42 48 54 203 193 143 0.25 0.36 0.78 
80:20 (CPH:SA) 75 35 52 168 158 143 0.22 0.36 1.03 
100 40 62 186 173 164 0.24 0.38 1.05 
Poly(CPH) 100 35 57 143 133 125 0.26 0.55 0.77 
122 47 71 166 158 142 0.30 0.50 0.64 
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Table 5.3. Avrami constants for each experiment determined from the evolution of Oy. 
Polymer 
T 
(°C) 
Z 
(sec"1) 
T 
(sec) 
n 
CPH:SA (20:80) 59 0.00037 - 1.11 
CPH:SA (50:50) 42 0.00221 - 1.00 
CPH-.SA (80:20) 75 0.000223 600 0.991 
CPH:SA (80:20) 100 0.00205 845 0.984 
Poly(CPH) 122 0.000980 637 1.08 
As researchers attempt to design controlled release devices from polyanhydrides, it 
has become apparent that the microstructure of the polymer plays a very important role in 
determining the drug release kinetics. In addition to discerning the kinetics of the 
crystallization, which may be used to control crystallinity during device fabrication, these 
results are essential to a comprehensive understanding of the morphological changes that 
occur during polyanhydride erosion. Previous work with polyanhydrides has demonstrated 
that the amorphous domains erode faster than crystalline domains and that the heterogeneous 
erosion results in a porous microstructure19'20'24. The evolution of the porous erosion zone 
affects the overall erosion kinetics. Additionally, drug release kinetics are also closely linked 
to the porosity, when drugs dissolve and diffuse through the pores. Because these pores are 
initially formed primarily from the erosion of the amorphous regions, this detailed 
description of the morphology is essential for understanding the erosion and drug release 
kinetics. 
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Our future investigations of the microstructure of polyanhydrides for drug delivery 
will focus on the effects of dissolved drugs on the crystallization kinetics and crystal 
morphology. 
5.6 Conclusions 
Morphological changes during the isothermal crystallization of polyanhydride 
copolymers can be accurately observed via in situ SAXS. The Avrami equation can be used 
to design fabrication processes for drug release devices, such that the crystallinity is 
accurately controlled. This study reveals that although it would be difficult to control the 
crystallinity in poly(SA), the 20:80 copolymer, and the 50:50 copolymer, the crystallinity in 
the 80:20 copolymer and poly(CPH) can be accurately controlled by controlling the thermal 
history. At equilibrium, the lamellar thickness for all polymers studied was between 30 and 
70 Â. Additionally, for all of the systems studied, this work provides accurate structural 
description of the lamellar thickness and degree of crystallinity. This microstructural 
characterization is an essential element of accurate erosion and drug release models. 
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CHAPTER 6 
NANOSCALE MORPHOLOGY OF POLYANHYDRIDE COPOLYMERS 
CHARACTERIZED BY SOLID STATE NMR AND SAXS 
A paper to be submitted to Macromolecules, 2004. 
Matt J. Kipper1,2, Sheng-Shu Hou3'4, Soenke Seifert5, 
P. Thiyagarajan6,Klaus Schmidt-Rohr3,7 and Balaji Narasimhan1,8 
6.1 Abstract 
The microphase separation of random polyanhydride copolymers composed of 1,6-
bis-(p-carboxyphenoxy)hexane and sebacic acid is described. Though the copolymers are 
random, the monomers are sufficiently long and the segment-segment interaction parameter 
is sufficiently high to support microphase separation when the composition is rich in one 
component. Solid state NMR spin diffusion experiments and synchrotron small-angle X-ray 
scattering are used to discern length scales of the microphase separation. Both techniques 
reveal a microstructure with domain sizes less than 25Â. This nanostructure is compared to 
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approximate calculations of chain dimensions based on a random coil model and discussed in 
the context of the use of these materials for drug delivery applications. 
6.2 Introduction 
Polyanhydrides are a class of surface-erodible polymers that have been investigated 
as potential vehicles for drug delivery and other biomedical applications1"6. The erosion 
kinetics of polyanhydride copolymers can be modulated by altering the copolymer 
composition, when the two constituent polymers have different erosion rates6,7. This strategy 
has proven effective for controlled release applications. In our previous work, we have 
demonstrated that some polyanhydride copolymers exhibit microphase separation, and that 
this microphase separation affects the mechanism of erosion and drug release kinetics when 
the relative erosion rates of the two constituent phases are different7"10. Rational design of 
controlled release formulations requires a detailed description of polymer microstructure in 
order to predict drug release kinetics. 
We have focused on copolymers based on 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
and sebacic acid (SA). Previously, we have described the crystallinity and crystallization 
kinetics of these copolymers by wide-angle X-ray scattering (WAXS), differential scanning 
calorimetry (DSC), and small angle X-ray scattering (SAXS)8'11. We have quantitatively 
studied the phase behavior of the poly(CPH)/poly(SA) blend system by SAXS, atomic force 
microscopy (AFM), optical microscopy, and molecular simulation in order to determine the 
segmental interaction parameter (x)12 as a function of temperature (based on the volume of 
an SA monomer). 
^ = -2.04 + — 
T (6.1) 
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We have also qualitatively described the microphase separation in CPH:SA copolymers by 
AFM and demonstrated its effects on drug release kinetics7'9. 
It is important to note that the copolymers we describe in this study are random 
copolymers. Their molecular architecture has been previously described by *H NMR7. 
However, since the monomer units are sufficiently long, and the segment-segment interaction 
parameter is sufficiently high, even relatively short sequence lengths (<15) support 
microphase separation at the nanometer length scale. Thus, we refer to these copolymers as 
"weakly segregated, block-like copolymers." Not all compositions of these copolymers 
exhibit such behavior. The synthesis route employed, melt polycondensation, results in high 
polydispersity (in chain length and presumably in sequence length). Thus, compositions 
containing nearly equal amounts of the two constituent monomers (e.g. poly(CPH:SA) 
(50:50)) do not demonstrate microphase separation. However, compositions relatively rich 
in one component (e.g. 80:20 poly(CPH:SA) (80:20) and 20:80 poly(CPH:SA) (20:80)) have 
molecular architecture characterized by relatively long segments (10 to 15) of the majority 
monomer punctuated by short sequences (2 to 4) of the minority monomer. A sequence of 
10 SA monomers contains 110 backbone bonds and a sequence of 10 CPH monomers 
contains 190 backbone bonds. 
Our hypothesis of the microphase separation is predicated upon detailed studies of the 
erosion and drug release kinetics from these copolymers and upon characterization of the 
copolymer microstructure by atomic force microscopy7'9 and solution NMR. In these studies 
we noted that as the polymer degrades, the two monomers are not released at the same rate. 
Additionally, in drug-loaded copolymers, the drug release kinetics is highly correlated to one 
of the individual monomer release profiles, depending on the monomer-drug compatibility. 
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We conclude from these observations that the copolymers have a microphase-separated 
structure that permits partitioning of the drug between the two phases. We have successfully 
modeled the erosion and drug release kinetics by assuming a microphase separated structure, 
but we have not described that structure in detail10. We further hypothesize that the 
microphase-separated domains are very small - on the order of a few nanometers in size, 
based on the average sequence lengths. In the current study, we use two experimental 
techniques that provide nanometer length scale resolution, solid state NMR and SAXS, to 
explore the morphology of these block-like copolymers. 
6.3 Experimental 
6.3.1 Polymer synthesis and characterization 
Details of the polymer synthesis and characterization are reported elsewhere11. The 
poly(CPH-.SA) (20:80) has an Mn of 9600 and a PDI of 2.2. The poly(CPH:SA) (80:20) has 
an Mn of 9700 and a PDI of 2.1. The degree of polymerization is 45 and 31 for the 20:80 and 
80:20 copolymers respectively. ^ NMR of the copolymers revealed that the actual 
compositions were 17:83 and 78:22, but we refer to them here by their nominal 
compositions, 20:80 and 80:20 respectively. The homopolymers were also synthesized and 
characterized as controls. The characterization of these materials is also reported 
elsewhere11. 
6.3.2 Solid state NMR 
Solid state NMR spin diffusion experiments for probing microphase separation in 
copolymers are conducted by first establishing a magnetization gradient that is based on 
some difference between the characteristic spectra of the two phases. Next a series of spectra 
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at different mixing times are taken that permits observation of the return to equilibrium 
magnetization. In our experiments a chemical shift filter is used to suppress the 
magnetization of the aliphatic nuclei in the SA monomers. Magnetization of the aromatic 
nuclei in the CPH monomers is passed to the aliphatic nuclei via cross polarization of !H 
with 13C in the process of "spin-diffusion." The kinetics of spin diffusion reveal details about 
the microstructure. Specifically, the time required to reach equilibrium is related to the 
domain size by13 
dA,NMR = rV4DtM / K (6.2) 
Here, d^NMR is the characteristic diameter of phase A (the magnetization donor), fg' is the 
proton density of the B phase (the magnetization receiver), D is the spin diffusion coefficient, 
and s is a parameter determined by the geometry. In this study, cylindrical domains are 
assumed (e = 2). 
6.3.3 Small-angle X-ray scattering 
Samples were prepared for SAXS by melting the polymer into DSC aluminum 
sample pans (Perkin Elmer). As we have reported previously11, these make ideal sample 
holders because the aluminum is fairly transparent to the high-brilliance X-rays used in this 
study, and they allow us to use the DSC to control the thermal history of the samples prior to 
the SAXS experiments. The thickness of each sample was accurately determined using a 
micrometer and the values were between 700 and 800 jj.m. Prior to the SAXS analysis, the 
samples were annealed in a DSC (DSC7, Perkin Elmer) by heating above the melting 
temperature for five minutes, and then rapidly quenched to below the Tg. The SAXS 
experiments were conducted at Beamline 12-ID at the synchrotron beam source at Argonne 
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National Laboratory15. The incident beam energy was 12 keV (X = 1.035 À). A 15 cm x 15 
cm CCD detector, at a distance of 0.805 m from the sample, was used to measure the 
intensity of scattering and the transmitted beam intensity was measured using a photodiode 
on the beam stop. The scattering data were appropriately corrected and azimuthally averaged 
to obtain the one-dimensional intensity data, I(q), as a function of scattering vector, q 
(q=47tsin(0/2)/X; 9=scattering angle; X=incident radiation wavelength). Five sets of data 
were collected and averaged for each sample. The resulting intensity data were corrected for 
the scattering from the blank aluminum sample pan. 
The SAXS data of interest in this study corresponds to very small length scales 
(~lnm) and relatively high values of q. In this region there is a significant contribution due 
to density fluctuations within the individual phases, which must be subtracted in order to 
obtain the correct absolute intensity. This background scattering is approximated by the sum 
of the scattering from the two homopolymers, weighted by their respective volume fractions 
in the copolymer15. 
6.4 Results and Discussion 
6.4.1 Solid state NMR 
The spectra for the poly(CPH:SA) (80:20) are shown in Figure 6.1. The peak 
intensity at 34 ppm representing aliphatic nuclei in the SA is used to characterize the spin 
diffusion. After correction for the ti relaxation, the normalized intensities as a function of 
mixing time (tm) are plotted in Figure 6.2, along with a fit to equation 6.2. Assuming 
cylindrical domains (e = 2) and a diffusion coefficient of 0.3 nm2/ms results in the values for 
the characteristic diameters shown in Table 6.1. The same procedure was used to extract 
domain sizes from the poly(CPH:SA) (20:80) NMR spectra (not shown). 
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6.1. Spectra for the poly(CPH:SA) (80:20) at different mixing times. 
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Figure 6.2. Intensities at 34 ppm from the poly(CPH:SA) (80:20) spectra plotted in Figure 
6.1. 
Table 6.1. Domain sizes obtained from solid state NMR and SAXS. 
Polymer 
dcPH,NMR 
(A) 
dsA,NMR 
(A) 
dcPH,SAXS 
(A) 
dsA,SAXS 
(A) 
Poly(CPH:SA) (20:80) 16 14 10.0 -
Poly(CPH:SA) (80:20) 20 10 - 9.1 
6.4.2 &LYS 
The SAXS data, shown in Figure 6.3, exhibit a peak corresponding to the periodicity 
of the microphase separation. This characteristic length scale is computed from Bragg's law. 
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Here, q* is the position of the peak. The length scale associated with the microphase 
separation from the SAXS profiles is also shown in Table 6.1. 
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Figure 6.3. SAXS intensity profiles for poly(CPH:SA) (20:80) (O) and poly(CPH:SA) 
(80:20) (•). 
Comparing the results from the SAXS and the solid state NMR, we find that the 
domain diameters observed in the NMR experiments are close to those indicated by the 
SAXS data (see Table 6.1). Both techniques indicate length scales smaller than 25Â for the 
microphase separation. This small discrepancy is attributed to the approximations necessary 
for interpretation of the NMR data (e.g., cylindrical domains, value for D). 
We interpret the significance of these results by comparison to calculations of random 
coil chain conformations. Table 6.2 shows the number average sequence lengths obtained 
from solution state NMR and reported previously, and the radius of gyration of the longer 
block-like sequence, Rg. 
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(6.4) 
Here, Cx is the characteristic ratio, n is the number of bonds in the block-like sequence, and 1 
is the average bond length. We have previously estimated the characteristic ratios for 
poly(CPH) and poly (SA) as 6.8 and 4.8, respectively, from molecular dynamics 
simulations12. The values of nl2/mer for poly(CPH) and poly(SA) were obtained in the same 
studies as 43.7 Â2 and 23.8 Â2, respectively. The radius of gyration of a block can be used to 
estimate the size of a domain of the majority component. For the minority component, the 
random coil approximation is not valid because of the relatively small number of bonds, so 
an estimate of the length scale associated with the minority component can be obtained by 
considering the contour length of a monomer, nl. Figure 6.4 is a schematic of our molecular 
description of the microphase separation in these weakly segregated block-like copolymers. 
Figure 6.4. Schematic of microphase separation in a weakly segregated block-like 
copolymer. The dimensions of the microphase separated domains can be approximated by 
the radius of gyration for the majority component, Rgi, (black) and the monomer contour 
length for the minority phase, nli (gray). 
Minority component monomer 
Majority component monomer 
Table 6.2. Number average sequence lengths computed from *H NMR and the calculated 
radius of gyration for the longer block-like sequence for the copolymers used in this study. 
Polymer Lcph Lsa Rg,i (A) nb (A) 
Poly(CPH:SA) (20:80) 
Poly(CPH:SA) (80:20) 10.4 
2.3 12.0 15.1 24.6 
1.7 22.7 15.1 
These computed radii of gyration are on the same order of magnitude as the domain 
sizes computed from the solid state NMR and the SAXS (see Table 6.1). These data support 
our hypothesis of a weakly segregated block-like nanostructure in these copolymers. The 
structure results from the block-like nature of the random copolymers coupled with the 
propensity for these materials to phase separate. Comparing the radii of gyration 
approximated from the random coil approximation to the domain sizes computed from SAXS 
and solid state NMR, we are led to the conclusion that in the bulk polymer, the blocks of 
CPH and SA can segregate to form the nanostructure without conformational entropie 
penalties. This work shows, for the first time, the nanometer length scale of the weakly 
segregated domains. 
6.5 Conclusions 
The solid state NMR and SAXS experiments offer nanoscale resolution of the 
microphase separation in weakly segregated block-like polyanhydride copolymers. These 
concentration fluctuations are characterized by length scales smaller than 25Â. Based on the 
relatively large sizes of the monomers in these polymers, we conclude that the microphase-
separated domains contain very few monomers and may be formed from a single block or a 
small number of blocks. This knowledge of the copolymer microstructure, coupled with 
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accurate erosion and drug release models, will help guide the design of these materials for 
drug delivery as we pursue the synthesis of polyanhydride block copolymers. 
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CHAPTER 7 
DESIGN OF AN INJECTABLE SYSTEM BASED ON BIOERODIBLE 
POLYANHYDRIDE MICROSPHERES FOR SUSTAINED DRUG DELIVERY 
Reprinted from Biomaterials 23(22): 4405-4412, Copyright ©(2002), 
with permission from Elsevier. 
Matt J. Kipper1,2, Elizabeth Shen3'4, Amy Determan1'5, and Balaji Narasimhan1'6 
7.1 Abstract 
The fabrication, morphological characterization, and drug release kinetics from 
microspheres of three bioerodible polyanhydrides, poly[l,6-bis(p-carboxyphenoxy)hexane] 
(poly(CPH)), poly(sebacic anhydride) (poly(SA)), and the copolymer poly(CPH-co-SA) 
50:50 (CPH-SA 50:50) is reported. The fabrication technique yields microspheres with 
different morphologies for each of the three polymers studied, ranging from very smooth 
exterior surfaces for poly(CPH) to coarse surface roughness with large pores for poly(SA). 
Release profiles for the model drug, p-nitroaniline are also different for each polymer. The 
release profile from poly(CPH) has a large initial burst and shows little additional release 
after two days. The release from poly(SA) is nearly zero-order and lasts for about 8 days. 
The release profile from CPH-SA 50:50 shows a relatively small burst and then exhibits 
zero-order release for about 1 month. The different release profiles are attributed to both 
polymer erosion rates and drug distribution characteristics of the microspheres. Tailored 
1 Department of Chemical Engineering, Iowa State University. 
2 Graduate student; primary author and experimenter. 
3 Department of Chemical and Biochemical Engineering, Rutgers University. 
4 Graduate student; secondary author. 
5 Undergraduate research assistant. 
6 Major professor, corresponding author. 
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release profiles of a burst followed by zero-order release are obtained by appropriately 
combining the microspheres. This technique enables independent modulation of both the 
burst and the zero-order release rate by varying the number of poly(CPH) and poly(SA) 
microspheres respectively. Additionally, the zero-order release can be extended from about a 
week to a month by including CPH-SA 50:50 microspheres. 
Keywords: Polyanhydrides, microspheres, drug delivery, controlled release. 
7.2 Introduction 
Bioerodible polymers show great potential as vehicles for drug delivery, offering 
significant improvements over conventional drug delivery methods. For example, devices 
made from bioerodible polymers have been used to increase the stability of macromolecular 
drugs [1], target specific organs and tissues [2], and achieve sustained and controlled drug 
release profiles [3-9]. 
Langer, Mathiowitz, and co-workers have shown that polyanhydrides are a 
particularly promising class of polymers for drug delivery, due to their chemistry [3-7, 10-
14] and biocompatibility [15, 16]. Polyanhydrides of aliphatic and aromatic dicarboxylic 
acids have hydrophobic regions separated by relatively hydrophilic acid anhydride bonds. 
The anhydride bonds are hydrolyzed under physiological conditions, resulting in polymer 
degradation and subsequent erosion. However, water does not penetrate into the bulk of the 
hydrophobic polymer [17]. Thus, degradation and erosion occur at the surface, rather than in 
the bulk. Surface eroding devices are particularly well suited for sustained release and drug 
stabilization. Additionally, polyanhydrides of varying hydrophobicity have erosion rates that 
span several orders of magnitude [6]. The potential for not only sustaining the release of a 
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drag, but also achieving desirable release profiles can be realized by combining 
polyanhydrides with differing erosion rates in an advantageous way. 
Bioerodible polymer microspheres as drug delivery vehicles offer the advantage of 
not requiring surgical implantation, since they can be injected in suspension; they also do not 
require surgical removal. Also, since the drug loaded in a microsphere remains separated 
from that in other microspheres, a further advantage is the potential to administer multiple 
drugs in a single injection, that for compatibility reasons would otherwise need to be 
separated. 
The effectiveness of a drug is dependent upon its concentration being within a 
specific therapeutic range, above which toxicity or other side effects dominate and below 
which concentrations are too small to provide significant benefit. However, maintaining 
drug concentrations is complicated by metabolism or consumption of the drug. Therapeutic 
levels are often maintained by multiple administrations (e.g. pain relievers, antibiotics, 
antidepressants). The faster a drug is metabolized or consumed, the more difficult 
maintaining therapeutic concentrations by multiple administrations becomes. All of these 
issues can be resolved by a single dose, which provides an initial burst of drug to reach a 
therapeutic concentration, followed by a zero-order release of drug that maintains the 
therapeutic level by compensating for metabolic loss. 
We propose a drug delivery system composed of polyanhydride microspheres with 
varying composition to realize a tailored drug release profile. The system of interest in this 
work consists of two anhydride monomers 1,6-bis(p-carboxyphenoxy)hexane, CPH, and 
sebacic acid, SA. The homopolymers of these monomers are shown in Figure 7.1. Poly(CPH) 
is aromatic and degrades on a time scale of over a year, whereas the aliphatic poly(SA) 
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degrades in a few days [18]. Random copolymers of SA and CPH have intermediate 
degradation times depending on the copolymer composition [19]. 
Figure 7.1. Chemical structures of CPH (top) and SA (bottom) repeat units. 
We have previously examined the microstructure of these copolymers using 
differential scanning calorimetry (DSC), wide-angle X-ray diffraction (WAXD), and atomic 
force microscopy (AFM) [19]. This study showed that copolymers rich in one component (> 
80 mol%) exhibit microphase separation forming two amorphous phases with different 
compositions at equilibrium. It was also shown that the 50:50 copolymer does not exhibit 
microphase separation. Because the copolymers are random, the 50:50 copolymer has short 
number average sequence lengths, but the 20:80 and 80:20 CPH:SA copolymers have weakly 
segregated block-like structures with relatively high number average sequence lengths of SA 
and CPH respectively [19, 21], These sequence characteristics combined with the difference 
in hydrophobicity of the monomer units results in the observed phase behavior. In the same 
study [19], DSC and WAXD showed that hydrophobic model drugs loaded into the 
o 
o 
n 
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semicrystalline polymer, poly(SA), lowered the crystalline melting point. The disruption of 
the lamellar structure suggests that the drug forms a solid solution with the polymer. 
We have also studied dissolution and drug release kinetics of homogeneous and 
microphase-separated copolymers of CPH and SA in tablet form [22]. In this study, it was 
found that when compatible drugs (i.e., drugs capable of forming a solid solution with the 
polymer) were dissolved in homogeneous polymer matrices (e.g. poly(SA) and 50:50 
CPH: SA) the drug release profile was dictated by the degradation rate of the polymer. We 
also showed that the presence of incompatible (i.e., sparingly soluble) drug and its interaction 
with the polymer had dramatic effects on the polymer erosion rate. For example, when 
hydrophobic p-nitroaniline (PNA) was incorporated into poly(SA) and 50:50 CPH:SA the 
drug and monomer release profiles were identical. Additionally, PNA did not significantly 
alter the erosion rates of either polymer. However when PNA is incorporated into 
microphase-separated 20:80 and 80:20 CPH:SA copolymers, its release is strongly correlated 
to the erosion of the CPH-rich phase. From these observations we concluded that PNA 
release from polymers with homogeneous microstructure follows polymer erosion without 
significantly affecting the erosion rate. Further, we also showed by atomistic simulations 
that the PNA is more compatible with poly(CPH) than with poly(SA). 
In this work, we discuss the fabrication and characterization of microspheres of 
poly(CPH), poly(SA) and CPH-SA 50:50. These polymers were chosen because they do not 
microphase-separate into multiple amorphous phases with different compositions. Thus, 
drug release kinetics is not affected by partitioning into equilibrium phases. A solvent 
removal technique employing an oil/water emulsion is used to produce drug-loaded 
microspheres. We also present release data of p-nitroaniline (PNA) from drug-loaded 
microspheres, showing how the release profile can be altered. Microspheres with different 
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time scales of erosion are made by selecting polymers with different copolymer 
compositions. A "cocktail" of such microspheres with different release kinetics is used to 
obtain the desired release profile: a burst followed by zero order release. 
7.3 Materials and Methods 
7.3.1 Materials 
Sebacic acid (99%) and p-carboxy benzoic acid (99+%) were purchased from Aldrich 
(Milwaukee, WI), 1,6-dibromohexane (98%) and polyvinyl alcohol) (99-100% hydrolyzed) 
were purchased from Acros (Fairlawn, NJ), /7-nitroaniline and sebacic acid were purchased 
from Sigma (St. Louis, MO), acetic anhydride, chloroform, Histo-Prep tissue embedding 
media and methylene chloride were purchased from Fisher (Fairlawn, NJ), deuterated 
chloroform was purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA), 
petroleum ether (hexanes, 55% n-hexane) was purchased from Fisher and dried and distilled 
over sodium and benzophenone (Fisher) before use. 
7.3.2 Polymer synthesis 
CPH diacid was synthesized by a method similar to that described by Conix for l,3-bis(p-
carboxyphenoxy) propane[23]. CPH and SA diacids were acetylated to form the 
prepolymers by the method reported by Shen et. al. [19]. Briefly, diacid was refluxed in 
excess acetic anhydride for 30 minutes (SA) or 60 minutes (CPH) under dry nitrogen sweep. 
Unreacted diacid was removed by filtration while the mixture was still warm. The SA 
prepolymer was isolated by evaporating the solution to dryness at 50°C under vacuum and 
purified by dissolution in chloroform, filtration, and subsequent precipitation in a 1:1 mixture 
of dry ethyl ether and dry petroleum ether. The precipitate was filtered and dried under 
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vacuum overnight. CPH prepolymer was crystallized from the filtrate by evaporating the 
solution down to a volume of about 150 ml and storing under refrigeration overnight. The 
crystals were obtained by filtration, washed with ethyl ether and dried overnight. Crude CPH 
prepolymer was re-dissolved in chloroform and filtered again to remove impurities. The 
chloroform solution was evaporated and dried overnight under vacuum. 
NMR was used to determine the degree of polymerization for each of the 
prepolymers. NMR spectra were obtained on a Varian VXR 300 MHz spectrometer (Varian 
Inc. Palo Alto, CA). Prepolymers were stored desiccated under dry argon to prevent 
hydrolysis and *H NMR was used periodically to monitor degree of hydrolysis. 
Homopolymers and 50:50 copolymer were synthesized by melt polycondensation of 
the prepolymers at 180°C under vacuum (<0.5 mmHg) for 90 minutes[13]. About 2ml of 
acetic anhydride was added to 4g of prepolymer prior to polymerization to ensure complete 
acetylation. The polymers were desiccated under dry argon to prevent degradation. 
7.3.3 Polymer characterization 
Neat polymers were characterized by *H NMR in deuterated chloroform (99.8% 
atom-J). Chemical shifts were calibrated to the chloroform peak. Gel permeation 
chromatography (GPC) was used to determine molecular weights. Samples were dissolved 
in chloroform and separation was done using PL Gel columns from Polymer Laboratories 
(Amherst, MA) on a Waters GPC system (Milford, MA). Elution times were compared to 
poly(methyl methacrylate) standards from Fluka (Milwaukee, WI). Differential scanning 
calorimetry (DSC) (DSC7, Perkin Elmer, Shelton, CT) was used to verify that crystalline 
melting points were the same as reported by Shen et. o/[19]. 
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7.3.4 Microsphere fabrication 
A solvent removal technique employing an oil/water emulsion was used to fabricate 
microspheres. An aqueous non-solvent phase was chosen to prevent hydrophobic drugs from 
diffusing out of the polymer solution during fabrication. Polymer (200mg) and PNA (30mg) 
were dissolved in methylene chloride (2 to 4ml). This solution was added to a 1% (w/v) 
aqueous solution (200ml) of 99% hydrolyzed poly(vinyl alcohol) (PVA) and immediately 
dispersed by agitation at 20,000rpm with a handheld homogenizer (Tisssue-Tearor™, 
Biospec Products Inc., Bartlesville, OK) for 1 minute. The water/oil emulsion was stirred for 
2h at 300rpm in a 400ml Berzelius beaker using a Caframo overhead stirrer with a 3-inch 
impeller (Wiarton, Ontario). The microspheres were obtained by centrifugation for 5min at 
375xg using an Eppendorf Centrifuge 5403 (Westbury, NY). The PVA solution was 
decanted off and fresh de-ionized water was added. The centrifugation and décantation was 
performed at least four times to remove as much of the PVA and undissolved drug as 
possible. The microspheres were re-suspended in less than 20ml of de-ionized water, flash 
frozen with dry ice and acetone, and lyophilized overnight. Finally, the microspheres were 
sieved to eliminate the particles that were larger than 53p.m. The fabrication technique was 
slightly altered for the different polymers. For the 50:50 copolymer, the precipitation was 
performed in an ice water bath, so that the precipitated polymer would be below its glass 
transition temperature of about 10°C. For the higher molecular weight poly(SA) a larger 
volume of methylene chloride was used (up to 4ml.). 
7.3.5 Microsphere characterization 
The yield of microspheres was calculated as the mass of microspheres recovered per 
mass of polymer used. Size distributions were obtained on a Malvern Mastersizer E particle 
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size analyzer (Southborough, MA). The morphology of the microspheres was investigated 
using scanning electron microscopy (SEM) (Hitachi S-2460N, San Jose, CA). Microspheres 
were sectioned by embedding in Histo-Prep tissue embedding media, followed by 
microtoming at -20°C, and lyophilization. Sections were also imaged using SEM. lH NMR 
(as described in section 7.3.3. for the polymer) was used to quantify the degree of hydrolysis 
that resulted from the aqueous microsphere fabrication. Detailed discussions of this 
procedure are in the literature[18, 21]. GPC (as described in section 7.3.3 for the polymer) 
was used to discern the loss of molecular weight. Drug loading levels (mass of drug loaded 
per mass of microspheres) were obtained by dissolving the microspheres in pH 7.4 phosphate 
buffer solution at 80°C and performing UV spectroscopy at 381 nm. The results are reported 
in Table 7.1. 
Table 7.1. Weight average (Mw) and number-average (M„) molecular weights of polymers 
before and after microsphere fabrication, molecular weight loss, yield of microspheres, and 
drug loading. 
Po| Mw/Mn of neat Mw/Mn of Mn loss Yield Loading 
y polymer microspheres (%) (%) (|ig PNA/mg microspheres) 
Poly(CPH) 7100/4100 7100/4000 2 58 5.3 
CPH:SA 50:50 8400/4100 7000/3400 17 50 4.9 
Poly(SA) 33000 / 9000 20000 / 6000 33 53 7.2 
7.3.6 Release studies 
Microspheres (2 to 10mg) were suspended in 1ml of phosphate buffer (pH 7.4) and 
incubated at 37°C with gentle agitation (lOOrpm). Samples were collected by centrifuging 
the microsphere suspensions (for 20 min at 4150xg), and removing a fraction of the 
supernatant. Supernatant was replaced with fresh buffer. The sample was diluted with fresh 
166 
buffer to increase the volume. UV spectroscopy using a Shimadzu 1601 UV-Visible 
Spectrophotometer (Columbia, MD), at a wavelength of 381 nm was used to measure the 
concentration of PNA in the supernatant. 
7.4 Results and Discussion 
7.4.1 Microsphere characterization 
7.4.1.1 Molecular weight loss and yield. Because the polyanhydrides are 
hydrolytically degraded it is necessary to quantify the molecular weight loss that occurs 
during the (aqueous) microsphere fabrication procedure. The number-average and weight-
average molecular weights of the polymers before and after microsphere fabrication are 
reported in Table 7.1. The molecular weight loss increases (from 2% for poly(CPH) to 33% 
for poly(SA)) as the polymer hydrophobicity decreases. Table 7.1 also shows the yields of 
each type of microsphere. Typically, the yields varied from 50-60%. 
7.4.1.2 Particle size distribution. The solvent removal process produces a size 
distribution of microspheres. The particle size distributions (in terms of surface area 
fraction) for the poly(CPH) and the poly(SA) microspheres are shown in Figure 7.2 (data for 
CPH-SA 50:50 copolymer is not shown). The distributions for all three polymers are 
essentially the same, showing that microspheres with diameters of about 20|im make up the 
largest surface area fraction of the total microspheres. The data also show that a significant 
fraction of the surface area is represented by very small microspheres (<2jxm). These 
phenomena can also be observed qualitatively from the SEM micrographs shown in Figure 
7.3. 
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Figure 7.2. Particle size distributions for PNA-loaded poly(CPH) (a) and poly(SA) (b) 
microspheres plotted as surface area fractions. 
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7.4.1.3. Morphology. Scanning electron micrographs of microspheres from each 
type of polymer are shown in Figure 7.3. Three distinct morphologies are represented. 
Figure 7.3a shows that the poly(CPH) microspheres are very spherical and have smooth 
external surfaces. The CPH-SA 50:50 microspheres shown in Figure 7.3b have mostly 
smooth outer surfaces as well, but some are deformed. Many have dents and some are 
ellipsoidal instead of spherical. The glass transition temperature of CPH-SA 50:50 is 
10°C[24]. The deformations are attributed to the rubbery nature of the polymer. Some 
surface roughness is also observed. Finally, the poly(SA) microspheres in Figure 7.3c show 
a very different surface morphology. Some of these microspheres have a macroporous 
surface. These observations are qualitatively consistent with the work of Mathiowitz et 
al.[5\. Surface roughness may be due to the partial degradation that occurs during 
microsphere fabrication (see MW loss in Table 7.1). 
All three types of microspheres had solid, non-porous internal structures. Figure 7.3d 
shows a SEM micrograph of a cross section of a poly(CPH) microsphere. 
7.4.2 Release kinetics 
7.4.2.1. PNA release from poly(SA), CPH-SA 50:50, and poly(CPH) microspheres. 
The release of PNA from microspheres of each of the three polymers studied shows unique 
characteristics. The release of PNA from poly(SA) is approximately zero-order for about 
eight days, after which time the release rate drops off precipitously (Figure 7.4). PNA 
release from CPH-SA 50:50 microspheres shows a small burst and then releases with a zero-
order profile for longer than two weeks (Figure 7.4). The release rate is slower than that for 
poly(SA) microspheres, and continues for a month. (Data shown is only for the first two 
weeks. Extended release is evidenced by the data for "cocktails" in section 7.4.2.2.) The 
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difference in release rate for these two polymers is attributed to the difference in relative 
polymer erosion rates. Also, since erosion occurs at the surface, the increased surface area of 
the poly(SA) microspheres due to their rough surface morphology (Figure 7.3c), enhances 
their degradation rate. 
Figure 7.3. Scanning electron micrographs of PNA-loaded (a) poly(CPH) microspheres, (b) 
50:50 CPH-SA microspheres, (c) poly(SA) microspheres showing characteristic sizes and 
surface morphologies obtained and (d) poly(CPH) microspheres showing solid internal 
structure. 
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Figure 7.4. Fraction of PNA released from poly(CPH) (•), poly(SA) (•), and CPH:SA 
50:50 (•) microspheres. 
In contrast to poly(SA) and 50:50 CPH-SA microspheres, the PNA release profile 
from poly(CPH) microspheres is not dominated by polymer degradation rate. Poly(CPH) has 
the lowest degradation rate of the three polymers studied. Also, PNA has a higher affinity 
for poly(CPH) than for poly(SA). Considering only these two characteristics of the system, 
one would anticipate a very slow PNA release from poly(CPH) microspheres. Instead, the 
release profile shown in Figure 7.4 is fast. A high rate of release is observed for less than 
two days. Any subsequent release occurs so slowly that it is not accurately detected. 
We have shown that the microspheres have a non-porous internal structure (Figure 
7.3d) and verified via SEM that the poly(CPH) microspheres erode only at the surface 
(micrographs not shown). Since our data clearly show that the microspheres are surface-
erodible and non-porous, we hypothesize that the release profile for poly(CPH) is the result 
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of non-uniform distribution of PNA within the poly(CPH) matrix. One possible reason for 
the non-uniform distribution is the polarity of PNA, which may cause it to behave as a 
surfactant during methylene chloride removal. Thus, the PNA concentrates near the surface 
of the poly(CPH) microspheres leading to the initial burst. Another possible factor that could 
alter the release kinetics is the diffusion of PNA through the poly(CPH) during release. We 
do not believe that this is the dominant mechanism of release since the concentration 
gradients are small and the polymer is glassy at 37°C. One would expect that diffusion, if it 
were significant, would be evident in the release data from the 50:50 CPH-SA copolymer 
since its glass transition occurs at about 10°C. The very slow release from the 
poly(CPH:SA) 50:50 suggests that diffusion is not important. 
The burst effect due to non-uniform distribution of the PNA is much less pronounced 
in the 50:50 CPH-SA copolymer microspheres and not detected at all in the less hydrophobic 
poly(SA) microspheres. We attribute this to the kinetics of the precipitation during 
microsphere formation. Since poly (SA) and 50:50 CPH-SA copolymer have higher 
molecular weights (see Table 7.1), it is reasonable to expect that they precipitate from 
solution faster than the poly(CPH). This faster precipitation may not allow enough time for 
PNA to migrate to the surface. 
Thus, each polymer shows a distinct characteristic release profile. The release 
profiles from poly(SA) and 50:50 CPH-SA are nearly zero-order with the release rate 
dictated by the degradation rate of the polymer. The release rate from poly(CPH) exhibits a 
burst over a short period of time, presumably due to non-uniform distribution of PNA within 
the microspheres. 
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6.4.2.2. PNA release from microsphere "cocktails." The release profiles from 
poly(CPH) and poly(SA) are of particular interest because the poly(SA) profile shows nearly 
zero-order release (without a burst) while the poly(CPH) profile exhibits a large burst. This 
suggests that "cocktails" of poly(CPH) and poly(SA) microspheres could be used to tailor 
release profiles in which a burst followed by zero-order release is obtained. The magnitude 
of the burst provided by the poly(CPH) microspheres can be modulated without affecting the 
zero-order release rate provided by the poly(SA) and vice versa. The only limitation is the 
length of time over which the poly(SA) microspheres release, which is fixed at a little longer 
than one week. However, additional flexibility can be realized by introducing CPH-SA 
50:50 microspheres, which have a longer release time than that of poly(SA). 
Release data from three cocktail formulations are presented in Figure 7.5. Cocktail I 
is made up of 80% poly(CPH) microspheres and 20% poly(SA) microspheres. The release 
profile for Cocktail I shown in Figure 7.5a shows a large burst (due to the high number of 
CPH microspheres) in the first six hours followed by a period of zero-order release that lasts 
until the end of day one. After this, a second period of zero-order release begins, which lasts 
until about day 8. The poly(CPH) microspheres continue to release at a slow rate for about 
one day. Thus the first region of zero-order release has a rate that is the sum of the release 
from the poly(CPH) and the poly(SA) microspheres. Once all of the PNA has been released 
from the poly(CPH) microspheres, the release rate falls to that of the poly(SA) microspheres. 
This release rate is very slow due to the small number of poly(SA) microspheres used. 
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Figure 7.5. Mass of PNA (in p.g) released from microsphere "cocktails" made up of (a) 80% 
poly(CPH) and 20% poly(SA), (b) 50% poly(SA) and 50% CPH-SA 50:50 and (c) 38% 
poly(CPH), 51% poly(SA), and 11% CPH-SA 50:50. 
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Figure 7.5. (Continued). 
Cocktail III is made up of 38% poly(CPH) microspheres, 51% poly(SA) 
microspheres, and 11% CPH-SA 50:50 microspheres (Figure 7.5c). The burst is evident in 
the first eight hours followed by sustained, zero-order release lasting for nearly one month. 
This profile also shows that CPH-SA 50:50 microspheres release PNA for at least 27 days. 
7.5 Conclusions 
We have shown that the release of PNA from microspheres of poly(CPH), poly(SA), 
and CPH-SA (50:50) is a function of polymer erosion rate and interactions of the drug with 
the polymer. Each polymer studied has a unique characteristic release profile. Release from 
poly(SA) microspheres is nearly zero-order for about eight days. The release from 
poly(CPH) microspheres exhibits a burst and shows almost complete release in about two 
days. The CPH-SA 50:50 microspheres show a small burst followed by zero-order release 
that lasts for about a month. 
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Release profiles can be tailored by combining microspheres in "cocktails" such that 
the sum of the release profiles from each type of microsphere yields the desired profile. 
Profiles containing a burst followed by zero-order release are desirable for many drug 
delivery applications. This drug release profile can maintain therapeutic drug concentrations 
while obviating the need for multiple administrations. The system presented here offers this 
capability. The magnitude of the burst can be varied independently (by changing the amount 
of poly(CPH) microspheres used) of the subsequent zero-order release rate (obtained from 
the poly(SA)), rendering the system flexible. Additional flexibility is introduced by the 
incorporation of CPH-SA 50:50 microspheres, which release drug for over a month. The 
continued study of drug release from these bioerodible systems will lead to the development 
of safer and more effective methods of delivering injectable therapeutic formulations. 
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CHAPTER 8 
SINGLE-DOSE TETANUS VACCINE BASED ON BIOERODIBLE 
POLYANHYDRIDE MICROSPHERES CAN MODULATE IMMUNE RESPONSE 
MECHANISM 
A paper to be submitted to Proceedings of the National Academy of Sciences of the United 
States of America, 2004. 
Matt J. Kipper1,2, Jennifer Wilson3'4, Michael Wannemuehler3'5, and Balaji Narasimhan1'6 
8.1 Abstract 
The development of a single-dose tetanus toxoid (TT) vaccine based on 
polyanhydride copolymer microspheres composed of 1,6-bis(p-carboxyphenoxy)hexane 
(CPH) and sebacic acid (SA) is reported. The release kinetics can be modulated by altering 
the copolymer composition, which allows unique immunization regimens to be developed. 
In vivo studies in mice demonstrate that the encapsulation procedure preserves the 
immunogenicity of the TT. The polymer itself has an adjuvant effect, enhancing the immune 
response to a small dose of TT, but as the dose of polymer is increased, a localized, dose-
dependent inhibition is observed. The sustained release of the antigenic/immunogenic 
protein is essential for the efficacy of a single-dose vaccine. TT released from the 
microspheres maintains its immunogenicity and antigenicity and the microspheres provide a 
1 Department of Chemical Engineering, Iowa State University. 
2 Graduate Student, Primary Author. 
3 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University. 
4 Graduate Student, Secondary Author. 
5Major Professor to Jennifer Wilson 
6 Major professor to Matt Kipper, corresponding author 
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prolonged exposure to TT sufficient to induce the secondary immune response (i.e., isotype 
switching and high titers) without requiring an additional administration. In addition to 
providing an immune response with a single immunizing dose, the microsphere delivery 
vehicle offers the opportunity to select the preferred immune response pathway. While TT 
administered in buffer alone is known to induce a T»2 immune response, we demonstrate that 
TT-loaded microspheres preferentially induce both the ThI and Th2 immune response 
pathways as evidenced by the IgG2a and IgGl antibody responses, respectively, when 
injected intramuscularly into mice. Though the T»2 immune response is higher for some 
formulations, it can be selectively inhibited by altering the vaccine formulation. The ability 
to induce immune deviation by utilizing the microsphere delivery system may allow for 
induction of immune responses that are more effective for some viral and other intracellular 
pathogens. We present a strategy for modulating the immune response by delivering the 
microspheres along with a small bolus of unencapsulated TT. This ability to tune the 
immune response without the administration of additional cytokines or noxious adjuvants is a 
unique and valuable feature of this delivery vehicle that may make it an excellent candidate 
for many vaccines. 
8.2 Introduction 
The National Institutes of Health identified the development of single-dose vaccines 
as one of 14 grand challenges in global health in 2003 (1). Even diseases for which effective 
vaccines exist, many remain a threat to public health because patient dropout rates after 
initial vaccine doses reach as high as 70% in developing countries (2). Improved vaccine 
delivery techniques that require only a single dose to confer protective immunity against 
childhood diseases would help make mass immunization programs successful. For instance, 
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tetanus is responsible for over 700,000 neonatal deaths annually, half of which could be 
prevented by immunization alone (3). Additionally, the ability to purposefully modulate the 
immune response to more effectively protect the host from a particular disease state would 
improve the effectiveness of vaccines in combating worldwide disease. While traditional 
alum-based vaccines, incorporating tetanus toxoid (TT) in particular, initiate primarily a T 
helper type 2 (Ty2) response (4, 5), a T helper type 1 (THI) response may be more effective 
for protection from or treating cancers and infections due to intracellular pathogens (6). The 
Th2 (humoral) response, characterized by the activation of B cells that secrete antibodies, is 
effective at neutralizing extracellular pathogens and toxins, and the ThI (cell-mediated) 
response, involving the activation of cytotoxic T cells and macrophages, is effective for 
fighting intracellular pathogens (7). Induction of the appropriate immune response is 
essential to the safety and efficacy of vaccines (7, 8). However, the mechanisms governing 
the type of immune response are complex and not well understood (8, 9). 
The goal of this study was to develop a single dose vaccine utilizing bioerodible 
polyanhydride microspheres that offers the potential to preferentially induce a ThI immune 
response, using TT as a model antigen. Single-dose vaccines must provide prolonged 
exposure to an antigen so that the secondary immune response occurs without the necessity 
of a second administration. Consequently, the protein must also be stabilized so that an 
immunogenic/antigenic form is released. Finally, we seek to target delivery of the protein to 
phagocytes of the immune system to take advantage of their ability to shape the nature of the 
adaptive immune response. 
Our previous work has characterized the erosion kinetics of and the drug release 
kinetics from polyanhydride copolymers composed of l,3-bis(p-carboxyphenoxy)hexane 
(CPH) and sebacic acid (SA) (10, 11). These polymers are shown in Figure 8.1. We have 
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also reported the fabrication of microspheres and the controlled release of small molecular 
mass compounds (12, 13). A key feature of these materials is that their performance in 
controlled release applications is enhanced by their hydrophobicity. Commonly used 
polyesters such as poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) have been 
studied for single-dose vaccines (14, 15). Unlike these polyesters, the polyanhydrides used 
in this study do not swell in the presence of water. This hydrophobic property of the 
microspheres results in the release of immunogen by a process of surface erosion. More 
importantly, the exclusion of water from the microsphere may aid the stabilization and 
prolonged immunogenicity of encapsulated proteins (16, 17). It has been shown that high-
moisture environments can cause proteins such as TT and diphtheria toxoid to form insoluble 
aggregates, losing about 75% of their solubility, and thus their immunogenicity, within one 
week (17). Another important feature of polyanhydrides is that the degrading microsphere 
does not form an acidic microenvironment as extreme as that formed by PLA and PLGA (17-
19). This is due in part to the limited solubility of the monomeric dicarboxylic acids released 
during erosion. We have previously described the stabilization of proteins in poly(CPH-SA) 
microspheres (20) and the ability to purposefully modulate the release profile, by changing 
the copolymer composition, and thus the hydrophobicity (10-12). 
o 
o 
Figure 8.1. Poly(CPH) (top) and poly(SA) (bottom). 
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Here we report the fabrication of TT-loaded polyanhydride microspheres, their in 
vitro antigen release kinetics, and the in vivo ability to induce an antigen-specific immune 
response. We observed a dose-dependent inhibition of the immune response by the polymer 
at high polymer doses, but as the polymer dose is reduced, the inhibition is eliminated and a 
stimulatory adjuvant effect is observed. No other adverse effects were observed, even when 
the immune response was inhibited. We also discuss the mechanism(s) that may govern the 
deviation of the immune response (THI V. TH2) as defined by changes in the TT specific 
IgGl and IgG2a antibody responses. The microspheres are capable of inducing a combined 
Th1/Th2 immune response when injected intramuscularly, rather than the Th2 immune 
response that is typical of alum-based vaccines (4) and TT in particular (5). By injecting the 
microspheres along with a small bolus of unencapsulated TT, the Th2 immune response can 
be selectively inhibited without reducing the overall TT specific antibody production. The 
bolus alone is not sufficient to induce a measurable immune response. We discuss possible 
mechanisms involved in shaping the immune response. 
8.3 Materials and Methods 
8.3.1 Polymer synthesis and characterization 
Poly(CPH-SA) (20:80) and poly(CPH-SA) (50:50) were synthesized by melt 
polycondensation from acetylated prepolymers as described previously (12). Gel permeation 
chromatography was performed on a Waters GPC system (Milford, MA) using PL Gel 
columns (Polymer Laboratories, Amherst, MA). The 20:80 copolymer had a weight average 
molecular weight (Mw) of 21,000 and a polydispersity index (PDI) of 2.2. The 50:50 
copolymer had an Mw of 13,000 and a PDI of 2.0. Polymers were stored desiccated under 
dry argon. 
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8.3.2 Microsphere fabrication 
Purified TT (1.5mg/ml, 490Lf/ml) was purchased from University of Massachusetts 
Biologic Laboratories (Jamaica Plain, MA). Protein was dialyzed against de-ionized water 
for 48 hours and lyophilized before encapsulation. TT-loaded microspheres were fabricated 
by a water/oil/oil double emulsion similar to the method reported by Esparza and Kissel for 
poly(D,L-lactide-co-glycolide) microspheres (21). Polymer (100 mg) was dissolved in 
methylene chloride (4 ml). Protein (4 mg) was dissolved in nanopure water (100 p.1). The 
protein solution was added to the polymer solution in a 50 ml centrifuge tube and 
immediately emulsified by agitation at 15,000 rpm with a handheld homogenizer (Tisssue-
Tearor™, Biospec Products Inc., Bartlesville, OK) for one minute. While still 
homogenizing, 4 ml of Dow Corning Fluid, saturated with methylene chloride, was added 
drop wise to form the microspheres. Homogenization was continued for an additional 
minute. To precipitate the microspheres, the double emulsion was transferred to a 400 ml 
Berzelius beaker containing 300 ml «-heptane on an ice water bath. The heptane was stirred 
at 300 rpm using a Caframo overhead stirrer (Warrington, Ontario) with a three-inch impeller 
for three hours to extract the methylene chloride. Heptane was periodically added during the 
solvent removal to replace the volume lost due to evaporation. The microspheres were 
isolated by filtration using Whatman #50 filter paper. The beaker and impeller were rinsed 
several times with fresh heptane to maximize recovery. The microspheres were washed at 
least three times with 50 ml of heptane to rinse off residual Dow Corning fluid, and dried for 
24 hours under vacuum. This procedure yielded a free-flowing powder with about 80% of 
the polymer mass being recovered. Blank microspheres were also fabricated by a similar 
technique that contained no inner water emulsion. 
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8.3.3 In vitro TT release kinetics 
Microspheres (3 to 6 mg) were suspended in 2 to 3 ml of 0.1 M phosphate buffer (pH 
7.4). Samples of the release buffer (100 (0.1) were taken periodically and the sample volume 
was replaced with fresh buffer. Release kinetics experiments were conducted in duplicate. 
Concentrations in the buffer solution were assessed by micro BCA Protein Assay (Pierce, 
Rockford, II). 
8.3.4 In vivo inhibition of immune response 
Mice (3 C3H/HeOuJ mice per group, at least 8 weeks of age) were injected 
intramuscularly in the right quadriceps with unencapsulated TT and blank 20:80 poly(CPH-
SA) microspheres both suspended in 50% cottonseed oil/saline emulsion. Doses for each 
group of mice are listed in Table 8.1. Groups I, II, and III received the same amount of TT (3 
p,g), and 3, 1, or 0.5 mg of polymer, respectively. Group IV received its TT injection (3 jag) 
in the same site as the microsphere injection (3 mg) three days later. Group V received only 
TT (3 (j,g) in the right leg and blank microspheres (3 mg) in left leg. Group VI received only 
TT (3 fxg). Mice were sampled weekly by collecting 100 |J,1 of blood from the saphenous 
vein. Serum was separated by centrifugation. TT specific antibody responses were assessed 
by enzyme-linked immunosorbant assay (ELISA) (see Section 8.3.6 below). Samples were 
collected from all three mice at each time point. 
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Table 8.1. Experimental groups in this study. 
Inhibition assay 
Group Microsphere Formulation Free TT 
I 3mg blank 20:80 CPH:SA 3^g 
II lmg blank 20:80 CPH:SA 
III O.Smg blank 20:80 CPH:SA 3pg 
IV 3mg blank 20:80 CPH:SA 3(ag (on day 3) 
V 3mg blank 20:80 CPH:SA 3jag (opposite leg) 
VI none 3WS 
Antibody response assay 
Group Microsphere Formulation* Free TT 
VII O.Smg blank 20:80 CPH:SA none 
VIII O.Smg blank 20:80 CPH:SA 0.5jag 
IX O.Smg TT-loaded 20:80 CPH:SA none 
X O.Smg TT-loaded 20:80 CPH:SA 0.5jxg 
XI O.Smg blank 50:50 CPH:SA none 
XII O.Smg blank 50:50 CPH:SA 0.5|ag 
XIII O.Smg TT-loaded 50:50 CPH:SA none 
XIV O.Smg TT-loaded 50:50 CPH:SA 0.5jxg 
XV none 0.5(xg 
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8.3.5 In vivo antibody response to vaccine formulations 
Mice (4 to 8 C3H/He0uJ mice per group, 8 weeks of age) were injected 
intramuscularly in the right quadriceps with either TT-loaded microspheres, TT-loaded 
microspheres plus a 0.5 |xg bolus of TT, blank microspheres, or blank microspheres plus a 
0.5 jo-g bolus of TT suspended in sterile saline containing 0.5% fetal calf serum (FCS). The 
treatments for each group are listed in Table 8.1. As controls, mice in group XV received a 
0.5 fig bolus injection of TT without any microspheres. Mice were sampled weekly by 
collecting 100 jj.1 of blood from the saphenous vein. Serum was separated by centrifugation. 
Antibody titers were determined by ELIS A (see Section 8.3.6 below). Samples were 
collected from all mice at each time point. 
The ELISA for antibody titers was performed in 96-well format. Immulon II high 
binding plates (Dynatech Laboratories, Inc., Chantilly, VA) were coated overnight with 100 
(j.1 of 1 (ig/ml TT in phosphate buffered saline (pH 7.4, PBS). Plates were washed with PBS 
containing 0.05% Tween 20 (PBST) and then blocked for two hours at room temperature 
with PBST containing 2% gelatin and 2% FCS. Serum samples from the individual mice 
were serially diluted in PBST with 2% FCS. Detection antibody was alkaline phosphatase-
labled affinity purified antibody to mouse IgG (H&L) (0.5 pig/ml) (KPL, Gaithersburg, MD). 
Phosphatase substrate (Sigma 104, phosphatase substrate, p-nitrophenyl phosphate, Sigma-
Aldrich, Saint Louis, MO) was diluted to 1 mg/ml in sodium carbonate buffer (pH 9.3) and 
allowed to react for 1 hour. Plates were read using Spectramax 190 Plate Reader (Molecular 
Devices, Sunnyvale CA). ELISA to determine IgG2a and IgGl antibody titers was 
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performed similarly. Detection antibodies were goat anti-mouse IgGl-AP and goat anti-
mouse IgG2a-AP (Southern Biotechnology Associates, Birmingham, AL). 
8.4 Results and Discussion 
The TT-loaded microspheres had sizes ranging from 10 to 50 |_im. Scanning electron 
micrographs of the TT-loaded microspheres are shown in Figure 8.2. The TT-loaded 
poly(CPH-SA) 20:80 microspheres have small (<l|o.m) particles flocculated on their surfaces. 
Blank microspheres did not exhibit this surface characteristic, nor did the TT-loaded 
poly(CPH-SA) 50:50 microspheres. We hypothesize that these surface particles are 
composed primarily of poly(CPH-SA) 20:80 polymer rather than protein as no significant 
burst is observed in the protein release profiles. The surfaces of some of the poly(CPH-SA) 
50:50 microspheres have large circular divots, as observed in Figure 8.2. These are probably 
formed when microspheres fuse together during the solvent removal and subsequently break 
apart after drying. Poly(CPH-SA) 50:50 microspheres fused together in small clusters were 
observed by the scanning electron microscope (not shown). Other than these characteristics, 
all formulations resulted in microspheres with smooth surfaces, free from pores and cracks. 
The in vitro release profiles for TT-loaded microspheres are shown in Figure 8.3. 
The loading efficiency was calculated from the total mass of protein released. The loading 
efficiency is 34% for the 20:80 copolymer and 51% for the 50:50 copolymer, leading to 
loading values of 1.4% and 2%, respectively. As anticipated, increasing the hydrophobicity 
of the polymer by increasing the CPH mole fraction decreases the release rate. Zero-order 
(uniform) release of the protein is obtained in both cases. The poly(CPH-SA) 20:80 
copolymer releases greater than 90% of the protein in one week, while the poly(CPH-SA) 
50:50 copolymer releases all the protein over a period of about 19 days. 
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Figure 8.2. TT-Loaded poly(CPH-SA) microspheres. 20:80 (top) and 50:50 (bottom). 
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Figure 8.3. In vitro TT release profiles for TT-loaded poly(CPH-SA) 20:80 (•) and 50:50 
(A) microspheres. 
Figure 8.4 shows the results from the inhibition assay. Groups I, II, and IV show 
significant inhibition compared to groups III, V, and VI. This demonstrates that the polymer 
induces a localized, dose-dependent inhibition. When the polymer dose is reduced to 0.5 mg 
the local inhibition is eliminated. Note that when polymer and TT are delivered in separate 
injection sites (group V) the inhibition is nearly eliminated. This indicates that the inhibition 
is primarily local, rather than systemic, and may involve the recruitment of antigen 
presenting cells to the injection site. The antibody response at week two for group III is the 
same as that for group V at the same time point, and by week four is not significantly 
different from the group that received no polymer at all (group VI). Based on these results, 
0.5 mg of polymer was chosen as the maximum dose for a single injection. This is also the 
dose extrapolated on an anticipated polyanhydride polymer weight per kilogram body weight 
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dose for human drug delivery (22). While several studies have been conducted to evaluate 
the effect of polyanhydrides on various tissues for therapeutic drug delivery (22-26), their 
effects on and engagement of the immune system have not yet been evaluated. 
The secondary immune response is evaluated by ELISA detecting TT-specific IgG. 
Figure 8.5 shows the antibody titers for groups VII through XV over the twelve weeks of this 
study. All of the mice given only blank microspheres (groups VII and XI, open circles) show 
no significant response. When a 0.5 fig bolus of TT is delivered along with blank 
microspheres (groups VIII and XII, filled circles) a small response is observed, but in both 
cases is much greater than the response induced by the bolus alone (group XV, crosses). 
Thus, the polymer itself offers an adjuvant effect, provided it is delivered in small doses. 
Group XII exhibited a greater response than group VIII. The maximimum titer for group XII 
was 8100 (week 6) and the maximum titer for group VIII was 2600 (week 7). We 
hypothesize that since the poly(CPH-SA) 50:50 microspheres likely remain at the injection 
site for a longer time (due to the increased hydrophobicity), the adjuvanticity of the polymer 
is enhanced. All of the mice receiving the TT-loaded microspheres (groups IX, X, XIII, and 
XIV, open and filled squares) exhibit a response. The responses of groups IX and XIII 
indicate that the protein is released from the microspheres in an immunogenic form. The 
prolonged exposure to immunogenic TT provided by the microspheres is sufficient to 
stimulate both a primary and secondary immune response, which is sustained over the 12 
weeks of the study. Groups XIII and XIV have titers between 20,000 and 60,000 over the 
last five weeks and groups IX and X have titer values between 50,000 and 110,000 over the 
last five weeks. 
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Figure 8.4. Optical densities from ELISA at 1:400 dilution for inhibition assay at week 2 (a) 
and week 4 (b). Error bars indicate standard error. All groups received the same dose of 
unencapsulated TT (0.5 (ig). Groups I, II, and III received 3, 1 and 0.5 mg of poly(CPH-SA) 
20:80 blank microspheres, respectively, at the same injection site. Group IV received 3 mg 
of blank microspheres three days prior to the TT dose at the same injection site. Group V 
received 3 mg of microspheres in the opposite leg as the TT injection. Group VI received no 
microspheres. The treatments for each group are detailed in Table 8.1. 
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Figure 8.5. Average antibody titers for (a) groups VII (o) VIII(e) IX(D) and X(e), which 
received poly(CPH-SA) 20:80 microspheres, and (b) groups XI (o) XII (•) XIII(•) and 
XIV(b), which received poly(CPH-SA) (50:50) microspheres. Group XV, which received 
only a 0.5 jag bolus of unencapsulated TT, is shown in both plots (+). In both plots o 
represents blank microspheres only, • represents blank microspheres plus the bolus of 
unencapsulated TT, • represents the TT-loaded microspheres, and • represents the TT-
loaded micorpsheres plus the bolus of unencapsulated TT. Treatments for each group are 
detailed in Table 8.1. 
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The 0.5(j.g bolus of TT added to the treatments for groups X and XIV does not 
significantly affect the overall TT-specific IgG antibody titer compared to groups IX and 
XIII, respectively. However, it does alter the nature of the immune response in the case of 
group X. In order to evaluate the nature of the immune response, IgGl and IgG2a antibody 
isotypes were assayed by ELISA at weeks zero, four, eight, and twelve for these four groups. 
Figure 8.6 shows the TT-specific antibody titers for IgGl and IgG2a isotypes for groups IX, 
X, XIII, and XIV at four, eight and twelve weeks. For group IX, which received only TT-
loaded poly(CPH-SA) 20:80 microspheres, a preference for IgGl production is observed, 
indicating a Ty2 dominant response. However, when the 0.5 jag bolus is delivered along with 
the microspheres (group X) the IgGl production is inhibited. At week 12, the IgGl antibody 
titer for group X is 76% lower than that for group IX at the same time point. The IgG2a 
antibody titer is not significantly altered by the addition of the bolus. In this case, the 
addition of the bolus has altered the nature of the immune response from a Th2 dominant 
response to a balanced TH2/TH1 response (i.e., THO). Despite the reduction in IgGl 
production observed for group X, the overall TT-specific IgG is not significantly altered by 
the addition of the bolus (Figure 8.5a). A hypothesis for the mechanism by which the 
immune response is altered is given below. Most vaccines currently approved for human use 
contain an alum-based adjuvant (27), which typically induces a Tr2 dominant response (4). 
The ThI immune response is a beneficial response for enhanced immunity to viral or other 
intracellular pathogens and the Th2 immune response has been implicated in the 
development of allergies. Thus, the ability to preferentially inhibit the Th2 immune response 
is a valuable and unique feature of this delivery vehicle. 
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Figure 8.6. TT-specific IgGl and IgG2a antibody titers for (a) groups IX and X, which 
received poly(CPH-SA) (20:80) microspheres and (b) groups XIII and XIV, which received 
poly(CPH-SA) (50:50) microspheres. Groups IX and XIII received only TT-loaded 
microspheres. Groups X and XIV received TT-loaded microspheres with a 0.5 \ig bolus of 
unencapsulated TT. Treatments for each group are detailed in Table 8.1. 
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Groups XIII and XIV, which received the poly(CPH-SA) 50:50 microspheres, 
without and with the 0.5 jag bolus, respectively, show significantly weaker IgGl and IgG2a 
production compared to groups IX and X, which is consistent with the total TT-specific IgG 
titers shown in Figure 8.5. The bolus administered to group XIV does not significantly alter 
the nature of the immune response as it does in the case of group X. 
The exact mechanism by which the bolus affects the nature of the immune response 
for group X is not clearly understood. Figure 8.7 illustrates possible differences in the 
immune response for groups IX, X, and mice receiving an equivalent dose of unencapsulated 
TT. Immediately following the administration of any of the three immunization 
regimen,inflammatory chemokines are produced at the injection site as a result of the injected 
materials (i.e., physical trauma), which results in the recruitment of macrophages, 
neutrophils, and dendritic cells. Dendritic cells can phagocytose microspheres (shown in 
Figure 8.7a. and b.) and pinocytose unencapsulated TT (shown in Figure 8.7b and c). When 
only microspheres are phagocytosed in the absence of unencapsulated TT (Figure 8.7a), the 
migration of the dendritic cells to the lymph node is delayed because the microspheres are 
processed as particulate antigen (28). But when unencapsulated TT is present (Figure 8.7b 
and c) the dendritic cells migrate to the lymph node more rapidly. When the dendritic cells 
reach the lymph node they stimulate either ThI cells, Th2 cells, or both. When only 
microspheres are delivered and the migration to the lymph node is delayed, the microspheres 
are allowed to degrade so that some dendritic cells either pick up released protein or have 
phagocytosed microspheres that subsequently degrade prior to the complete maturation of the 
dendritic cell. Delay in the migration of the dendritic cells also permits the inflammatory 
response to wane, thus hindering DC activation and migration. When the dendritic cell 
reaches the lymph node, the type of T helper cell stimulated is primarily antigen driven, as 
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most of the microspheres have degraded. Since TT preferentially induces the Th2 immune 
response, the production of IgGl dominates. When only unencapsulated TT is administered 
(Figure 8.7c), the migration of the dendritic cells is not delayed, and again, the immune 
response is antigen driven leading to a T»2 dominant immune response, which we and others 
have observed (data not shown) (5). However, when both unencapsulated TT and TT-loaded 
microspheres are delivered, the migration of the dendritic cells to the lymph node is 
uninhibited because some dendritic cells have pinocytosed unencapsulated antigen. In this 
case, some dendritic cells reach the lymph node with intact microspheres. These dendritic 
cells process the TT in the context of particulate antigen and produce interleukin 12 (IL-12). 
IL-12 preferentially stimulates ThI cells that produce interferon y (INF-y) in sufficient 
quantity to suppress IgGl production. In this case, both IgGl (not shown in Figure 8.7b) and 
IgG2a are produced and neither isotype dominates, leading to a ThO phenotype. 
Based on the results shown in Figure 8.6b, we hypothesize that the 50:50 
microspheres do not release sufficient immunogenic protein in a short enough time span to 
induce a strong T-cell response. The weak T-cell response is characterized by no preference 
for IgGl or IgG2a production and weak affinity antibody. This would be consistent with the 
lower antibody titers depicted in Figures 8.5 and 8.6 for groups XIII and XIV (i.e., the groups 
receiving the poly(CPH-SA) 50:50 microspheres) compared to groups IX and X (i.e., the 
groups receiving the poly(CPH-SA 20:80 microspheres). 
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8.5 Conclusions 
Tetanus toxoid was successfully encapsulated in and released from polyanhydride 
microspheres. Smooth microspheres in the form of a free flowing powder are obtained from 
a water/oil/oil double emulsion technique. Altering the copolymer composition modulates 
the in vitro release kinetics and protein that is released maintains its immunogenicity and 
antigenicity. The polymer itself has an adjuvant effect, enhancing the immune response to a 
small dose of TT, but as the dose of polymer is increased a localized, dose-dependent 
inhibition is observed. The sustained release of the antigenic protein is essential for the 
efficacy of a single-dose vaccine. The microspheres prolonged the exposure to 
immunogenic/antigenic TT sufficiently to induce the secondary immune response, without 
requiring an additional administration of the vaccine. 
In addition to providing an effective single dose vaccination regimen , the 
microsphere delivery vehicle offers the opportunity to select the preferred immune response 
pathway. The poly(CPH:SA) 20:80 microsphere formulations induce both the TH1 and Th2 
immune response pathways. When the microspheres are delivered alone, the immune 
response appears to be antigen driven, leading to a T»2 dominant response for TT. However, 
when the microspheres are delivered along with a small bolus of unencapsulated TT, the Ty2 
immune response is selectively inhibited, leading to a combined Trather than the Th] immune 
response that is typical of alum based vaccines and of TT in particular. The overall TT-
specific IgG is unaffected by the isotype switch. The preferential reduction of the T»2 
immune response and the ability to induce a balanced immune response is a unique and 
valuable feature of this delivery vehicle that may make it an excellent candidate for 
developing vaccines to intracellular pathogens including HIV/AIDS. Though it is not clear 
exactly how the antigen presenting cells are processing the encapsulated antigen resulting in 
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different immune responses, the immune response may be governed by the combination of 
the microsphere release kinetics and the propensity for dendritic cell migration from the 
injection site to be delayed in the context of particulate antigen. 
The poly(CPH-SA) 50:50 microspheres induce a weak T-cell response, characterized 
by no preference for IgGl or IgG2a production and weak affinity antibody. This could either 
be due to poor stabilization of the antigen, or the prolonged slower release leading to the 
induction of tolerance. 
Further investigation of the interactions between polyanhydride microspheres and 
lymphocytes will improve our understanding of the immune response mechanism, and guide 
the design of controlled release vaccines that selectively induce the desired immune 
response. 
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CHAPTER9 
MECHANISTIC UNDERSTANDING OF DEGRADATION IN BIOERODIBLE 
POLYMERS FOR DRUG DELIVERY 
A paper reprinted from AIChE Journal 48(12):2960-2970. Copyright ©(2002), The 
American Intsitute of Chemcial Engineers. 
Domenico Larobina1'2, Matt J. Kipper3'4, Giuseppe Mensitieri1'5, and Balaji Narasimhan3,6 
9.1 Abstract 
A new model has been developed to understand the mechanism of erosion in 
bioerodible polymers. A fundamental understanding of the mechanism of erosion in these 
polymers is essential to accurately predict drug release and precisely design controlled 
release devices. This model takes into account the phenomenon of microphase separation 
that has been observed for polyanhydrides of certain copolymer compositions. The model 
assumes that erosion is dominated by degradation and thus, in a system with a fast eroding 
and a slow eroding species, two rate constants, one for each species, essentially control the 
evolution of the polymer microstructure. Expressions have been derived for the fraction of 
each monomer released as well as for the porosity in the system. A partition coefficient 
accounts for thermodynamic partitioning of drug into the micro-domains. The solutions of 
the model equations have been fitted to experimental data on monomer release kinetics from 
two polyanhydride systems to obtain the erosion rate constants. Drug release kinetics 
1 Department of Materials and Production Engineering, University of Naples "Federico II." 
2 Graduate student; primary author; contributed to model development and solution. 
3 Department of Chemical Engineering, Iowa State Univeristy. 
4 Graduate student, author, contributed to model development and solution. 
5 Major professor (Larobina). 
6 Major professor (Kipper); corresponding author. 
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experiments are compared to the model solution for drug release and the partition coefficient 
of the drug is obtained from the fits. The comparisons to the data are promising, while 
pointing out the limitations of the model. The model does not account for oligomer 
formation prior to monomer release or for the dependence of the rate constants on parameters 
such as the degree of crystallinity, the local pH, and the polymer molecular weight. 
Keywords: Degradation, Bioerodible, Mathematical Model, Polyanhydrides, Drug Release 
9.2 Introduction 
The use of biodegradable polymers as carriers for controlled release systems has been 
the object of research over the past two decades due to their advantages over other competing 
systems. The biodegradable structure of the polymer obviates the need to surgically remove 
the device. Biocompatibility of the degradation products has also been established. For 
example, the FDA has approved the use of the copolymer, poly[l,3-bis(p-
carboxyphenoxy)propane-co-sebacic anhydride], p(CPP-SA) 20:80, for human use, and the 
delivery of anti-cancer proteins has been reported (Dang et al., 1996). 
For clarity, it is important to distinguish between the terms "degradation" and 
"erosion". The term "degradation" refers to the chain scission process by which polymer 
chains are cleaved into oligomer or monomer units. The term "erosion" refers to mass loss 
from the bulk polymer. In other words, erosion could be considered as the sum of several 
elementary processes, one of which is degradation. 
The pioneering work of Langer, Mathiowitz, and co-workers (Leong et al., 1985; 
Leong et al., 1986; Mathiowitz and Langer, 1987; Chasin et al., 1988; Mathiowitz et al., 
1988; Mathiowitz et al., 1990a; Mathiowitz et al., 1990b; Tamada and Langer, 1992; Shieh 
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et al., 1994; Goepferich and Langer, 1995) has established the potential of biodegradable 
polyanhydrides based on aromatic and aliphatic dicarboxylic acids as carriers for therapeutic 
compounds. This class of polyanhydrides consists of a backbone of monomeric carboxylic 
diacids joined by anhydride linkages; these bonds are hydrolyzed upon exposure to an 
aqueous environment, forming water-soluble monomeric degradation products. In spite of 
the hydrophilicity of the characteristic anhydride functional group, the presence of aromatic 
and aliphatic groups in the monomer confers a high hydrophobicity to the polymer. As a 
consequence, water is prevented from penetrating into the bulk of the polymeric device 
causing the erosion process to occur on the surface of the device (Goepferich, 1996a; 
Goepferich, 1996b). This is in contrast to "bulk-erodible" polymers such as poly(lactic acid), 
poly(glycolic acid), and their copolymers, in which water penetrates into the bulk of the 
polymer (Langer, 1990; Peppas and Langer, 1994). The polyanhydride system is extremely 
versatile due to the differences in the homopolymer erosion rates; in fact, by simply 
employing different co-monomer ratios, the erosion times can be varied from a few weeks to 
a few years (Leong et al., 1985). 
Several studies report in vitro erosion of copolymeric polyanhydrides. Some of the 
earlier work with this system reported only total mass loss (Leong et al, 1985; Mathiowitz 
and Langer, 1987; Chasin et al., 1988; Mathiowitz et al., 1988; Mathiowitz et al., 1990a; 
Tamada and Langer, 1992; Shieh et al., 1994); but, more recently, individual monomer 
release has been reported because this information provides a more detailed view of the 
mechanism of degradation (Tamada and Langer, 1990; Shen et al., 2002). Recent studies 
conducted by our group have shown that depending on the copolymer composition, the 
system based on sebacic anhydride (SA) and l,6-bis(p-carboxyphenoxy)hexane (CPH) (see 
Figure 9.1) undergoes microphase separation (Shen et al., 2001). For compositions that 
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contain one component in excess of ~80mol%, we have shown earlier, using a combination 
of nuclear magnetic resonance (NMR), atomic force microscopy (AFM), differential 
scanning calorimetry (DSC), and wide angle X-ray diffraction (WAXD), that the polymer 
microstructure exhibits microphase separation. The presence of microphase separation in 
such systems is due to a combination of two factors. First, the reactivity ratio of the co-
monomers, SA and CPH, are both close to unity (Ron et al., 1991; Shen et al., 2002), and 
hence, if there is an excess of the SA component, SA-SA bonds are more abundant than SA-
CPH or CPH-CPH bonds. Second, the relative hydrophobicity of the two co-monomers are 
different (manifested by their vastly differing degradation rates), and thus in situations where, 
for example, when SA-SA bonds are numerous, the fewer CPH moieties thermodynamically 
prefer to form "micro-domains" within a matrix of SA. Thus, on a microscopic scale, two 
equilibrium phases are formed with each phase containing predominantly one constituent. 
This structure is represented schematically in Figure 9.2. 
o 
o 
Figure 9.1. Chemical structures of CPH (top) and SA (bottom) repeat units. 
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Figure 9.2. Schematic of microphase separation in polyanhydrides. 
Furthermore, it can be argued that if there is microphase separation in polyanhydrides 
of certain copolymer composition, drugs loaded into such polymers may thermodynamically 
partition into one phase or the other, depending on the compatibility of the drug with the 
constituent monomers. Careful examination of the literature on in vitro drug release from 
polyanhydrides of specific compositions reveals that drug release profiles (Mathiowitz and 
Langer, 1987; Chasin et al., 1988) do not match polymer erosion profiles over the entire 
duration of release. In fact, drug release profiles match individual monomer release profiles 
depending on their compatibility to the monomer phase. Thus for example, the release ofp-
nitroaniline (PNA), which is mainly dissolved in the slowly eroding phase (CPP or CPH), 
mimics the erosion profile of that phase once the fast eroding phase (SA) is dissolved (Shen 
et al., 2002). Qualitatively similar inferences can be drawn by observation of release data of 
other compounds loaded into copolymers of the same family (Leong et al., 1985; Mathiowitz 
and Langer, 1987; Chasin et al., 1988; Mathiowitz et al., 1988; Mathiowitz et al., 1990a; 
209 
Mathiowitz et al, 1992; Shieh et al, 1994; Chickering et al, 1996; Olivi et al, 1996; Kuntz 
and Saltzman, 1997; Park et al, 1997; Park et al, 1998). 
A fundamental understanding of the mechanism of degradation is essential to 
accurately predict drug release and precisely design controlled release devices. The 
development of a preliminary model that accounts for both microphase separation and drug 
partitioning is the main subject of this paper. The next section provides a brief summary of 
current models that describe polymer degradation and drug release. The following two 
sections present the assumptions and the salient features of the new model, and discuss the 
estimation of key model parameters from comparisons to experimental data, limitations of 
the model, and suggestions for improvements. The last section highlights the main 
conclusions of this work. 
9.3 Previous Models 
One of the first mathematical models describing the diffusive release of a drug from a 
polymeric device undergoing surface erosion was developed by Thombre and Himmelstein 
(Thombre and Himmelstein, 1984). They assumed that the erosion front moves with a zero-
order velocity and that Fickian diffusion occurs in the non-eroded zone under pseudo-steady 
state conditions. Consequently, two boundaries simultaneously move from the surface of the 
device to its center. This analysis, which was also extended to similar devices with a 
secondary membrane, fundamentally aimed to characterize the concentration profile of the 
drug inside the device and was able to predict fractional mass loss based on the drug 
concentration profile within the polymer. The same authors (Thombre and Himmelstein, 
1985) have developed another model, which accounts for diffusion of all the species involved 
in the process. In addition, autocatalytic reaction of the polymer during degradation is taken 
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into account. The system studied was made of a poly(orthoester) matrix in which an acid 
anhydride and a bioactive agent are uniformly distributed. The presence of the acid 
anhydride catalyzed degradation of the polymer matrix according to an elementary three-step 
reaction, which ultimately hydrolyzed the polymer. 
A different approach to understand the mechanism of degradation was proposed by 
Zygourakis (Zygourakis, 1990; Zygourakis and Markenscoff, 1996). He used the cellular 
automata method, first discretizing the system into cells, each one defined as either polymer 
or drug. Furthermore, each type of cell was characterized by a time constant for dissolution 
upon exposure to solvent. Dissolution time steps were then iterated to compute the temporal 
evolution of the erosion front and drug release. The resulting profiles showed almost linear 
fractional mass release profiles in contrast with the sigmoidal release that many experimental 
data show (Chasin et al., 1988; Mathiowitz et al., 1988; Shieh et al, 1994; Park et al., 1998; 
Shen et al, 2002). 
Goepferich and Langer (Goepferich and Langer, 1993) developed a stochastic model 
using Monte Carlo methods that considers the presence of multiple phases in the polymer 
matrix, which was otherwise similar to the cellular automata approach of Zygourakis. An 
important similarity between the models of Zygourakis and Goepferich and Langer is that 
erosion is considered an elementary process. The models differ in that Goepferich and 
Langer assumed finite probabilities for each erosion event, instead of assigning a constant 
velocity for erosion, and did not consider drug loading. Their model was applied to 
polyanhydrides using two types of polymer cells with different characteristic erosion times 
corresponding to crystalline and amorphous zones. The time constants were evaluated by 
fitting to experimental in vitro erosion data, and not explicitly correlated to physical 
processes such as hydrolysis, dissolution, and subsequent diffusion. Goepferich and Langer 
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further developed this model (Goepferich and Langer, 1995) to include monomer diffusion 
through the resulting porous network. 
More recently, a quantitative model was developed by Batycky et al. (Batycky et al., 
1997) to predict mass loss, molecular weight change, and macromolecular drug release as 
function of time for the case of bulk eroding microspheres. In this model, the two 
mechanisms of chemical degradation, i.e., random chain scission and end scission, were 
combined to obtain a more accurate prediction of the observed mass and molecular weight 
evolution. Two (coupled) drug release processes are accounted for: desorption from the 
surface in contact with the buffer solution, and Fickian diffusion through mesopores. The 
desorption leads to a burst release from the initially exposed surface in contact with the 
buffer solution. A subsequent lag time in the drug release is attributed to the induction time 
associated with the growth of micropores and their coalescence to form mesopores 
sufficiently large for release of additional macromolecular drug. 
It is worthwhile to note that all the models described above were developed for 
polymers with homogenous composition; thus, the drug is uniformly distributed throughout 
the polymer matrix, and there is no thermodynamic partitioning. One model that does 
account for partitioning was developed by Varelas et al. (Varelas et al., 1995a; Varelas et al., 
1995b). In this model, drug is encapsulated in a polymeric dispersed phase and diffuses 
through a continuous phase. The continuous phase is a hydrogel in which the drug is only 
slightly soluble. Thus, the dispersed phase acts as a reservoir, a pseudo-steady state is 
obtained during release, and release is zero-order. The device is not bioerodible. 
The existence of microphase separation in polymers and consequent partitioning of 
drugs into the micro-domains necessitates the development of new models that incorporate 
these phenomena into the analysis. This is the main goal of the current work. In addition, 
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physical significance will be assigned to model parameters by linking them to elementary 
physical processes. Furthermore, the parameters will be compared to independent 
experiments to verify the validity of the assumptions intrinsic to the model. 
9.4 Model Development 
In general, polymer erosion is a complex phenomenon that depends on many factors 
such as: polymer degradation, polymer chemistry and composition, crystallinity, 
hydrophobicity, polymer molecular weight, and diffusivity of monomers and oligomers. 
Each of these factors plays a different role in determining the rate of erosion. Schematically 
the erosion process is composed of the following elementary steps: 
1) Water ingress: Initially the polymeric device is exposed to an aqueous buffer solution, 
which leads to water ingress. Two kinds of degradation mechanisms can be 
distinguished: bulk and surface, depending on the polymer hydrophobicity. 
2) Chemical degradation: The water randomly breaks the chemical bonds in the polymer 
and produces the constituent monomers and oligomers. 
3) Dissolution: Finally, the monomers dissolve in the buffer and diffuse through the 
device into the bulk. 
Thus, the erosion process could be viewed as the sum of different elementary processes, each 
characterized by a time constant. The analysis of these processes with the associated time 
constants allows us to discern which ones might be rate limiting and, consequently, which 
could be ignored in order to achieve a simplified model. 
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A new model has been developed that describes the surface erosion of biodegradable 
polymers comprising of microphase-separated domains. We have chosen the copolymeric 
polyanhydride system based on SA and CPP (or CPH) as a starting point. In this system, 
microphase separation occurs when one component of the copolymer is present in excess 
{i.e., > 80mol%) (Shen et al., 2001). 
We have recently performed experiments (Shen et al., 2002) in which we analyzed 
the release of each the constituent monomers of the CPH-SA system, in addition to the 
overall polymer erosion. The system consisted of a tablet whose thickness was small 
compared to the diameter (aspect ratio -10), so that one-dimensional transport could be 
assumed. The coordinate system of choice has its origin at the center of the tablet of total 
thickness 2LQ. Symmetry enables the development of model equations for 0 < x < LQ. From 
these experiments, we know that: 
1) the thickness of the matrices prepared from these copolymers does not change for 
several days during erosion; 
2) the erosion front that separates the eroding and the non-eroded zones always moves 
parallel to the polymer surface that is exposed to the buffer solution (see Figure 9.3). 
3) the hydrophobic nature of the copolymers does not allow water to penetrate into the 
core of the tablet; thus, degradation occurs on the surface. 
Additionally, the rate of scission of the bonds for the copolymer p(SA-CPP) was recently 
evaluated using NMR spectroscopy (Heatley et al., 1998; McCann et al., 1999). The results 
showed that the degradation rate of the SA-SA bond is of the same order of magnitude as that 
of the CPP-SA bond and two orders of magnitude less than that of the CPP-CPP bond. 
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L Lo 
Figure 9.3. Schematic of a polyanhydride tablet of half-thickness, Lo, the non-eroded core, 
and the progression of the eroding zone, represented by the broken line L(t). 
Starting from these considerations it is clear that the reaction/transport process that 
takes place within the copolymer is essentially governed by two different time constants, one 
associated with SA erosion ("fast" eroding species) and the other with CPP or CPH erosion 
("slow" eroding species). For the sake of simplicity, we will refer to the fast eroding species 
(SA monomer) as A and the slowly eroding species (CPH or CPP monomer) as B. 
As reported previously (Goepferich and Langer, 1995; Goepferich, 1996a; 
Goepferich, 1996b), after a short period of time referred to as the "induction period," which 
is attributed to several phenomena (the most important of which is the initial appearance of 
the monomer), the erosion of A proceeds at constant velocity, independent of the A 
concentration outside the tablet. This indicates that the diffusion rate of A through and the 
dissolution rate of A within the eroding zone of the tablet may play a minor role in 
determining the overall erosion kinetics. From these observations, we assume as a first 
215 
approximation that the erosion process of each constituent of the copolymer is controlled by 
the degradation of the corresponding monomer-monomer bond. We note however, that 
Goepferich and Langer also showed considerable build-up of monomer crystals near the 
surface of the polymer during erosion, indicating that polymer degradation and monomer 
dissolution may not occur simultaneously (Goepferich and Langer, 1993). If the drug release 
kinetics can be well correlated to monomer release, the need to treat monomer crystallization 
and dissolution in the foregoing model is obviated. Thus, these effects can be essentially 
lumped into an erosion rate constant. The erosion of species A can be described by a surface 
zero-order reaction: 
^ = MAS>„(l-p)k; (9-1) 
dt 
In equation 9.1, mA is the mass of species A lost from the tablet; MA is the molecular weight 
of species A; S' is the effective surface area in contact with the buffer solution; <j>Ao is the 
surface fraction of A domains; k'A is the molar average surface erosion rate; and p is the 
mole fraction of B present in the A domains. The erosion rate constant, k\ is assumed to be 
constant, though slow diffusion of polymer degradation products may have a considerable 
effect on the local pH as reported by Mâder et al., accelerating erosion (Mâder et al., 1997). 
Previous studies using atomic force microscopy (AFM) are in agreement with the 
result predicted from theoretical calculations of the phase diagram that a small fraction of the 
constituent of the dispersed phase may be present within the matrix phase (Shen et al., 2001). 
In the absence of experimental data, the parameter <|)AO can be estimated as the volume 
fraction of the A domains and p can be estimated by considering the probability of finding an 
A-B bond in a randomly distributed medium of A-A, A-B, and B-B bonds. 
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In order to model the polymer surface, we hypothesize that S' is the product of the 
cross sectional area S and a constant term r that accounts for the roughness of the surface. In 
general, the surface roughness changes continuously during erosion so the assumption is only 
valid in the limit of short induction periods and for pseudo-steady state conditions. Since S' 
is written as Sr and the term r is independent of the geometrical configuration of the tablet, it 
can be combined with the k'A constant, leading to a single constant kA that contains all the 
information about the erosion process (i.e., kA = k'A r). Thus, we can define the molar 
average surface erosion rate, kA, as the rate at which the erosion front L is moving inside the 
tablet. Hence, we have: 
Here p is the average molar density of the A domains, and pA and pB are the mass densities 
of A and B respectively. (The units of kA are moles per area per time.) By integration of 
equation 9.2 with the condition that at t = 0, L = Lo, the position of the erosion front as 
function of time (for constant kA) is: 
This equation is valid for 0 < t < tA, where tA is the time required for all of the A phase (the 
fast-eroding phase) to erode. This is the time at which the erosion front reaches the center of 
the tablet. This time constant tA can be calculated by setting L = 0 in equation 9.3. 
(9.2) 
L -  L0  ~t (9.3) 
P 
_
L 0  P (9.4) 
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Integrating equation 9.1, the mass of A lost during erosion of the A domains is: 
mA = MaS <j>A0 (1 -  p)kAt (9.5) 
The corresponding transport equation that describes the release of species B from the A 
domains is: 
Analogous to the model equations for the fast eroding zone, transport equations can 
be written for the slowly eroding zone, considering a zero order reaction for the degradation 
of B. In this case, the disappearance of the A domains and the shrinking of the B domains 
induces a change in the B surface area exposed to the buffer; therefore, the porosity of the 
tablet e(x,t) continuously varies with both time and position (i.e., along the tablet thickness). 
To model the porosity, a mass balance for species B in a differential element dx positioned at 
distance x from the center of the tablet is written: 
mB = MBS^AOpkAt (9.6) 
(Lq-x)-P 
kA 
(9.7) 
(Lq-xIP Pb 
KA 
Here kg is the surface erosion rate associated with the scission of B-B bonds and dissolution 
of the B monomer and c(x,t) represents the surface area of B in contact with the buffer per 
218 
unit volume. To find an expression for o(x,t), the B phase is modeled as spheres with an 
average diameter do (note that this is a surface-area average), for each infinitesimal volume 
Sdx. It is important to recognize that these spheres could be interconnected or disconnected. 
If they are interconnected, the device retains its mechanical integrity; if not, the spheres erode 
away into the surrounding buffer, which acts as an infinite medium, and degrade. Then, 
o(x,t) becomes a function of time through the cube root of the porosity 7 and is given by: 
Applying the Leibniz rule to integrate equation 9.7 and imposing the condition that at time t 
= 0+ the porosity in the infinitesimal volume Sdx is equal to the volume fraction of A 
domains, we obtain an analytical expression for the porosity e(x,t): 
It is important to note that the functionality for s with respect to the spatial dimension x is 
obtained considering that A domains between x = Lo and the surface at x must completely 
degrade for the surface at x to be exposed to the water. Here, a is defined as: 
(9.8) 
(9.9) 
(9.10) 
h fi_ y> 
For spherical domains a=— and _ _ i—E where subscript 0 indicates initial condition. 
d d0 v <{*BO ) 
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The term a represents a time constant for the degradation of phase B with dimensions of 
reciprocal time. As a consequence, equation 9.9 is valid for values of x and t such that s is 
always greater than zero. In other words, the B domains present in each of the infinitesimal 
volumes of the tablet erode after being in contact with water for a time equal to tg. 
Additionally, tg can be viewed as the time at which the tablet starts to shrink, i.e., when x = 
Lo, the time at which s = 1 is tg and is given by tB = 1/a. Thus, the total time required for the 
complete erosion of the tablet is the sum of the two time constants, tA and tg. 
It is instructive to recognize that the condition tA > tg could also occur in the systems 
under consideration. For this condition to occur, do must be decreased or Lo must be 
increased. Decreasing do causes the spherical domains to be unconnected, thus 
compromising the mechanical integrity of the device; increasing Lo may violate the 
assumptions of no diffusion control and one-dimensional transport; hence, this case is not 
considered here. Thus, tA is always less than tg in this work. 
9.5 Results and Discussion 
9.5.1 Model solution 
When tA < tg, three different regimes [0, tA] [tA, tg] [tg, tA+tB] may be distinguished. 
For each of these regimes, the mass of B eroded can be calculated by integration with respect 
to position (x E [0,Lo]) and time (t G [0,t]) of the mass balance of B species in B domains. 
mB=ê™ï£7l1™ (1"al)4l t£'A (911> 
m B _ ( 1 _ a t ) 4 ]  - t -  t  (9.12) 
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mB -~"~T~T(1-a(t-tA))4 tg <t < t g +tA  (9.13) 
3 a 12a 
^ = 6 k ^ M » S k A  
Adding the mass of B lost from the A domains and normalizing with respect to the initial 
mass of B in the tablet, the mass fraction of B eroded can be obtained. Finally, the mass 
fractions of A (xA) and B monomer (xb) released from the tablet during the three regimes are: 
x A = ~  =  - f -  t £ t «  ( M S )  
AO A 
mB t 
MB0 TA 
xB  =—— = -^— ^ [ l  — ( l -  art)4  ]  t<tA  (9.16) 
xB — "——-l-<?'[(l-«(t-tA))4  -(l-at)4] tA<t<tB (9.17) 
MB0 
X -B — 
mB0 
-1-J-[l-a(t-tA)]4  tA < t < tB +tA (9.18) 
p 8 = 
12a' (9.19) 
From the above equations, it is clear that in the first regime, the erosion rate of B 
increases with the exposed surface, and reaches a maximum by the time all of the A is 
eroded. In the second regime, the erosion rate of B decreases as consequence of the 
decreasing exposed surface; and, at the end, in the third regime the mass fraction of B eroded 
approaches unity with zero slope. 
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9.5.2 CPP-SA and CPH-SA 20:80 erosion 
Equations 9.15-9.18 can be used to fit monomer release data from CPP-SA 20:80 (or 
CPH-SA 20:80) copolymers. From the fit of equation 9.15 to SA release data, the SA 
erosion rate kA can be obtained. Once kA is obtained, tA can be calculated using equation 9.4. 
Knowing tA, the fit of equation 9.16 to CPP (or CPH) release data in the first regime (t < tA) 
can be used to obtain the CPP (or CPH) erosion rate, kg. Once both kA and kB are known, the 
CPH release profiles in regimes 2 and 3 can be predicted by the model using equations 9.17 
and 9.18. The parameters that are known in this analysis are Lo, do, p, pA, PB, Ma, MB, and 
the copolymer composition. From AFM experiments (Shen et al., 2001), the value of do is 
estimated to be of the order of 25nm. The value of p has been chosen to be 0.07 based on 
image analysis of the surface fraction of SA and CPH domains in the AFM experiments of 
Shen et al. (Shen et al., 2001). The density values have been taken from Mathiowitz et al. 
(Mathiowitz et al, 1990b). The values of these parameters for the two experimental systems 
considered below are shown in Table 9.1. 
A combination of UV-Vis spectrophotometry and high pressure liquid 
chromatography can be used to measure the release of the individual monomers, SA and CPP 
(or CPH) (Tamada and Langer, 1990). Using these methods, Tamada and Langer have 
obtained release data for SA and CPP release from CPP-SA 20:80 copolymer tablets 
degrading in phosphate buffered saline solution (pH = 7.4) at 37°C (Tamada and Langer, 
1990; Tamada and Langer, 1992). The SA release data (open circles) is fit with equation 
9.15 and is shown in Figure 9.4. The value of kA obtained from this fit is 1.1 x 10"4 mol cm"2 
day"1. Using this value of kA, tA for this system is calculated from equation 9.4 as 3.3 days. 
The CPP release data (open squares) for t < 3.3 days is fit with equation 9.16 and is also 
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shown in Figure 9.4. The value of kg obtained from this fit is 2.2 x 10"9 mol cm"2 day"1. As 
expected, the SA erosion rate is much higher (~5 orders of magnitude) than the CPP erosion 
rate. It is instructive to note here that k& represents the erosion rate of both SA-SA and SA-
CPP bonds. Using the values of kg just obtained, the value of tg can be calculated using tg = 
1/a, and for this system, tg = 8.4 days. Thus, the total time required for erosion of the CPP 
domains should be tA + tg = 11.7 days. In addition, the CPP release for regimes 2 and 3 can 
be predicted using equations 9.17 and 9.18. These predictions are compared to the 
experimental release data in Figure 9.4 and as shown, the agreement is excellent. It is 
important to note that the theoretical CPP release profiles in regimes 2 and 3 and the total 
CPP release time are predicted from the model once kA and kg are known. 
Table 9.1. Model parameters determined by experiments. 
Parameter Value 
Lo 0.075cm 
do 25nm 
P 0.07 
PA l.lg/cm3 
PB l.lg/cm3 
Ma 182 
Mg; CPH 342 
Mg, CPP 300 
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Figure 9.4. Comparison of the model with experimental results for CPP (•) and SA (O) 
monomer release for the erosion of CPP-SA 20:80 tablets (Tamada and Langer, 1990). The 
solid lines represent model fits to monomer release (equations 9.15-9.18) 
We have extended the method developed by Tamada and Langer to monitor 
individual release of SA and CPH monomer from tablets of CPH-SA 20:80 copolymers 
(Shen et al., 2002). The details of the experimental techniques are described elsewhere 
(Shen et al., 2002). The theoretical fits of individual monomer release from the current 
model and the experimental data are shown in Figure 9.5. The value of kA obtained from this 
fit (using equation 9.15) is 2.2 x 10"4 mol cm"2 day"1. Using this value of kA, tA for this 
system is calculated from equation 9.3 as 2.0 days. It is instructive to note that the value of 
kA obtained from this fit is of the same order of magnitude as that obtained from the SA 
released in the CPP-SA 20:80 system (see Table 9.2 for a summary of the calculated 
parameters of the CPP-SA 20:80 and CPH-SA 20:80 systems). The CPH release data (open 
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squares) for t < 2.0 days is fit with equation 9.16 and is also shown in Figure 9.5. The value 
of kg obtained from this fit is 5.2 x 10"10 mol cm"2 day"1. Once again, the SA erosion rate is 
much higher (>5 orders of magnitude) than the CPP erosion rate. In addition, the CPH 
erosion rate is slower than the CPP erosion rate (see Table 9.2). This is expected since CPH 
is more hydrophobic than CPP (see Figure 9.1). Using the value of kg just obtained, the value 
of tg can be calculated using tg = 1/a, and for the CPH-SA system, tg = 7.7 days. Thus, the 
total time required for erosion of the CPH domains should be tA + tg - 9.7 days. In addition, 
the CPH release for regimes 2 and 3 can be predicted using equations 9.17 and 9.18. These 
predictions are compared to the experimental release data in Figure 9.5 and as shown, the 
model correctly predicts the shape of the release profile. However, the model over-predicts 
the CPH release in the second and third regimes. The reasons for this discrepancy are 
discussed later. 
Using the values of kA and kg, the porosity, s, in the CPH-SA system can be plotted 
as a function of both position and time using equation 9.9. This porosity profile is shown in 
Figure 9.6. As expected, s approaches 1 at the surface (x = Lo) at t = tA. 
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Figure 9.5. Comparison of the model with experimental results for the erosion of CPH-SA 
20:80 tablets (Shen et al, 2002). The solid lines represent model fits to monomer release 
(equations 9.15-9.18). 
Table 9.2. Model parameters from fits to experimental monomer release data. 
Parameter CPP-SA 20:80 CPH-SA 20:80 
kA 1.1 x 10"4 mol cm"2 day"1 2.2 x 10"4 mol cm"2 day"1 
U 3.3 days 2.0 days 
ke 2.2 x 10"9 mol cm"2 day"1 5.2 x 10"10 mol cm"2 day"1 
% 8.4 days 7.7 days 
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Distance (cm) 
Figure 9.6. Porosity distribution within CPH-SA 20:80 tablet as a function of position and 
time (equation 9.9). 
9.5.3 Drug release from CPH-SA 20:80 
Based on experimental data of drug release from polyanhydrides with microphase 
separation (e.g. CPH-SA 20:80), we have proposed that the compatibility of the polymer and 
drug drives the thermodynamic partitioning of the drug within the micro-domains of the 
polymer (Shen et al., 2002). Heterogeneous polymers such as CPH-SA 20:80 and 80:20 
provide a microphase-separated environment in which the drug can preferentially partition 
itself. Drug molecules loaded into such polymers will attempt to distribute themselves into 
compatible regions until saturation is reached. If very few compatible domains are present, 
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the excess drug will be forced to distribute itself into less compatible regions, resulting in a 
pronounced burst effect. Drug solubility also plays a key role in determining the release 
profile characteristics from bioerodible polymers. In heterogeneous systems, the drug 
preferentially partitions itself into compatible domains. Once these domains become 
saturated, the drug attempts to solubilize within the less compatible regions. Any excess 
drug precipitates out, resulting in an initial burst. 
An example of a solute exhibiting this partitioning behavior is p-nitroaniline (PNA), 
for which experimental evidence points to the preferential partitioning within the aromatic-
rich (CPP- or CPH-rich) domains in CPP-SA or CPH-SA 20:80 copolymers (Mathiowitz and 
Langer, 1987; Shen et al., 2002). Thus, we define a partition coefficient, P, as the ratio of 
drug concentration in the B (CPP or CPH) phase to that in the A (SA) phase. The excess 
drug in the system is released in the form of a burst. It is important to understand that the 
amount of drug released in the burst is the sum of the amounts released from both phases. 
However the model in its current form does not distinguish between the drug released during 
the burst from either phase. Thus, the drug released during the burst is treated only as a 
consequence of the supersaturation in the polymer. It can be proved that the fraction of drug 
released, xD, is given by 
Here b is the fraction of drug released in the burst and xD,p is the fraction of drug released that 
is partitioned within the polymer. The total mass of drug released that is partitioned within 
the micro-domains of the polymer is given by 
(9.20) 
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MD,P XA^AO^^O^D,AO ~*~XB (9.21) 
Here xA is the mass fraction of A released (given by equation 9.15), xb' is the mass fraction 
of B released from the B phase (given by subtracting equation 9.6 from equation 9.11 and 
normalizing with respect to the total mass of the B phase), CD,AO is the initial concentration of 
drug in the A phase, and CD,BO is the initial concentration of drug in the B phase. The initial 
mass of drug that is partitioned within the two phases is 
Using the definition of the partition coefficient, dividing equation 9.21 by equation 9.22, and 
using equation 9.20, the fractional drug released from the CPH-SA 20:80 polymer can be 
derived as 
The burst is modeled as the fraction of drug released in the early stages of release by 
comparison with the experimental data. Then, the drug release data can be fit to equation 
9.23 in each regime of release and P, the partition coefficient can be estimated by fitting 
equation 9.23 to the first regime. In addition, since experimental data for monomer release 
from drug-loaded polyanhydrides is available, the monomer release rate constants, kA and kg, 
can also be estimated using the method described earlier. 
Figure 9.7 shows the release of SA, CPH, and PNA from a CPH-SA 20:80 copolymer 
containing 10%w/w of PNA. The drug-containing copolymer is in the form of llOmg tablet 
(9.22) 
(9.23) 
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with a diameter of 10mm and a thickness of 1.5mm. The SA release is fitted to equation 9.15 
and the value of kA obtained from the fit is 1.9 x 10"4 mol cm"2 day"1. This value is relatively 
unchanged from the value of kA obtained when no PNA is present (see Table 9.2). This 
suggests that the presence of PNA does not affect the release of SA or, in other words, PNA 
does not interact strongly with SA in CPH-SA 20:80. The CPH release during the first 
regime (t < 2.3 days) is fitted to equation 9.16 and the value of kg obtained from the fit is 1.1 
x 10"9 mol cm"2 day"1. This value is about 5 times the value of kg when no PNA is present 
(see Table 5.2). This suggests that the presence of PNA affects the release of CPH; it 
accelerates the rate of release of CPH. As before, the CPH release in regimes 2 and 3 is 
predicted using the value of kg obtained from the fit of the data in the first regime to the 
model. 
By observation of the PNA release data (filled circles) in Figure 9.7, the value of b is 
estimated as 0.41. Using equation 9.23, the value of P is estimated from the PNA release 
data in the first regime (t < 2.3 days) as 2.55. This value of P indicates that the PNA is 2.55 
times more soluble in the CPH phase as it is in the SA phase; thus, the model shows that the 
PNA partitions into the CPH phase in the CPH-SA 20:80 copolymer. This result from the 
model is in agreement with several experimental studies (Mathiowitz and Langer, 1987; Shen 
et al., 2002) of PNA release from p(CPP-SA) 20:80 copolymers that suggest PNA affinity to 
CPH. 
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Figure 9.7. Comparison of the model with experimental results for CPH (•), SA (O) and 
PNA (•) release from PNA-loaded p(CPH-SA) 20:80 tablets. The solid lines represent 
model fits to monomer release (equations 9.15-9.18) and the dotted line represents the model 
fit to PNA release (equation 9.23). 
9.5.4 CPH-SA 80:20 erosion 
As stated earlier, the CPH-SA and CPP-SA systems exhibit microphase separation 
when one component is present in excess of 80mol%. The preceding discussion was 
concerned with the case for which the fast eroding component A was present in excess of 
80mol%. Now the analysis is extended to the situation when the slowly eroding component 
B is present in excess of 80mol%. In the former case, it was assumed that the fraction of A 
within the B domains is negligible; here, we assume that there is no B within the A domains, 
i.e., p = 0. Once again, the basis of this assumption is the AFM data in Shen et al. (Shen et 
al., 2001). 
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In this case, the disappearance of the A domains and the growth of the B domains 
induces a change in the B surface area exposed to the buffer; therefore, the porosity of the 
tablet e(x,t) continuously varies with both time and position (i.e., along the tablet thickness). 
As before, a mass balance for species B in a differential element, dx, positioned at distance x 
from the center of the tablet is written (see equation 9.7 for the integral form). To find an 
expression for a(x,t), the surface area of B in contact with the buffer per unit volume, the A 
phase is modeled as spheres with a (surface-area average) diameter do, for each infinitesimal 
volume Sdx. Then, a(x,t) becomes a function of the porosity, e, and is given by: 
The factor (1 - s) accounts for the decrease in surface area as the micro-domains coalesce. 
Substituting equation 9.24 in equation 9.7, we obtain an ordinary differential equation for the 
porosity e(x,t) given by: 
The porosity can be obtained via numerical integration of equation 9.25 once k* and kg are 
known. The expression for the mass of A released is given by equation 9.11. This release of 
A induces porosity in the CPH-SA 80:20 polymer and thus, the mass of B released as a 
function of time is given by 
do 
(9.24) 
(9.25) 
t 
mB  = Jmb  ( l-p)(f-^A 0)SkA  dt '  
0 
(9.26) 
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The total mass of B released is normalized with respect to the initial mass of B in the system 
to obtain the fraction of B released as a function of time. We have obtained experimental 
data for SA and CPH release from p(CPH-SA) 80:20 tablets (Shen et al., 2002). This data 
and the model fits are shown in Figure 9.8. From the fit of the SA release data, the value of 
kA is obtained as 1.4 x 10"4 mol cm"2 day"1. This value is of the same order of magnitude as 
the value obtained for the CPH-SA 20:80 copolymer, which is expected since kA describes 
the rate of scission of SA-SA bonds and subsequent dissolution of the SA monomer. Also 
shown in Figure 9.8 is the fit of the CPH release data for a period of 60 days. During this 
period, about 30% of the CPH was released. The value of kg obtained from the fit is 8.0 x 
10"11 mol cm"2 day"1. This value is about 6 times slower than the value of kg obtained for 
CPH release from CPH-SA 20:80, suggesting that there are attributes of the microstructure in 
the 80:20 case that are different from that of the 20:80 case. This discrepancy is discussed in 
the next section. 
Using the values of kA and kg, the porosity, s, in the CPH-SA system can be plotted 
as a function of both position and time. This porosity profile for the first 60 days of release is 
shown in Figure 9.9. It is instructive to note that s approaches -0.33 after about 60 days of 
release, in reasonable agreement with -30% of CPH released after the same time. 
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Figure 9.8. Comparison of the model with experimental results for CPH (•) and SA (O) 
with for the erosion of CPH-SA 80:20 tablets (Shen et al, 2002). The solid lines represent 
model fits to monomer release (equations 9.15 and 9.26). 
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Figure 9.9. Porosity distribution within CPH-SA 80:20 tablet as a function of position and 
time (obtained from integration of equation 9.25). 
9.5.5 Limitations of the model 
The model assumes that 1<a and kg are the rates at which monomers are produced as 
reaction products when the polymer is exposed to buffer. In reality, when the polymer is 
exposed to buffer solution, the degradation process that takes place is probabilistic and leads 
to products with a distribution of chain lengths. In other words, oligomeric species are first 
produced before monomer is released. This explains the over-prediction observed in Figures 
9.5 and 9.7. On the other hand, the model appears to work well for the CPP release from 
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CPP-SA 20:80. This indicates that apart from the distribution of chain lengths, kA and kg 
must depend on other factors. This is discussed next. 
It is well known that both the CPP-SA and the CPH-SA systems are semicrystalline 
(Mathiowitz et al., 1990b). It has also been shown that monomer crystals form during 
erosion (Goepferich and Langer, 1993). The model does not explicitly treat the effects of 
crystallinity on erosion. This may also explain the differences between the value of kg 
obtained for CPH-SA 20:80 and 80:20. It has been shown by Mâder et al. that the local pH 
during erosion of CPP-SA decreases, leading to increased solubility of the degradation 
products, and thus accelerated erosion (Mâder et al., 1997). We argue that this increase in 
solubility is compensated for by the formation of monomer crystals during degradation, thus 
canceling the effect of both phenomena. This effect may be less pronounced in the CPH-SA 
case since CPH is less crystalline than CPP and degrades much more slowly (Mathiowitz et 
al., 1990b; McCann et al., 1999). 
Another factor that limits the model is the absence of any molecular weight and/or 
polydispersity dependence of the rate constants. The number average molecular weights for 
the CPH-SA 20:80 and 80:20 used in the experiments that the model is fitted to are 8,800 and 
5,500 respectively (Table 9.2). New expressions for and kg need to be developed that 
account for the statistical distribution of chain lengths, degree of crystallinity, the local pH, 
and polymer molecular weight. 
Other aspects that currently limit the model include the lack of reliable data for the 
parameters do and p and the absence of polymer-drug interactions. These parameters have 
been estimated by comparison to AFM data obtained on the CPH-SA system, but more detail 
on the solid-state microstructure of the copolymers is needed to correctly estimate these 
parameters. As seen in the data of Figure 9.7, the presence of the drug influences the 
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degradation rate, suggesting the presence of polymer-drug interactions. The model "lumps" 
these interactions within the partition coefficient, P, but a more thorough understanding of 
the nature of the interactions and their effect on the monomer release is needed. Further, a 
more detailed argument for the burst effect needs to be developed. Refinements of the 
current model based on these considerations are underway. 
9.6 Conclusions 
A new model was developed to understand the mechanism of degradation and drug 
release kinetics of surface-erodible polymers. This model takes into account the 
phenomenon of microphase separation that has been observed for polyanhydrides of certain 
copolymer compositions. The model assumes that erosion is dominated by degradation and 
thus, in a system with a fast eroding and a slow eroding species, two rate constants, one for 
each species, essentially control the evolution of the polymer microstructure. Expressions 
were derived for the fraction of each monomer released as well as for the porosity in the 
system. When drugs are loaded into such heterogeneous polymers, they undergo 
thermodynamic partitioning depending upon their compatibility with each phase of the 
copolymer. This aspect has been modeled via a partition coefficient. The solutions of the 
model equations were fitted to experimental data on monomer release kinetics from two 
polyanhydride systems to obtain the erosion rate constants. Drug release kinetics 
experiments were compared to the model solution for drug release and the partition 
coefficient of the drug is obtained from the fits. The comparisons to the data are promising, 
while pointing out the limitations of the model. The model does not account for oligomer 
formation prior to monomer release or for the dependence of the rate constants on parameters 
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such as the degree of crystallinity, the local pH, and the polymer molecular weight. These 
limitations will be addressed in a future publication. 
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CHAPTER 10 
A MOLECULAR LEVEL EROSION MODEL FOR SURFACE-ERODIBLE 
SEMICRYSTALLINE HOMOPOLYMERS AND COPOLYMERS 
A paper to be submitted to Macromolecules, 2004 
Matt J. Kipper1, and Balaji Narasimhan2 
10.1 Abstract 
A new model for the erosion kinetics of semicrystalline surface erodible 
homopolymers and copolymers is presented. The model was derived for a class of surface-
erodible polyanhydride copolymers, with the goal of describing erosion in terms of 
fundamental, elementary processes. This model is based on an accurate description of 
copolymer microstructure and can thereby account for the heterogeneous erosion due to 
microphase separation and crystallinity. In addition to accurately predicting the overall 
erosion profile and the release of individual monomer species, several key phenomena that 
occur during erosion are described. These include precipitation of slightly soluble 
degradation products inside the pores of the erosion zone and pH changes during erosion due 
to dissolution of acidic monomers and the consequent changes in monomer solubility. This 
model also motivates future experiments to investigate predicted phenomena such as the 
effects due to local changes in pH and degradation rate constants for crystalline and 
amorphous moieties. The design of biomedical devices such as vehicles for drug delivery 
1 Graduate student, primary author. 
2 Major professor, corresponding author. 
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and scaffolds for tissue engineering will be aided by the application of this model and future 
extensions of it. 
10.2 Introduction 
Bioerodible polymers are ideal for a variety of biomedical applications. Their 
chemistries can be tailored to stabilize macromolecular drugs1, their surfaces can be modified 
to target delivery to specific cells and tissues2, and their erosion kinetics can be modulated by 
a variety of techniques3"9. Bioerodible polymers have been used to fabricate scaffolds for 
tissue engineering10,11, implants for orthopedic applications12, and vehicles for targeted and 
controlled drug delivery13"18. In all of these applications, the erosion kinetics is key to the 
performance of the device. The erosion kinetics can be modulated by altering copolymer 
composition when the two constituent polymers erode at different rates or by changing the 
crystallinity when crystalline and amorphous domains erode at different rates. 
Surface eroding polymers, such as polyanhydrides and poly(orthoesters), are a 
particularly promising class of bioerodible polymers for many biomedical applications. They 
do not swell in the presence of water. Rather, their hydrophobicity prevents the ingress of 
water. This hydrophobic environment may be advantageous for stabilizing macromolecular 
drugs such as proteins, growth hormones, and vaccines19. For controlled release applications, 
drug release kinetics is controlled by the erosion kinetics, rather than by swelling and 
diffusion as in some bulk eroding systems. Since the eroding zone is limited to the surface, 
the bulk polymer maintains its shape and mechanical integrity as the device shrinks, which 
may be desirable for orthopedic applications. 
However, the erosion kinetics is complicated when phases or components are added, 
as in the case of semicrystalline polymers or microphase-separated copolymers. When the 
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two phases erode at different rates, surface eroding polymers begin to exhibit some 
characteristics of bulk eroding polymers. The erosion of a fast eroding phase may leave 
behind a porous microstructure of the slow eroding phase. Water may then penetrate into the 
eroding zone, drugs may diffuse out of the material, and the mechanical properties in the 
eroding zone are subject to significant change. The design of biomedical devices based on 
surface-eroding phase-separated polymers requires a detailed understanding of the 
mechanisms of erosion that lead to these phenomena. 
Several approaches to understand and model the erosion mechanisms of surface-
erodible polymers have appeared in the literature. Thombre and Himmelstein have 
developed a phenomenological model in which the erosion front progresses through the 
device while diffusion is permitted in the intact zone20. A diffusion barrier representing an 
external membrane is added. An extension of this model accounts for diffusion of the 
degradation products and for catalyzed polymer degradation21. Zygourakis proposed a 
cellular automata approach in which individual volume elements are assigned erosion times 
upon exposure to water. A porous microstructure develops as the polymer erodes22'23. 
Gôpferich and Langer have proposed a similar model. In their model each volume element 
erodes stochastically24 and an extension of the model accounts for monomer diffusion 
through the porous erosion zone25. Batycky et al. developed a mechanistic model that 
explicitly accounts for polymer degradation by both random chain scission and end chain 
scission rather than simply modeling erosion as an elementary process26. Drug release is also 
accounted for by desorption from the polymer matrix and by diffusion through mesopores. A 
non-homogeneous distribution of drug is accounted for in a drug release model proposed by 
Varelas el al., but the polymer matrix does not erode27,28. In this model isolated domains act 
as reservoirs from which drug diffuses through a polymer matrix. We have developed a 
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phenomenological erosion and drug release model that accounts for microphase separated 
domains that erode at different rates and for partitioning of encapsulated drugs within the 
phase separated domains29. However, our previous model assumes that erosion is primarily 
controlled by degradation and ignores the subsequent mass transfer phenomena of dissolution 
and diffusion. 
10.3 Experimentally Observed Features of Polyanhydride Erosion 
Most polyanhydride copolymers that have been synthesized for biomedical 
applications are semicrystalline30. It has been demonstrated experimentally that the 
amorphous phase of semicrystalline polyanhydrides erodes faster than the crystalline phase31" 
33
. In most cases, the spherulitic structure of the crystalline phase remains intact as the 
amorphous phase degrades, leaving behind a porous matrix, the morphology of which is 
defined by the original morphology of the crystalline/amorphous phase separation. 
The erosion mechanism of semicrystalline, surface-erodible copolymers is complex 
and consists of several elementary steps, beginning with degradation. In the case of binary 
A-B copolymers, three types of bonds are available for degradation: A-A bonds, A-B bonds, 
and B-B bonds. It has been shown that for copolymers of sebacic anhydride (SA) and 1,3-bis 
(p-carboxyphenoxy) propane (CPP) the SA-SA bonds and SA-CPP bonds are hydrolyzed at a 
faster rate than the CPP-CPP bonds34,35. This also leads to the observed heterogeneous 
release of degraded monomer from these copolymer systems36,37. 
In addition to the reactivity of the anhydride bonds, the monomer solubility may also 
affect polyanhydride erosion kinetics. Gôpferich et al. have demonstrated the precipitation 
of monomers inside the eroding zone of CPP-SA copolymers38 and fatty acid dimer-SA 
(FAD-SA) copolymers39. This phenomenon occurs because anhydride bonds in the polymer 
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backbone degrade, resulting in monomer formation at a rate faster than the rate of monomer 
dissolution. As the solution inside the porous eroding zone of the polymer approaches 
saturation, monomer crystals accumulate. Closely coupled to the precipitation and 
dissolution of the monomers, is their effect on the pH of the microenvironment inside the 
eroding polymer matrix. This pH has been successfully measured in 20:80 CPP-SA 
copolymer tablets by Mâder et al using spectral spatial electron paramagnetic resonance 
imaging (e.p.r.i.)40. They detected pH levels as low as 4.7 in the eroding zone, which rose as 
the polymer continued to erode and the monomer diffused from the device. The decrease in 
pH further limits the monomer solubility as the dicarboxylic acid monomers become much 
less soluble at low pH38. 
The decrease in pH inside the eroding zone may not have a strong effect on the 
degradation kinetics; the degradation of polyanhydrides is known to be base catalyzed41,42. 
However, the dissolution kinetics and solubility of the dicarboxylic acid monomers is most 
likely affected by pH. 
Our goal in this paper is to understand the mechanism of polymer erosion at a 
molecular level and to accurately describe the erosion kinetics of surface-eroding phase-
separated copolymers. This work is also motivated by our previous experiments with 
polyanhydride copolymers composed of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 
g^i3,37,43-46 amj on body of experimental and theoretical work describing this and similar 
copolymer systems. We would like to point out that this model can be generalized to other 
surface eroding systems such as poly(ortho esters) and could be modified to describe bulk-
eroding systems (such as poly(lactide-co-glycolide) copolymers). Additionally, some of our 
model predictions motivate additional experiments to measure the effects of various 
phenomena. 
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10.4 Model Development 
Polymer erosion is the sum of several elementary processes.. 
1. Polymer degradation (monomer formation) 
2. Monomer dissolution 
3. Diffusion of monomer from the eroded zone 
Our view of this complex erosion process is shown in Fig. 1. This figure shows a tablet of 
half-thickness L, exposed to water on the right at three stages during erosion. 
x = L x = 0 x = L x = 0 x = L x = 0 
Figure 10.1. Schematic illustrating erosion process of a tablet with half-thickness L, 
exposed to buffer on the right. 
We model step one, monomer formation, as a first order process with respect to the 
surface area of exposed polymer. The exposed polymer surface area is converted to 
undissolved monomer. Monomer formed in step one is assumed to be in the form of a 
monolayer, crystallized on the surface and prevents the underlying polymer from degrading. 
Figure 10.1a shows four pores that have formed at the exposed surface of a polymer tablet. 
Figure 10.1b shows the monolayer of undissolved monomer (thick line). Step two, monomer 
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dissolution, results in mass loss from the device. As monomer dissolves, it exposes 
undegraded polymer. Dissolved monomer is represented in Figure 10.1c by the particles 
inside the pores. Some particles remain undissolved, adsorbed to the surface of the pores. A 
distinction is made between monomer formed from crystalline polymer and monomer formed 
from amorphous polymer. Probabilities are assigned for the exposure of amorphous polymer 
and crystalline polymer as the monomer from each of these phases dissolves. This is 
illustrated in the inset in Figure 10.1c. Here, the two polymer phases are represented by the 
light gray and the dark gray regions. The monomers formed from these two phases are 
represented by the striped blocks. The probability that light gray monomer will dissolve to 
expose light gray polymer is greater than the probability that light gray monomer will 
dissolve to expose dark gray polymer. For copolymers, the microphase separation can be 
accounted for in a similar way. In step three the monomer diffuses out of the eroding zone in 
response to the concentration gradient formed in step two. Surface area fractions of each 
type of monomer and each type of polymer are functions of both position and time. 
Likewise, the pore radius, porosity, specific surface area, and concentration of dissolved 
monomer are also functions of position and time. 
As monomer dissolves, the pH of the solution inside the eroding zone changes, which 
alters the dissolution kinetics by changing the saturation concentration. We assume no pH 
dependence of the degradation kinetics as we anticipate only acidic conditions in the eroding 
zone. This is consistent with experimental observations for polyanhydrides42, but could be 
modified for acid catalyzed degradation as is the case for poly(ortho-esters). Dimensionless 
model variables and parameters are listed in Tables 10.1 and 10.2, respectively. 
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Table 10.1. Dimensionless model variables. 
Variable Definition 
fmal Surface area fraction of monomer formed from amorphous polymer of type one 
fma2 Surface area fraction of monomer formed from amorphous polymer of type two 
fmcl Surface area fraction of monomer formed from crystalline polymer of type one 
fmc2 Surface area fraction of monomer formed from crystalline polymer of type two 
Kl Dissolution rate for monomer one 
K2 Dissolution rate monomer two 
fal Surface area fraction of amorphous polymer of type one 
fa2 Surface area fraction of amorphous polymer of type two 
fcl Surface area fraction of crystalline polymer of type one 
fc2 Surface area fraction of crystalline polymer of type two 
R* Average pore radius 
8 Porosity 
%1 Concentration of dissolved monomer of type one 
%2 Concentration of dissolved monomer of type two 
a Specific surface area 
Paa Probability of amorphous monomer dissolving to expose amorphous polymer 
Pca Probability of crystalline monomer dissolving to expose amorphous polymer 
^al Fraction of the amorphous polymer represented by polymer one 
<t>cl Fraction of the crystalline polymer represented by polymer one 
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Table 10.2. Dimensionless model parameters. 
Parameter Definition 
P Ratio of degradation rate constants for crystalline polymer of type one to that 
for amorphous polymer of type one 
Y Ratio of degradation rate constants for amorphous polymer of type two to that 
for amorphous polymer of type one 
8 Ratio of degradation rate constants for crystalline polymer of type two to that 
for amorphous polymer of type one 
X  Long period of crystalline lamellae 
di* Diffusion coefficient for monomer of type one 
d2* Diffusion coefficient for monomer of type two 
S Distance from the surface 
X Time 
a  Degree of crystallinity 
kdi Dissolution rate constant for monomer of type one 
kd2 Dissolution rate constant for monomer of type two 
The surface of the pores is characterized by the fractional coverage of amorphous 
polymer of components one and two, fai and fa2, crystalline polymer of components one and 
two, fci and fC2, and monomer arising from the degradation of each type of polymer, fmai, 
fma2, fmci, and fmc2- Equations 10.1 through 10.4 determine the surface area fraction of each 
type of monomer on the surface of a pore. These equations are first order in the surface area 
fraction of polymer and pseudo-first order in the surface area fraction of monomer since the 
dimensionless dissolution rates, Ki and K%, are functions of concentration. 
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df. mal 
ÔT 
= fa.-fmaA 
Ôf. ma 2 
ÔT ~ fîal fma2
/<:2 
Ôf. mcl 
ÔT 
E 
ÔT 
(10.1) 
(10.2) 
(10.3) 
(10.4) 
It is necessary to distinguish between the four types of monomer, because as monomer 
dissolves, it exposes undegraded polymer, as mentioned earlier and illustrated in the inset of 
Figure 10.1c. The ratio of the degradation rate constant for the crystalline polymer of type 
one to that for amorphous polymer of type one is p. The degradation rate constants for 
amorphous polymer of type two and crystalline polymer of type two are normalized similarly 
to form the ratios y and ô, respectively. The dimensionless time parameter, x, is normalized 
by the degradation rate constant for amorphous polymer of type one. 
r = — (10.5) 
p y  
Here, t is time (s), kai is the degradation rate constant for amorphous polymer of type one (g 
cm"2 s"1), p is the density of the polymer (g cm"3), and y is the characteristic length scale (cm) 
associated with a monolayer of monomer. 
Equations 10.6 through 10.9 determine the surface area fraction of each type of 
polymer. The first term on the right-hand side of each of these equations accounts for 
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polymer degradation, and the second term accounts for exposure of the undegraded polymer 
as monomer dissolves. 
= -fal + [(Paafmal + Pcafmcl K + (Paafma2 + VcJmc2 )K2 Kl (10.6) 
^ = ~Xa2 + [(Paafmal + Pcafm=, K, +(Paafm= 2 +  P=afmc2 K K1 ~ A, ) (10.7) 
= -Ml + {[(1 - P aa Xmal + 0" Pea Xncl K + K1 " Paa Xma2 +0 "Pea Xnc2 2 Kl (10.8) 
= -«=,+®i-p„X-,+(i-p„ X-, k+[0-p-X„2+(i-p„ X«= k Xi - ) (10.9) 
The probability that monomer from amorphous polymer will expose amorphous polymer 
upon dissolution is paa and the probability that crystalline polymer will expose amorphous 
polymer is pca. The estimation of these probabilities is based on the degree of crystallinity, 
a, and the microstructure. Appendix 10.A.1 describes how these parameters are estimated 
based on a balance of the total interfacial area initially present. The chemical identity of the 
monomer is also important since the two types of monomers dissolve at different rates. The 
fraction of component one in the amorphous and crystalline phases are <|>ai and <j)ci, 
respectively. 
The average dimensionless radius of a pore, R*, changes as monomer dissolves (see 
Figure 10.1b and 10.1c). 
™ = (fmai + fmcl X + (fma2 + CzK 
O T  
(10.10) 
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The porosity, s, is the fraction of the total volume that represented by pores. The pore 
volume is computed assuming cylindrical pores of average dimensionless radius R*. The 
number of pores is the initial number of amorphous domains, found by dividing the total 
volume by the volume associated with a long period for the crystalline lamellae. It is 
assumed that pores eventually overlap and coalesce. This is accounted for by multiplying the 
pore volume by the total polymer volume. Thus, as the porosity increases, the probability 
that a pore will intersect another pore increases. Multiplying by the polymer volume 
prevents counting the volume of the overlap more than once, via a mean field approximation 
on the porosity distribution. 
8. = 8(1-.)R-8R1 (1„.n) 
ô t  A dz 
Here, X is the dimensionless long period of the crystalline lamellae and is used to estimate 
the number of pores. 
The dimensionless concentrations of monomer of type one and two, %i and %2, in the 
erosion zone are given by a diffusion equation with a source term for dissolution from the 
surfaces of the pores. 
_ (fmai ftncl)'^*1<-r . pi * ^ Xî CIO I"') 
"57 " ; ' W  
_ (La2 + Lc2 , n ' ^  fl 0 1 ^  
"67 - ; + ^   (10-13) 
Here, B, is the dimensionless position from the original surface of the eroding polymer. Di* 
and D% are the dimensionless diffusivities of monomers one and two respectively. Diffusion 
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only in the direction of propagation of the erosion front is considered. In other words, perfect 
mixing is assumed in the radial direction inside the pores. Both concentrations are assumed 
to be zero outside the pores. The dimensionless surface area per unit volume, a, is computed 
by assuming cylindrical pores and accounting for coalescence of the pores. 
2f(l - s )  
<r= R* (10.14) 
The dimensionless parameters Ç, R*, D*, and %n, are: 
f (10.15) 
R -— (10.16) 
Dn* = ^- (10.17) 
kalY 
%.=— (10.18) 
P 
Here, x is the distance from the original surface of the polymer, Dn is the diffusivity of the 
dissolved monomer of type n, and c„ is the concentration of dissolved monomer of type n. 
The specific surface area, s, and the long period, 1 are also normalized by the length scale y to 
give the parameters a and X respectively. 
cr = sy (10.19) 
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X  (10.20) y 
The dimensionless dissolution rate for each of the monomers is computed as shown below. 
Here, c„ and csatjn are the concentration of dissolved monomer of type n and the concentration 
of dissolved monomer at saturation of monomer type n, respectively, and kd„ is the 
dissolution rate constant for monomer of type n. 
Initial values for the porosity, pore radius, and surface area fractions are all set to 
zero, with the exception of the surface area fractions of amorphous polymer of types one and 
two, which are initialized in accordance with the copolymer composition. This assumes that 
the amorphous polymer preferentially partitions to the surface32,33. Two additional 
parameters, E,ef and Çs are the respective positions of the erosion front and the surface. Both 
of these parameters are initially set to zero, and the erosion front moves through the polymer 
at the same velocity with which the pores radius grows at the erosion front. 
n 
(10.21) 
a&f _ at' (10.22) 
a? ^ ^ 
The position of the surface is taken as the lowest value of E, for which the porosity is less than 
1. At Çef an additional source term is added to equations 10.11 and 10.12 to account for the 
dissolution occurring at the surface normal to the direction of propagation of the erosion 
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front. The cumulative fractional mass loss can be computed by integrating the porosity at 
any time point 
Here, mœ is the total mass of the polymer. The cumulative mass loss for each type of 
polymer is computed by integrating the dissolution rate for the corresponding monomer. 
The remaining equations have significant nonlinearities that suggest a modified finite 
difference solution. The Crank-Nicolson method was used to formulate finite difference 
equations (FDEs). Thus, solutions to equations 10.1 through 10.4 and 10.6 through 10.13 are 
obtained implicitly with the exception of the parameters kj, K2, <|>i, §2, Paa, and pca. These 
parameters are computed from the previous time step. Since the equations may be stiff, 
depending on the values of the parameters (3, y, Ô, k<n, and kd2, the second order Gear method 
was used to integrate the FDEs47. 
10.5 Model Parameterization 
Each of the elementary processes listed at the beginning of section 10.5 that constitute 
the erosion process has an associated rate constant. The relationships between these rate 
constants will ultimately determine the nature of the erosion process. Overall erosion rate 
constants have been reported for several polyanhydrides including copolymers30. Diffusion 
coefficients have been reported for the SA and CPP monomers25. Dissolution rate constants 
for dicarboxylic acid monomers however, are not reported in the literature. To obtain the 
dissolution rate constants, we melt pressed 10 mm diameter, 100 mg tablets of CPH and SA 
using a Carver Press (Wabash, Indiana) at 3 metric tons for 5 minutes just above the melting 
(10.23) 
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point of the dicarboxylic acid. Tablets were weighed and allowed to dissolve in 900 ml of 
0.1 M phosphate buffer (pH 7.4) at 37 °C. The dissolution media was stirred at 100 rpm. 
Dissolution experiments were conducted in an SR8-Plus Dissolution Test Station (Hansen 
Research Inc., Chatsworth, California). The tablets were removed at specified intervals and 
dried under vacuum for 24 hours. The masses of the tablets were recorded at each of at least 
10 time points for each monomer and the experiments were performed in duplicate. 
Dissolution rate constants are reported in Table 10.3. 
Table 10.3. Physical constants for the dicarboxylic acids. 
Dicarboxylic acid Dissolution rate pKai pKa2 
monomer constant (g cm"2 s"1) 
CPH 1 .4x10*  3.7 6.7 
SA 1.4x10* 4.8 5.6 
The saturation concentration at different pH values for each dicarboxylic acid was 
determined by adding excess dicarboxylic acid to 10ml of 0.1 M phosphate or acetate buffer. 
Vials were incubated at 37 °C for two days with gentle agitation. Concentrations were 
determined by UV absorbance at 202 nm for SA and 249 nm for CPH37. For SA the 
saturation data were also compared to that reported by Gôpferich and Langer38. The 
saturation concentration as a function of pH is shown in Figure 10.2. From these saturation 
curves, the pKa values for the diacids can be estimated by the positions of the inflection 
points. These values are also reported in Table 10.3. 
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Figure 10.2. Saturation concentrations of SA (•) and CPH (A)  as a function of pH. Some 
data points for SA taken from Gôpferich and Langer38. 
The data in Figure 10.2 indicate that the saturation concentration for SA is at least an 
order of magnitude greater than that for CPH over the pH range from 5.0 to 7.5. Thus, we 
suggest that the SA concentration is likely to dominate the pH, and propose that the pH 
inside the eroding zone could be estimated by considering only the SA concentration. If the 
dissociation of the two carboxylic acids on the SA monomer is considered along with the 
dissociation of water, a quartic equation for the hydrogen concentration as a function of SA 
monomer concentration results. Our method for solving this is presented in Appendix 
10.A.2. The results in appendix 10.A.2 demonstrate that a pH below about 4.75 is not 
obtainable, because the concentration of SA required to obtain that pH is above the saturation 
concentration. This is qualitatively consistent with the experimental findings of Mâder et al 
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noted earlier40. They observed a pH of about 4.7 inside the eroding zone of SA containing 
copolymers, which would indicate saturation of the erosion zone. 
10.6 Model Solution for Poly(SA) 
We first investigate the case of semicrystalline poly(SA) homopolymer erosion. For 
homopolymers, equations 10.2, 10.4, 10.7, 10.9 and 10.13 are unnecessary and equations 
10.6, 10.8, and 10.10 are simplified by the absence of the terms related to component two. 
Additional parameters are listed in Table 10.4. The parameters kai and (3 were used to fit the 
model to experimental data for erosion of poly(SA) tablets37. The values for X and a were 
taken from our previous characterization of the crystallinity[Shen, 2001 #26]. 
Table 10.4. Parameters used to model poly(SA) erosion kinetics. 
Parameter Value 
kai 8.0 x 10"7 (g cm"2 s"1) 
P 1.05 (g cm"3) 
kdi 1.4 x 10"6 (cm s"1) 
Di 6.8 x 10^ (cnf s"') 
P 0.001 
X 2.8 x 10'6 (cm) 
a 0.6 
y 1.0 (nm) 
The model was solved with a time step of 0.05 s and a position step of 1 nm. Several 
reports of experimental results for erosion of poly(SA) are found in the literature37,38,48. We 
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compare our model to the experimental results we have previously obtained37. In these 
experiments, 110 mg tablets, 10mm in diameter and 1.3 mm thick were degraded in 900 ml 
of pH 7.4 phosphate buffer at 37 °C with agitation at 100 rpm. The cumulative fractional 
mass loss as a function of time is plotted in Figure 10.3 for the experiment and the model. 
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Figure 10.3. Cumulative fractional mass loss for poly(SA) erosion from experiment37 (•) 
and model (line). 
In addition to accurately predicting the overall erosion profile, the new model offers a 
detailed description of the erosion process. Of particular interest are the microstructural 
characteristics that can be obtained, including the ratio of the crystalline to amorphous 
polymer remaining in the erosion zone, the porosity, and the pH in the erosion zone. Figure 
10.4 shows the evolution of the porosity for the first hour of erosion. During the first hour, 
the erosion front moves 13pm into the tablet, and the porosity at the surface does not go to 1 
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until 51 minutes after the erosion begins. By this time, the erosion front has moved about 
11 |4,m into the tablet. Once the porosity at x = 0 reaches one, the surface begins to move. At 
this point, a pseudo steady state develops with the position of the surface and the position of 
the erosion front moving at the same velocity. The erosion zone at any time consists of the 
region between the surface, x = xs, and the position of the erosion front, x = xef. Since there 
is a pseudo steady state, the thickness of the erosion zone remains about llpm until the 
erosion front reaches the center of the tablet, x = xmax. Note that initially the porosity 
increases rapidly as the amorphous polymer degrades, leaving behind a network rich in 
crystalline domains. The progress of erosion at a given position continues to decelerate as 
the porosity approaches unity. 
Position, x (pm) 
Figure 10.4. Model results for porosity evolution in the first 60 minutes of erosion for 
poly(SA). 
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The surface area fractions of crystalline polymer, amorphous polymer, and monomer 
are plotted in Figure 10.5. Figure 10.5a shows the surface area fractions as a function of the 
time after the erosion front passes for constant position. Figure 10.5b shows the surface area 
fractions as a function of position from the erosion front at constant time. Figure 10.5a 
demonstrates that within about 15 seconds of the erosion front passing through a point, the 
surface area fractions have reached a steady state, and the exposed surface area is dominated 
by crystalline polymer. The two types of monomer and the amorphous polymer together 
make up about 0.1% of the total surface area. Figure 10.5b shows that at a given time, the 
surface area fractions vary over only a very narrow distance from the position of the erosion 
front. 
The concentration of SA diacid and the resulting pH in the erosion zone is shown as a 
function of position in Figure 10.6 after the pseudo steady state develops. The concentration 
reaches the saturation concentration at about 7pm from the surface. The pH prediction is in 
good agreement with the experimental results of Mâder et al40. 
Although the pore surface within the erosion zone is overwhelmingly dominated by 
crystalline polymer, a significant fraction of amorphous polymer remains throughout the 
erosion process. This is evident from the plot shown in Figure 10.7. Here, the crystallinity, 
a, is plotted as a function of distance from the erosion front. At the erosion front, the 
crystallinity is 0.6 (the value in the bulk), and just past the erosion front the crystallinity rises 
sharply to a value of 0.77 inside the erosion zone (inset). Closer to the surface, the 
crystallinity rises gradually to about 0.82. The region near the erosion front is shown in the 
inset. 
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The crystallinity plot shown in Figure 10.7 compares well with the experimental 
results reported in several studies, which indicate that the crystallinity inside the erosion zone 
is increased over that in the bulk, uneroded polymer31-33. 
10.7 Model Solution for Poly(CPH:SA) 20:80 
To demonstrate the ability of this model to account for copolymer erosion, we present 
the solution for poly(CPH:SA) 20:80 erosion. In order to estimate the degradation rate 
constants for CPH, we compare the molar erosion rate constants for poly(CPH) and poly(SA) 
reported by Leong et a/.49'50. The ratio of the erosion rate constants for poly(SA) to that for 
poly(CPH) is used as a first approximation for the ratio of degradation rate constants for the 
SA-SA and CPH-CPH bonds, ksA-sA and kcpn-SA, respectively. We then estimate the 
degradation rate constant for CPH in the copolymer, kCpH, as: 
2K _ (KÇPH ~L)K-CPH-CPH +2kcPH-SA 
1 + Lcph 
Here, LCPH is the number average sequence length of CPH in the copolymer reported by Shen 
et al}1, and kcpn-SA is the rate constant for the degradation of CPH-SA bonds, approximated 
here as KSA-SA- The rate constant for degradation of SA-SA bonds is approximated as 2k$A-
The degradation rate constant for SA does not change in the copolymer since ksA-sA is equal 
to kcpn-SA- This procedure is used to estimate the degradation rate constants for both 
crystalline and amorphous CPH. 
The microphase separation that exists in the copolymer must be accounted for. In this 
case we account for the microphase separation by setting the parameter y to 1.5 nm. This is a 
good approximation for the thickness of a monolayer, as the average monolayer thickness 
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increases when CPH is added. This is also the approximate length scale associated with the 
microphase separation. Since our model is discretized at this length, the parameters <t>ai and 
<)>ci in equations 10.6-10.9 appropriately account for the microphase separation with a mean 
field approximation. The crystalline/amorphous phase separation is accounted for by the 
probabilities in equations 10.6-10.9. 
The parameters listed in Table 10.4, the parameters used to model the 20:80 
copolymer are listed in Table 10.5. The model was solved with a time step of 0.5 s and 
compared to data for tablet erosion similar to the experiments described above for the 
poly(SA). The parameter (3 is used to fit the erosion data to the model. 
Table 10.5. Parameters used to model poly(CPH-SA) 20:80 erosion kinetics. 
Parameter Value 
kai 8.0 x 10"? (g cm^ s'i) 
ka2 7.8 x 10 * (g cm'2 s"') 
P 1.05 (g cm"3) 
kdi 1.4 x 10"6 (cm s"1) 
kd2 1.4 x 10"8 (cm s"1) 
D, 6.8 x 10"* (cm2 s"') 
D2 7.2 x 10"* (cm2 s') 
P 0.025 
8 2.5x10-4 
X 5.6 x 10"* (cm) 
a 0.467 
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The overall erosion profile (cumulative fractional mass loss) is shown in Figure 10.8. 
The erosion profile shows a brief initial lag time of about 4 hours. This is due to 
inhomogeneous erosion as will be explained shortly. 
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Figure 10.8. Cumulative fractional mass loss for poly(CPH:SA) 20:80 erosion from 
experiment37 (•) and model (line). 
The porosity evolution for the first 14 hours is shown in Figure 10.9. Similar to the 
poly(SA), a pseudo steady state develops, wherein the position of the erosion front (xef and 
the position of the surface (xs) move through the device with the same velocity. In this case, 
the erosion zone is about 83 pm thick. Inside the erosion zone, the composition of the surface 
can be characterized as it was for the poly(SA). As might be expected, the surface is 
dominated by crystalline poly(CPH), as this is the most slowly degrading species. About 
1.3% of the surface inside the erosion zone is occupied by undissolved CPH monomer. The 
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delay in the erosion profile noted earlier can be associated with the time required for the 
surface of the tablet to approach a porosity of one. 
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Figure 10.9. Porosity as a function of time and position for CPH:SA (20:80) copolymer 
erosion. 
The individual monomer release profiles from the model and experiment are shown in 
Figure 10.9. We can see in Figure 10.9 that the release of CPH monomer lags behind the 
release of SA monomer. This is consistent with our experimental observations and 
observations made by others of similar copolymer systems36,37. We also find that similar to 
the homopolymer case, the erosion zone quickly becomes saturated with SA diacid. The pH 
inside the pores reached the same value as that for the homopolymer until all of the SA was 
depleted (data not shown). The pH effect limits the solubility of the CPH diacid inside the 
pores similar to the effect observed for the SA diacid. 
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The model accurately predicts the overall erosion kinetics and the CPH monomer 
release kinetics, but fails to accurately predict the SA monomer release kinetics. It is 
possible that the SA monomer release kinetics is accelerated by some initial porosity in the 
system that this model does not account for. We also assumed that the ratio of the 
degradation rate constants for the crystalline to amorphous polymer was the same for both 
species, though this need not necessarily be the case. Allowing for y to be an adjustable 
parameter, could also improve the fit to experiment. Despite this drawback, the model 
accurately describes important features of the microenvironment inside the eroding zone 
including concentrations of dissolved monomer species and the resulting pH. Further, this 
model motivates additional experiments that could describe the erosion process in more 
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detail, such as measurements of the degradation rate constants for crystalline and amorphous 
moieties, and porosity and pH within the eroding zone. Though this model was developed 
for polyanhydride copolymers, it could be used for a variety of surface and bulk eroding 
systems. Indeed, the results for the copolymer indicate the system is not purely bulk eroding, 
as the erosion zone represents a significant fraction of the device. Just as the current 
formulation of the model allows for pH dependence of the dissolution kinetics, pH dependent 
polymer degradation could also be accounted for. Further extensions of the model could also 
account for the release of encapsulated drugs. 
10.8 Conclusions 
The new model for erosion of surface-erodible materials presented here offers the 
ability to describe many interesting phenomena on a microscopic scale that are difficult to 
observe directly by experiment. Not only is the erosion kinetics of individual phases 
discerned, but also the information is resolved at the nanometer length scale. Furthermore, 
this model can be used to predict phenomena such as monomer precipitation and pH inside 
the pores of the eroding polymer. 
The case study results presented here motivate further experimentation to discern 
additional parameters. Of particular interest are the individual degradation rate constants for 
crystalline and amorphous polymer. Here we assumed values of the ratios of these rate 
constants without any direct experimental support. For design of drug-loaded systems for 
controlled release applications, it is also necessary to have an accurate description of the 
thermodynamics of the polymer/drug system. Adding a drug may compatibilize the polymer 
system, affect polymer crystallinity, or form a third phase. Any of these three effects could 
be dealt with by moderate modifications to the new model. 
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10.A.1 Appendix. Estimation of Probabilities paa and pca 
In equations six through nine, the crystalline/amorphous phase separation is 
accounted for by considering the probability that dissolving monomer exposes amorphous 
polymer or crystalline polymer. The probability depends upon the identity of the monomer 
element. The probabilities are computed by considering the initial volume associated with 
the interfacial area. This fractional interfacial volume, Vjnt, is computed according to: 
z ^ .x Volume of amorphous polymer at interface (l-aWayAx (l-a)4 
VintvM - 0) - ——" — - - — r - -
Volume of polymer 7zda Ax A 
(10.A.1) 
Here, da is the diameter of an amorphous domain and the volume of amorphous polymer at 
the interface is the interfacial area multiplied by the thickness of a monolayer, y. The 
probabilities are then computed as: 
Paa =1-— (10.A.2) 
Pca=— (10.A.3) 
Here, va and vc are the volume fractions of the crystalline and amorphous phases, 
respectively. These are obtained by integrating the dissolution rate of each type of monomer 
at each time step and are functions of position and time. 
272 
10.A.2 Appendix. Saturation Concentration and pH Calculations 
Equation 21 computes the dissolution rate, K, as a function of the saturation 
concentration, csat. The saturation concentration is a strong function of the pH as illustrated 
in Figure 10.10. The pH of the microenvironment in the erosion zone is determined by the 
SA concentration. Five equations are needed to solve for the concentrations of the five 
species, SA, SA", SA2", H+, and OH". These five equations are the equilibria of SA, SA", and 
water dissociation, the mole balance on the SA derived species, and the charge balance. 
K
-
, s i = ( 1 0
'
A
'
4 )  
k . „  
KW(37°C) = [H+][OH~] = 2.39x10 -14 
Msa = [SA] + [SA~] + [SAZ"] 
[H+] = [SA~] + 2[SA2~] + [OH] 
(10.A.6) 
(10.A.7) 
(10.A.8) 
The bracketed variables are molarities of the bracketed species and MSA is the total SA 
molarity. These five equations can be combined to form a quartic equation for [H+] based on 
MSA-
MsaIh*]2  +2K I 2„[H*])=—!— [H*r +[H*]= + 
IX 
* al,SA 
+ KwKa2 SA 
Ka2,SA + v 
\ al,SA J 
[H+]2 +KW[H + ] 
(10.A.9) 
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Most of the terms in this equation over at least a portion of the expected pH range remain if 
the relatively small terms are neglected. Thus, rather than solving the quartic equation at 
each x and t for the pH and then predicting csat, we offer empirical equations that fit csat,cPH 
and Csat,SA as functions of Csa-
c*, S A - C s A  =-8.58x10 -11 f11 2 f 1 1 + 1.79x10"' 
<CSAy  <CSAy 
1.06x10" (10.A.10) 
logic kat.cpH ) = 0.23 lc3 + 3.36c2 + 14.9c + 17.7 (10.A.11) 
C 
= ^ °§10 (C sat,SA ) 
In these equations all of the concentrations have units of g l"1. These are plotted in Figure 
10.A.1 along with the saturation data. The relationship between C$A and pH is also fit to an 
empirical equation 
pH-0.277,n(=SA)+3.42 
The solutions to equations 10.A.10 through 10.A.12 are plotted in Figure 10.A.1 along with 
the saturation data. This plot shows that the minimum pH that can be obtained is about 4.75, 
as the SA concentration required to obtain lower pH is above the saturation concentration. 
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CHAPTER 11 
CONCLUSIONS AND FUTURE DIRECTIONS 
The overall goal of this research is to develop platforms based on polyanhydride 
copolymers for controlled release applications such as single-dose vaccines. The specific 
goals of this work are: 
SGI. To describe in detail the microstructure of polyanhydride copolymers and the effects 
of this microstructure on drug/antigen distribution and release from microphase-
separated polyanhydrides. 
SG2. To design TT-loaded polyanhydride microspheres and perform in vitro and in vivo 
studies to discern antigen release profiles and antibody production in order to 
maximize protective immunity. 
SG3. To formulate and solve a mathematical model to predict and tailor copolymer 
microstructure effects on drug/antigen release mechanisms. 
Here we have focused on copolymers of 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
and sebacic acid (SA), because this system offers a range of erosion times and the potential 
to tailor phase behavior and microstructure to tailor material properties. SGI is addressed in 
Chapters 4, 5, and 6. In Chapter 4 the phase behavior of poly(CPH)/poly(SA) blend system 
is investigated by scattering, microscopy and molecular simulations. The resulting phase 
diagram exhibits upper critical solution temperature (UCST) behavior. In addition to the 
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phase diagram, this work yielded the segment-segment interaction parameter, XCPH-SA, which 
could be used to further characterize the phase behavior of copolymer systems. The 
semicrystalline microstructure and crystallization kinetics of the copolymers and 
homopolymers is investigated in Chapter 5 by synchrotron small-angle X-ray scattering 
experiments (SAXS). The crystallization kinetics may be important for determining 
processing conditions that yield the optimum crystalline microstructure for a given 
application. We determined that it is difficult to control the crystallinity of the copolymers 
rich in SA and the poly(SA) homopolymer. Avrami constants for all copolymer 
compositions studied were reported. In Chapter 6, additional details of the amorphous 
microphase separation are discerned by SAXS and solid state nuclear magnetic resonance 
experiments. These experiments provide molecular resolution of the microstructure in these 
polymers. Random copolymers rich in either CPH or SA showed microphase separation with 
domain sizes on the order of l-3nm. Though this microstructure is too small to affect the 
encapsulation and release of macromolecular drugs, such as vaccines, it can play a key role 
in determining the performance of controlled release formulations for small molecular weight 
drugs. 
Future investigations of the copolymer microstructure should include studies of how 
the microstructure changes when solutes are added to the polymer system. Presumably, 
drugs dissolved in the microphase separated copolymer will either partition into the phase in 
which they are most soluble, form a third phase, or misciblize the polymer system. Each of 
these possibilities has the potential to exhibit unique release kinetics that must be understood 
for the efficient design of controlled release formulations. The microstructure of copolymers 
with different molecular topologies should also be investigated including block copolymers, 
ternary copolymers and copolymer blends. These systems have the potential to offer a wide 
280 
array of microstructural characteristics that could be of use for biomedical applications. 
Block copolymers could offer larger microphase separated domains. Blends could be used to 
create even larger domains or core/shell type microspheres, and ternary systems offer the 
potential to from more complex phase morphologies that could be used to encapsulate 
multiple drugs, aid in the stabilization of macromolecular drugs, or produce more complex 
release profiles. 
Chapters 7 and 8 focus on S G 2. In Chapter 7 we demonstrate the fabrication and in 
vitro release kinetics of polyanhydride microspheres loaded with a model small molecular 
weight drug. In addition to describing the fabrication of an injectable drug delivery system 
based on the poly(CPH-SA) system, we demonstrate the ability to tailor the release kinetics 
by making "cocktails" of microspheres that have different release profiles. Chapter 8 reports 
the design of tetanus toxoid (TT)-loaded microspheres as single dose vaccines. It is shown 
that although high doses of the polymer induce a dose-dependent, localized inhibition, small 
doses have a beneficial adjuvant effect. TT released from the microspheres maintains its 
immunogenicity and antigenicity and the microspheres provide a prolonged exposure to TT 
sufficient to induce the secondary immune response without requiring an additional 
administration of vaccine. In addition to providing an immune response with a single dose, 
the microsphere delivery vehicle has the capability to modulate the immune response 
mechanism. It is well known that traditional alum-based vaccines typically induce primarily 
a Th2 (humoral) immune response, as does unencapsulated TT. The ability of this delivery 
vehicle to preferentially induce a balanced (THO) response mechanism is a unique and 
valuable characteristic that may make it valuable for treating a variety of viral and 
intracellular pathogens. A TH2 dominant response can also be obtained from the 
microspheres by altering the formulation. 
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Future work with this system should involve encapsulation of different small 
molecules to ascertain the effects of small molecule chemistry on the release kinetics. The 
release kinetics can be combined with the microstructural characterization to further enhance 
understanding of the interplay between the macroscopic (release kinetics) and the 
microscopic (microstructural) features of this polymer system. The results of Chapter 8 
motivate several further studies. Additional vaccines should be studied and future work 
could also draw relationships between release kinetics and immune response. In particular 
the mechanism of the preferential induction of immune response pathways requires further 
investigation to understand. The interactions between polyanhydride microspheres and 
lymphocytes such as dendritic cells could offer insights into the observed phenomenon. 
Another potential of this system is to provide a low level exposure to an antigen in order to 
induce tolerance. This has potential for treatment of a variety of disease states, such as 
autoimmune disorders. Mechanisms of immune tolerance induction are just beginning to be 
understood and this system could be useful in future studies of tolerance. Controlled release 
formulations may also be a means of inducing model chronic disease states in otherwise 
healthy animals. 
Chapters 9 and 10 are concerned with SG3. In Chapter 9 an erosion model is 
introduced that successfully accounts for the proposed microphase separation and 
partitioning that exists in the copolymers. Comparisons to experiment provide insights into 
the phenomenon of drug partitioning in microphase separated copolymers and permit the 
determination of a partition coefficient. This model, like many models in the literature, does 
not account for the several elementary processes that make up erosion, namely polymer 
degradation, monomer dissolution, and diffusion. In order to more fully understand the 
effects of these several phenomena on the erosion mechanism, Chapter 10 offers an improved 
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model that accounts for these elementary processes. This model is capable of accounting for 
several key experimental observations that previous models neglect such as the accumulation 
of undissolved monomer and changes in pH of the microenvironment during erosion. These 
phenomena may not only affect the erosion kinetics, but may also affect the stability of 
macromolecular drugs. The model is fit to experimental monomer release kinetics. Detailed 
descriptions of the microenvironment of the erosion zone are obtained. Parameters such as 
the pH and concentration of dissolved and undissolved monomers in the erosion zone are 
difficult to measure experimentally, but are described in detail by this model. This model 
also motivates additional experiments to ascertain parameters such as the degradation rate 
constants for amorphous and crystalline polymer and phenomena such as the pH of the 
microenvironment in an eroding polyanhydride device. 
In summary, this work combines materials science theory, device design and 
fabrication, testing of novel drug delivery devices, and complex kinetic modeling to further 
the development of controlled release formulations based on polyanhydrides. In addition to 
the development of a novel vaccine delivery system, this work resulted in the development of 
two new erosion and drug release models that offer new insights into the mechanisms of 
erosion, and characterization of a valuable multicomponent polymer system. Additional 
research is motivated by new questions generated from this research. 
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